




European
Crohn's and Colitis
Organisation

Copenhagen
Denmark

Inflammatory Bowel Diseases

Final Programme



© Den Blå Planet, National Aquarium Denmark

14th Congress of ECCO
Bella Center Copenhagen
March 6-9, 2019

www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation

Become a member!

3-year membership:
Regular & Y-ECCO
Members save up to 20%



Be a bee in our hive to experience the ECCO Spirit

To reach our objectives, our members can access the following ECCO Initiatives:

- Reduced Congress fee
- JCC – Journal of Crohn's and Colitis (12 online issues/year)*
- e-CCO Learning Platform incl. e-Courses & e-Library
- Monthly eNewsletter
- Access to online Members' Area
- Voting rights in General Assembly
- Quarterly ECCO News – the society's magazine
- Educational and networking activities
- Guidelines, ECCO Fellowships, Grants and Travel Awards
- Priority access to UR-CARE - United Registries for Clinical Assessment and Research

Scan and contact the ECCO Office
www.ecco-ibd.eu



*For Regular Members (incl. Y-ECCO) only; online access only

Word of welcome

Dear Colleagues,

Welcome to the 14th Congress of ECCO in the wonderful city of Copenhagen, Denmark! Copenhagen blends tradition and state-of-the-art design in a city full of contrast and balance. The qualities of this city are reflective of what is valued in this year's congress programme. In this country of continuous and significant medical research, the ECCO Congress is in an environment that embraces new methods and research while holding on to well-established knowledge and traditions.



Silvio Danese


After a very successful ECCO Congress in Denmark in 2014, it is a great privilege to return to Bella Center for the ECCO Congress in 2019. The immense growth in the recent years has firmly established the ECCO Congress as THE major IBD meeting in the world. Attracting over 6,500 participants, ECCO offers opportunities for nurses, dietitians, surgeons, gastroenterologists and physicians in the field of IBD to exchange knowledge and participate in a growing spectrum of Educational Courses and Masterclasses. Additionally, ECCO reaches out to young clinicians and scientists offering this international platform to pursue improvement in every pillar of IBD patient care.

As we witness major breakthroughs of innovation in new drugs hitting clinics and also new personalised approaches for individual patient treatments, the ECCO Congress theme for this year is suitably titled "Research drives clinical care".

The Congress sessions are focused on the present best practices for adult IBD patients, including paediatric and surgical lectures, and also highlighting the newest trends for patient management. As new challenges in IBD approach, now, more than ever, research must strive for best clinical care. For this reason, active participation and interaction is vital and fuels success in reaching our goal of improving IBD patient care.

On behalf of the whole ECCO Team and the Organising Committee, I extend a warm welcome to you all!

Yours sincerely,

A handwritten signature in blue ink that reads "Silvio Danese".


Silvio Danese

ECCO President 2018-2020 & Chair of Organising Committee

Table of contents

Word of welcome	3
ECCO Structure	5
Scientific Information: A-Z.....	11
Opening hours	18
Scientific programme day by day	19
Abstract presentation format.....	37
Digital oral presentations	41
Hard copy poster presentations/poster exhibition	65
Educational programme	69
17 th IBD Intensive Advanced Course.....	69
3 rd School for Clinical Trialists.....	72
10 th N-ECCO School	73
6 th ECCO-ESGAR Ultrasound Workshop – Advanced.....	75
4 th Advanced ECCO: EduCational COurse for Industry	76
5 th Y-ECCO Basic Science Workshop.....	77
11 th Y-ECCO Career Workshop.....	78
1 st ECCO-ESGAR Basic Imaging Workshop.....	79
7 th SciCom Workshop.....	83
1 st Guideline Methodology and GRADE Workshop.....	84
6 th P-ECCO Educational Course.....	85
13 th N-ECCO Network Meeting	86
8 th S-ECCO IBD Masterclass in collaboration with ESCP	88
4 th ECCO-AOCC Forum: East meets West	91
4 th H-ECCO IBD Masterclass.....	93
4 th D-ECCO Workshop	96
Congress information	98
Industry sponsored satellite symposia	106
ECCO Interaction: Hearts and Minds.....	115
Corporate Members	116
Floor plans.....	119
Index of authors	122

ECCO Structure



Governing Board

President
President-Elect
Past-President and Liaison Officer
Secretary
Treasurer
Education Officer
Scientific Officer

Silvio Danese (Italy)
Laurent Peyrin-Biroulet (France)
Julián Panés (Spain)
Willem Bemelman (The Netherlands)
Ailsa Hart (United Kingdom)
James Lindsay (United Kingdom)
Gerhard Rogler (Switzerland)

ClinCom

Chair
Members

Clinical Research Committee

Marc Ferrante (Belgium)
Krisztina Gecse (The Netherlands)
Javier Gisbert (Spain)
Uri Kopylov (Israel)
John Mansfield (United Kingdom)

D-ECCO

Chair
Members

Dietitians of ECCO

Rotem Sigall-Boneh (Israel)
Marjo Campmans-Kuijpers (The Netherlands)
Konstantinos Gerasimidis (United Kingdom)
Arie Levine (Israel)
Catherine Wall (United Kingdom)

EduCom

Chair
Members

Education Committee

Antonio López-Sanromán (Spain)
Marietta Iacucci (United Kingdom)
Pascal Juillerat (Switzerland)
Paulo Kotze (Brazil)
Giovanni Maconi (Italy)
Henit Yanai (Israel)

EpiCom

Chair
Members

Epidemiological Committee

Marieke Pierik (The Netherlands)
Naila Arebi (United Kingdom)
Laurent Beaugerie (France)
Nynne Nyboe Andersen (Denmark)
Valerie Pittet (Switzerland)

GuiCom

Chair
Members

Guidelines Committee

Christian Maaser (Germany)
Glen Doherty (Ireland)
Tim Raine (United Kingdom)
Joana Torres (Portugal)
Stephan Vavricka (Switzerland)

H-ECCO

Chair
Members

Histopathologists of ECCO

Roger Feakins (United Kingdom)
Paula Borralho Nunes (Portugal)
Gert De Hertoghe (Belgium)
Magali Svrcek (France)
Monika Tripathi (United Kingdom)

N-ECCO

Chair
Members

Nurses of ECCO

Kay Greveson (United Kingdom)
Wladyslawa Czuber-Dochan (United Kingdom)
Petra Hartmann (Germany)
Susanna Jäghult (Sweden)

P-ECCO

Chair
Members

Paediatricians of ECCO

Patrick van Rheenen (The Netherlands)
Marina Alois (Italy)
Lissy de Ridder (The Netherlands)
Jaroslaw Kierkus (Poland)
David Wilson (United Kingdom)

SciCom

Chair
Members

Scientific Committee

Janneke van der Woude (The Netherlands)
Shomron Ben-Horin (Israel)
Florian Rieder (United States)
Michael Scharl (Switzerland)
Sebastian Zeissig (Germany)

S-ECCO

Chair
Members

Surgeons of ECCO

Yves Panis (France)
Michel Adamina (Switzerland)
Christianne Buskens (The Netherlands)
Antonino Spinelli (Italy)
Hagit Tulchinsky (Israel)

Y-ECCO

Chair
Members

Young ECCO

Nuha Yassin (United Kingdom)
Dominik Bettenworth (Germany)
Johan Burisch (Denmark)
Nik Sheng Ding (Australia)
Charlotte Hedin (Sweden)

Organising Committee – 14th Congress of ECCO

Chair
Members

Silvio Danese (Italy)
Laurent Peyrin-Biroulet (France)
Willem Bemelman (The Netherlands)
Janneke van der Woude (The Netherlands)
Antonio López-Sanromán (Spain)

National Representatives

(as of February 1, 2019)



Christoph Högenauer
Alexander Moschen



Tamás Molnár
Károly Palatka



Cathérine Reenaers
Pieter Dewint



Jane McCarthy
Garret Cullen



Ante Bogut
Emil Babić



Matti Waterman
Henit Yanai



Zoya Spassova
Izkren Kotzev



Emma Calabrese
Sandro Ardizzone



Željko Krvnarić
Ante Tonkic



Aleksejs Derovs
Jelena Derova



Ioannis Kaimakliotis
Theodora Demetriou



Limas Kupčinskas
Gediminas Kiudelis



Tomáš Douda
Pavel Drastich



Pierre Ellul



Jørn Brynskov
Signe Wildt



Vlada Dumbravă
Svetlana Turcan



Karin Kull
Triin Remmel



Kristin Kaasen Jørgensen
Marte Lie Høivik



Clas-Göran af Björkestén
Tuire Illus



Maria Kłopocka
Małgorzata Śladek



Arnaud Bourreille
Xavier Roblin



Ana Isabel Vieira
Rosa Isadora



Britta Siegmund
Raja Atreya



Mihai Mircea Diculescu
Adrian Goldis



Ioannis Koutroubakis
Giorgos Bamias



Alexander Potapov
Pavel Makarchuk



Mirjana Cvetkovic
Srdjan Djuranovic



Pierre Michetti
Frank Seibold



Martin Huorka
Mária Zakuciová



Andrea van der Meulen-de Jong
Dirk de Jong



David Drobne
Gregor Novak



Yusuf Ziya Erzin
Filiz Akyüz



Pilar Nos Mateu
Manuel Barreiro de Acosta



Tetyana Zvyagintseva
Andrey Dorofeyev



Michael Eberhardson
Ann-Sofie Backman



Tariq Ahmad
Ian Arnott

Honorary Members

(as of February 1, 2019)

Filip Baert (Belgium)
Renzo Caprilli (Italy)
Yehuda Chowers (Israel)
Jean-Frédéric Colombel (United States)
Geert D'Haens (The Netherlands)
Axel Dignass (Germany)
Miquel Gassull (Spain)
Daniel Hommes (The Netherlands)

Gerassimos Mantzaris (Greece)
Pierre Michetti (Switzerland)
Pia Munkholm (Denmark)
Walter Reinisch (Austria)
Herbert Tilg (Austria)
Simon Travis (United Kingdom)
Séverine Vermeire (Belgium)
Boris Vucelić (Croatia)

Corporate Members

(as of February 1, 2019)

AbbVie
Amgen
Biogen
Bristol-Myers Squibb
Bühlmann Laboratories
Celgene
Celltrion

Cosmo Pharmaceuticals
Dr. Falk Pharma
Eli Lilly and Company
Ferring
Gilead
Janssen
MSD

Pfizer
Roche
Sandoz
Takeda
Tillotts Pharma
Vifor Pharma



European
Crohn's and Colitis
Organisation

Announcement
2020

Inflammatory Bowel Diseases



15th Congress of ECCO
Vienna, February 12-15, 2020

- Reed Messe Wien
- EACCME applied
- Register at www.ecco-ibd.eu/ecco20

Scan and contact the ECCO Office
www.ecco-ibd.eu



Scientific Information: A-Z

Abstracts

ECCO is proud to announce that a total of 1228 abstracts have been submitted to the 14th Congress of ECCO. A panel of expert reviewers have evaluated and selected the strongest, most scientifically relevant abstracts for presentation at this year's Congress. Authors of the best abstracts have been invited to present their studies as oral presentations, digital oral presentations and hard copy poster presentations. For details regarding abstract presentation, see pg. 37.

Business meetings

Attendance at business meetings is upon invitation only. The General Assembly will be held in C1-M1 at Bella Center, on Thursday, March 7, 20:00-21:00. Stop by the ECCO Booth for more information on business meetings.

Compliance

Based on the EFPIA HCP Code and the guidelines and codes of practice applicable to Denmark, ENLI (Danish Ethical Board for Pharmaceutical Industries) and the Danish Medicines Agency, ECCO has adopted measures that allow compliance with applicable regulations regarding publicity and promotion of medicines at the ECCO Congress 2019.

- Exhibitors have been asked to respect the Code of Practice in the context of the ECCO'19 Exhibitor & Sponsor Prospectus.
- Exhibitors have been alerted to the regulations about the promotion of prescription-only medicine, explaining that non-HCPs congress delegates can be identified with the non-HCP sign on the congress badge. Furthermore non-HCPs have no access to areas where advertising for HCPs is allowed.
- In the course of the online and onsite registration, the congress delegates are also informed about the regulations regarding publicity and promotion of medicine and are asked to indicate their HCP/non-HCP status accordingly.

Disclosure policy

ECCO has diligently maintained a disclosure policy of potential Conflicts of Interest (CoI) with the aim of fostering transparency and ensuring scientific rigour and objectivity in all scientific and educational activities. Therefore, all presenters, including invited faculty members and abstract presenters, are required to disclose relevant financial support and relationships that may generate potential conflict. Please note that the presenting author holds responsibility for the content of his or her presentation.

All presenters are required to complete a Conflict of Interest form disclosing any financial support and advisory/consultancy roles in the biomedical industry. These forms are made public on the ECCO Website at www.ecco-ibd.eu/about-ecco/ecco-disclosures providing a comprehensive overview of potential Conflicts of Interest of presenters. Once published, the ECCO Office will notify IBD Community in an eNewsletter of the online access to the up-to-date CoI forms.

All conflicts are to be disclosed on the 2nd slide of each PowerPoint presentation. To facilitate and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential Conflicts of Interest in their presentation in line with European Union of Medical Specialists (UEMS) regulations.

A draft Col slide will be prepared for each speaker based on the submitted Col form, and will be made available in the Speakers' Centre to be included in the presentation. Please be reminded that if the respective presentation does not yet include a disclosure form, the slide draft should be checked and amended before it is inserted into the presentation.

Conflicts of Interest may include, but is not limited to, financial relationships, whether the individual had the opportunity to influence the content of a presentation, grants, honoraria, shares, and paid positions on advisory boards. ECCO expects many presenters to have some Conflicts of Interest, which do not prevent them from presenting their work given that the conflict is disclosed.

EACCME – Continuing Medical Education

The 14th Congress of ECCO in Copenhagen is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activities for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu.



Event	CME Credits
14 th Congress of ECCO Scientific Programme	15
1 st ECCO-ESGAR Basic Imaging Workshop	7
1 st Guideline Methodology and GRADE Workshop	3
3 rd School for Clinical Trialists	3
4 th D-ECCO Workshop	3
4 th ECCO-AOCC Forum	N/A
4 th Advanced ECCO: EduCational COurse for Industry	N/A
4 th H-ECCO IBD Masterclass	6
5 th Y-ECCO Basic Science Workshop	3
6 th ECCO-ESGAR Ultrasound Workshop - Advanced	3
6 th P-ECCO Educational Course	2
7 th SciCom Workshop	2
8 th S-ECCO IBD Masterclass	6
10 th N-ECCO School	N/A
11 th Y-ECCO Career Workshop	2
13 th N-ECCO Network Meeting	N/A
17 th IBD Intensive Advanced Course	10

The submission of the ECCO'19 Congress evaluation serves as a prerequisite to receiving CME credits. At the conclusion of the Congress, delegates will receive an e-mail with a link to the online evaluation platform.

On the evaluation platform, you are invited to evaluate the Scientific Programme and all educational activities you attended. Upon submission of these evaluations, your CME Certificates will be available for download or print.

ECCO Fellowships & Grants 2019

On Friday, March 8, 2019 15:45-15:55, ECCO officially announces the following prizes:

- ECCO Pioneer Award 2019
- ECCO Fellowships 2019
- ECCO Grants 2019
- ECCO-AOCC Visiting Travel Grant 2019
- ECCO Travel Awards 2019
- ECCO-Pfizer Research Grant on Predictors of response to JAK inhibitors 2019
- ECCO-Pfizer Research Awards 2019

The awarded candidates will formally receive their prizes and announce the titles of their fellowship or grant research projects in this session of the Scientific Programme.

For further information and guidelines for these awards please refer to www.ecco-ibd.eu.

Plenary session

The plenary session is held from Thursday to Saturday, March 7-9, 2019, starting with an official welcome and the opening of the core scientific programme. This programme includes talks and presentations from a collection of official and invited speakers, as well as oral presentations of the best submitted scientific abstracts.

Scientific congress theme

The theme of the 14th Congress of ECCO is "Research drives clinical care".

Top tips for chairs

All chairs are kindly invited to watch the "Top tips for chairs" on the ECCO Website:

www.ecco-ibd.eu/toptips. In this video, Laurence Egan shares instructions on how to chair scientific sessions in a highly humorous manner – do not miss out on it!



How to receive your CME Certificates



Submit your evaluation forms online!

CME Certificates for the ECCO'19 Scientific Programme and accredited Educational Courses will be available online at the end of the Congress. To download your certificates, follow these steps:

Check your account details

- Visit the ECCO Website to make sure your e-mail address and login details are up-to-date.

Check your e-mail

- At the end of the Congress, you will receive an e-mail with a link to the online evaluation platform.

Fill out your evaluation forms

- You will be able to evaluate the Scientific Programme and any Educational Activities you attended.

Download your certificates

- Once you have submitted your surveys, your CME Certificates will be available for download or print.

Scan and contact the ECCO Office
www.ecco-ibd.eu



Educational programme

	Room	08:00-08:30	08:30-09:30	09:30-11:30	11:30-12:30	12:30-13:30	13:30-14:00	14:00-14:30	14:30-16:15	16:15-16:30	16:30-16:45	16:45-17:00	17:00-18:00	18:00-19:00
WED March 6, 2019	HB4 M1-2	17 th IBD Intensive Advanced Course												pg. 69
	B3 M1-2	6 th ECCO-ESGAR Ultrasound Workshop Advanced												pg. 75
	B3 M5-6	10 th N-ECCO School												pg. 73
	B3 M7-8	5 th Y-ECCO Basic Science Workshop												pg. 77
	Auditorium 15	3 rd School for Clinical Trialists												pg. 72
		4 th Advanced ECCO: EduCational COurse for Industry												pg. 76

	Room	07:30-08:00	08:00-08:45	08:45-08:50	08:50-10:00	10:00-10:30	10:30-11:40	11:40-12:00	12:00-13:30	13:30-16:45	16:45-17:15		
THU March 7, 2019	HB4 M1-2	17 th IBD Intensive Advanced Course										pg. 69	
	B3-M1-2	1 st ECCO-ESGAR Basic Imaging Workshop										pg. 81	
	B3 M7-8	1 st Guideline Methodology and GRADE Workshop										pg. 84	
	B3 M9-10	7 th SciCom Workshop										pg. 83	4 th H-ECCO IBD Masterclass
	C1 M 0	6 th P-ECCO Educational Course										pg. 85	13 th N-ECCO Network Meeting
	C1 M2	8 th S-ECCO IBD Masterclass										pg. 88	
	C1 M3	4 th ECCO-AOCC Forum										pg. 91	

	Room	08:00-08:15	08:15-12:00	12:00-12:25
FRI March 8, 2019	HB4 M1-2	4 th D-ECCO Workshop		
	B3 M9-10	4 th H-ECCO IBD Masterclass		pg. 93

Programme overview Congress theme: "Research drives clinical care"

Scientific programme

	Room	10:30-11:00	11:00-12:00	12:00-12:15	12:15-12:30	12:30-13:00	13:00-14:00	14:00-14:30	14:30-16:00	16:00-17:20	17:20-17:30	17:30-18:30	18:30-18:45	18:45-19:00	19:00-19:45
THU March 7, 2019	Plenary Hall (Hall A)		ISSS 1a pg. 106		Welcome and Opening pg. 19	SS1: Silencing IBD pg. 19			SS2: Complementary treatments: The good and the bad pg. 20	SS3: Precision medicine: Lessons to learn and paths to the future pg. 20				ISSS 2a pg. 107	
	C1 M4-5		ISSS 1b pg. 107											ISSS 2b pg. 108	
	Auditorium 15		ISSS 1c pg. 107		Overflow room - Scientific programme				Overflow room - Scientific programme					ISSS 2c pg. 108	
	Hall B													Poster Exhibition pg. 65	
	Exhibition Hall (Hall C)			Industry Exhibition pg. 117			Coffee Break					Industry Exhibition pg. 117			
	C1 M0, C1 M1 C1 M2, C1 M3 C1 M4-5												DOP Sessions 1-5 pg. 41		

	Room	07:15-08:15	08:15-08:30	08:30-09:30	09:30-10:30	10:30-11:00	11:00-11:30	11:30-12:30	12:30-12:40	12:40-13:20	13:20-13:30	13:30-14:40	14:40-15:10	15:10-15:55	15:55-16:50	16:50-16:55	16:55-17:20	17:20-18:20	18:20-18:35	18:35-19:00	19:00-19:35
FRI March 8, 2019	Plenary Hall (Hall A)			SS4: Best practice in UC pg. 22		SS5: IBD around the world pg. 24			ELSS LS1 pg. 110			SS6: New ways of doing endoscopy and imaging in IBD pg. 25		SS7: ECCO Fellowships and Grants pg. 26	SS8: IBD Horizons pg. 27					ISSS 4a pg. 112	
	C1 M4-5	ISSS 3b pg. 109							ELSS LS2 pg. 110					SS9: Basic Science: Immune cells and microbes: A happy marriage? pg. 29							
	Auditorium 15	ISSS 3c pg. 109			Overflow room - Scientific programme				ELSS LS3 pg. 110			Overflow room - Scientific programme							ISSS 4c pg. 112		
	Hall B																		pg. 65		
	Exhibition Hall (Hall C)			Industry Exhibition pg. 117	Coffee Break	Industry Exhibition pg. 117	Lunch break and Guided Poster Session			Industry Exhibition pg. 117	Coffee Break				Industry Exhibition				pg. 117		
	C1 M1								ELSS LS3 pg. 110										ISSS 4d pg. 112		
	C1 M0, C1 M1 C1 M2, C1 M3 C1 M4-5													DOP Sessions 6-10 pg. 41							

	Room	08:00-08:15	08:15-08:30	08:30-09:30	09:30-10:20	10:20-10:50	10:50-12:20	12:20-12:50	12:50-12:55	12:55-13:00
	Plenary Hall (Hall A)			SS10: The cycle of IBD life in clinical practice pg. 32			SS11: Towards the future of IBD pg. 34	SS12: ECCO Lecture pg. 35	Awards and closing remarks pg. 35	The ECCO Film 2019 pg. 35
	Hall B						Poster Exhibition			pg. 65
	Exhibition Hall (Hall C)			Industry Exhibition pg. 117	Coffee Break			Industry Exhibition		pg. 117

SS = Scientific session

ISSS = Industry sponsored satellite symposium

ELSS = Educational lunchtime satellite symposium

DOP = Digital oral presentation



European
Crohn's and Colitis
Organisation

Copenhagen
Denmark

e-CCO Learning

Open access
preview @ the
ECCO Booth

e-CCO



Congress special: Open access preview

Are you looking for educational material? Check out...

27 e-Courses

Case-based e-Courses to learn and test your knowledge about common clinical scenarios in IBD

New ECCO e-Library

Refined search functions:
Congress abstracts, Congress presentations, webcasts, scientific articles and tools

31 Talking Heads

Two or three Key Opinion Leaders in IBD debating a controversial topic

10 Educational Audio Podcasts

Opinions of recognised experts on specialised topics in IBD

4 Skills Videos

Skills Videos provide ECCO Members with practical tips and tricks on performing IBD related procedures

ECCO IBD Curriculum

A framework for ECCO's educational activities, outlining what gastroenterologists need to know



Scan and visit
www.e-learning.ecco-ibd.eu





European
Crohn's and Colitis
Organisation

Research Grants and Fellowships 2020



Fund your innovative scientific research with ECCO's Fellowships and Grants

ECCO Pioneer Award

- EUR 250,000 for innovative and collaborative research projects between at least 2 IBD Centres
- First Application deadline: June 3, 2019**

ECCO Fellowships

- EUR 60,000 for young and enthusiastic scientists to research in a host institute abroad

ECCO Grants

- EUR 50,000 for innovative, and original research projects

N-ECCO Research Grant

- EUR 20,000 for international IBD Nursing research

ECCO Travel Awards

- EUR 1,500 for young doctors, nurses and dietitians to enable visits of European IBD Centres

Application deadline: June 3, 2019

Scan and visit

www.ecco-ibd.eu





European
Crohn's and Colitis
Organisation

ECCO Pioneer Award



Fund your innovative scientific research
with the ECCO Pioneer Award

**The ECCO Pioneer Award aims to enhance visionary, collaborative,
and interdisciplinary scientific research in IBD Centres.**

2020: Open to all topics in IBD

- EUR 250,000 prize
- 1 exceptional award per year
- Fund up to 24 months of basic/clinical research in IBD
- For innovative and collaborative research projects between at least 2 equal participating institutions

Application deadline (1st phase): June 3, 2019

Scan and contact the ECCO Office
www.ecco-ibd.eu



Opening hours

Cloakroom

Wednesday, March 6, 2019	07:00 - 19:30
Thursday, March 7, 2019	07:00 - 21:15
Friday, March 8, 2019	06:45 - 20:00
Saturday, March 9, 2019	08:00 - 13:30

ECCO Congress Office and Registration Desk

Wednesday, March 6, 2019	07:00 - 19:00
Thursday, March 7, 2019	07:00 - 19:00
Friday, March 8, 2019	07:00 - 19:00
Saturday, March 9, 2019	08:00 - 13:00

Industry and Poster Exhibition

Thursday, March 7, 2019	10:30 - 19:45
Friday, March 8, 2019	07:15 - 19:45
Saturday, March 9, 2019	08:00 - 13:00

Members' Lounge (exclusive for ECCO Members)

Thursday, March 7, 2019	10:30 - 19:45
Friday, March 8, 2019	07:15 - 19:45
Saturday, March 9, 2019	08:00 - 13:00

Poster exhibition

Thursday, March 7, 2019	13:00 - 19:00
Friday, March 8, 2019	08:30 - 19:00
Saturday, March 9, 2019	08:00 - 13:00

Speakers' Centre

Wednesday, March 6, 2019	07:30 - 18:00
Thursday, March 7, 2019	07:00 - 19:30
Friday, March 8, 2019	06:30 - 19:45
Saturday, March 9, 2019	08:00 - 13:00

"Research drives clinical care"

Thursday, March 7, 2019

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

11:00 - 12:00	Industry sponsored satellite symposia 1a & 1b & 1c See pg. 106
12:15 - 12:20	1: Welcome President of Dansk Selskab for Gastroenterologi og Hepatologi Henning Glerup, Silkeborg, Denmark
12:20 - 12:30	2: Opening Silvio Danese, Milan, Italy
12:30 - 14:00	Scientific Session 1: Silencing IBD Peter Irving, London, United Kingdom Britta Siegmund, Berlin, Germany
12:30 - 12:50	3: Can we prevent IBD? Jean-Frédéric Colombel, New York, United States
12:50 - 13:00	4: OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease S. Hu¹, A. Vich Vila¹, R. Gacesa¹, V. Collij¹, R. Xavier², C. Stevens³, M. Daly³, C. Wijmenga⁴, H. van Dullemen¹, G. Dijkstra¹, M. Visschedijk¹, E. Festen¹, J. Fu⁵, A. Kurihikov⁴, A. Zhernakova⁴, R. Weersma¹ ¹ Universitair Medisch Centrum Groningen, Gastroenterology & Hepatology, Groningen, Netherlands, ² Massachusetts General Hospital, Molecular Biology, Boston, United States, ³ Broad Institute, Boston, United States, ⁴ Universitair Medisch Centrum Groningen, Genetics, Groningen, Netherlands, ⁵ Universitair Medisch Centrum Groningen, Pediatrics, Groningen, Netherlands
13:00 - 13:20	5: Can we cure IBD? Arthur Kaser, Cambridge, United Kingdom
13:20 - 13:30	6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn's Disease C. Li, J. Kuemmerle Virginia Commonwealth University, Internal Medicine, Richmond, United States
13:30 - 13:40	7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT J. Cosin-Roger^{1,2}, D. Ortiz-Masia³, F. Canet¹, A. Trescoli-Garcia¹, S. Calatayud¹, M. D. Barrachina¹ ¹ University of Valencia, Pharmacology, Valencia, Spain, ² Hospital Dr Peset, Valencia, Spain, ³ University of Valencia, Medicine, Valencia, Spain
13:40 - 14:00	8: Are fibrotic complications reversible? Geert D'Haens, Amsterdam, The Netherlands Massimo Pinzani, London, United Kingdom
14:00 - 14:30	Coffee break

OP = Oral presentation – Best abstracts

Thursday, March 7, 2019, cont.*Scientific programme day by day (as of February 1, 2019)*

Plenary Hall, Hall A, Bella Center

14:30 - 16:00	Scientific Session 2: Complementary treatments: The good and the bad Shomron Ben-Horin, Tel Aviv, Israel Pascal Juillerat, Bern, Switzerland	
14:30 - 14:50		9: The crazy stuff – what your patients are taking and why? Fernando Gomollón Garcia, Zaragoza, Spain
14:50 - 15:00		10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response A. Dias ¹ , M. Pereira ¹ , A. Correia ¹ , I. Alves ¹ , V. Pinto ¹ , L. Azevedo ² , L. Maia ³ , R. Marcos-Pinto ³ , M. Vilanova ¹ , P. Lago ³ , S. Pinho ¹ ¹ Institute for Research and Innovation in Health (i3S), Immunology, Cancer & GlycoMedicine, Porto, Portugal, ² Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, ³ Porto Centre Hospital, Gastroenterology, Porto, Portugal
15:00 - 15:20		11: ECCO Topical Review on complementary medicine Joana Torres, Lisbon, Portugal Stephan Vavricka, Zurich, Switzerland
15:20 - 15:30		12: OP05: Crohn's Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn's Disease: A prospective randomised controlled trial J. Van Limbergen ^{1,2} , E. Wine ³ , A. Assa ⁴ , R. Sigall Boneh ⁵ , R. Shaoul ⁶ , M. Kori ⁷ , S. Cohen ⁸ , S. Peleg ⁹ , H. Shamaly ¹⁰ , A. On ¹¹ , P. Milman ¹² , L. Abrams ⁵ , T. Ziv Baran ¹³ , S. Grant ¹⁴ , A. Levine ^{5, 13} ¹ Dalhousie University, Halifax, Canada, ² IWK Center, Halifax, Canada, ³ University Alberta, Edmonton, Canada, ⁴ Schneider Medical Center, Petach Tikva, Israel, ⁵ Wolfson Medical Center, Holon, Israel, ⁶ Meyer Hospital, Haifa, Israel, ⁷ Kaplan Hospital, Rehovot, Israel, ⁸ Dana Childrens Hospital, Tel Aviv, Israel, ⁹ HaEmek Hospital, Afula, Israel, ¹⁰ French Hospital, Nazareth, Israel, ¹¹ Poriah Hospital, Tiberias, Israel, ¹² Hadassah Hospital, Jerusalem, Israel, ¹³ Tel Aviv University, Tel Aviv, Israel, ¹⁴ Mount Saint Vincent University, Halifax, Canada
15:30 - 15:40		13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression F. Humbel ¹ , P. Juillerat ² , M. Scharl ¹ , B. Misselwitz ² , P. Schreiner ¹ , A. Macpherson ² , G. Rogler ¹ , R. von Känel ³ , B. Yilmaz ^{4,5} , L. Biedermann ^{1,5} ¹ University Hospital Zurich, Department of Gastroenterology & Hepatology, Zurich, Switzerland, ² Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, ³ University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, ⁴ University of Bern, Maurice Müller Laboratories, Bern, Switzerland, ⁵ *Equal Contribution, Switzerland
15:40 - 16:00		14: Psychological support in IBD Yoram Inspector, London, United Kingdom

OP = Oral presentation – Best abstracts

Thursday, March 7, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

16:00 - 17:20 <i>Scientific Session 3: Precision medicine: Lessons to learn and paths to the future</i>	
Axel Dignass, Frankfurt am Main, Germany Jesús Rivera-Nieva, San Diego, United States	
16:00 - 16:20	15: What is system biology? Dermot McGovern, Los Angeles, United States
16:20 - 16:40	16: Multi-omics profiling of IBD Jonas Halfvarson, Örebro, Sweden
16:40 - 16:50	17: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn's Disease due to autophagy impairment L. Gui ¹ , E. Jones ^{1,2} , Z. Matthews ³ , P. Sudhakar ^{1,2,4} , A. Treveil ^{1,2} , D. Divekar ^{2,3} , J. Buck ³ , M. Jefferson ³ , S. Armstrong ⁵ , A. Watson ^{2,3} , S. Carding ^{2,3} , U. Mayer ⁶ , P. Powell ³ , I. Hautefort ¹ , T. Wileman ^{2,3} , T. Korcsmaros ^{1,2} ¹ Earlham Institute, Norwich, United Kingdom, ² Quadram Institute, Norwich, United Kingdom, ³ Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁴ KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ⁵ University of Liverpool, National Institute of Health Research, Liverpool, United Kingdom, ⁶ School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
16:50 - 17:00	18: OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn's Disease: The OPERA II study G. D'Haens ¹ , W. Reinisch ² , S. D. Lee ³ , D. Tarabar ⁴ , E. Louis ⁵ , M. Kłopocka ⁶ , J. Klaus ⁷ , S. Schreiber ⁸ , D. I. Park ⁹ , X. Hébuterne ¹⁰ , K. J. Gorelick ¹¹ , S. W. Martin ¹² , A. Banerjee ¹² , P. Nagy ¹³ , Y. Wang ¹⁴ , F. Cataldi ¹⁴ , W. J. Sandborn ¹⁵ ¹ Academic Medical Centre, Amsterdam, Netherlands, ² Medical University of Vienna, Vienna, Austria, ³ University of Washington, Seattle, WA, United States, ⁴ Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, ⁵ University Hospital of Liège, Liège, Belgium, ⁶ Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, ⁷ University Hospital Ulm, Ulm, Germany, ⁸ University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, ⁹ Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, ¹⁰ University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, ¹¹ Zymo Consulting Group, Newtown Square, PA, United States, ¹² Pfizer, Cambridge, MA, United States, ¹³ Shire, Zug, Switzerland, ¹⁴ Shire, Lexington, MA, United States, ¹⁵ University of California San Diego, La Jolla, CA, United States
17:00 - 17:20	19: Stratifying by disease biology to choose the right drug for the right patient Charlie Lees, Edinburgh, United Kingdom
17:30 - 18:30	Digital Oral Presentations (Sessions 1-5) See pg. 41
18:45 - 19:45	Industry sponsored satellite symposia 2a & 2b & 2c See pg. 108

OP = Oral presentation – Best abstracts

Friday, March 8, 2019*Scientific programme day by day (as of February 1, 2019)*

Plenary Hall, Hall A, Bella Center

07:15 - 08:15	Industry sponsored satellite symposia 3b & 3c See pg. 109
08:30 - 10:30	Scientific Session 4: Best practice in UC Andre D'Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel
08:30 - 08:50	20: When do you start a biologic? Simon Travis, Oxford, United Kingdom
08:50 - 09:00	21: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis L. Peyrin-Biroulet ¹ , J. Panés ² , M. Chiorean ³ , J. Zhang ⁴ , S. Vermeire ⁵ , V. Jairath ⁶ , A. Yarur ⁷ , C. Cabell ⁸ , S. Naik ⁹ , W. J. Sandborn ⁸ ¹ University Hospital of Nancy, Vandoeuvre-lès-Nancy, France, ² Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ³ Virginia Mason Medical Center, Seattle, United States, ⁴ Arena Pharmaceuticals, Inc., San Diego, United States, ⁵ University Hospitals Leuven, Leuven, Flanders, Belgium, ⁶ Western University, London, Ontario, Canada, ⁷ Medical College of Wisconsin, Milwaukee, United States, ⁸ University of California San Diego, La Jolla, United States
09:00 - 09:10	22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis J. Brooks ^{1,2} , D. Modos ³ , P. Sudhakar ^{4,5} , D. Fazekas ^{4,6} , A. Zoufir ³ , A. Watson ^{1,7} , M. Tremelling ¹ , B. Verstockt ⁸ , S. Vermeire ⁸ , A. Bender ³ , S. Carding ^{2,7} , T. Korcsmaros ^{2,4} ¹ Norfolk and Norwich University Hospital, Gastroenterology, Norwich, United Kingdom, ² The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, United Kingdom, ³ Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, United Kingdom, ⁴ Earlham Institute, Norwich Research Park, Norwich, United Kingdom, ⁵ KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ⁶ Eötvös Loránd, Department of Genetics, Budapest, Hungary, ⁷ University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ⁸ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
09:10 - 09:20	23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture K. Arnauts ^{1,2} , B. Verstockt ^{1,3} , M. Vancamelbeke ¹ , S. Vermeire ^{1,3} , C. Verfaillie ⁴ , M. Ferrante ^{1,3} ¹ KU Leuven, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Leuven, Belgium, ² KU Leuven, Department of Development and Regeneration, Leuven, Belgium, ³ KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
09:20 - 09:40	24: Where is the exit? Marc Ferrante, Leuven, Belgium

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

09:40 - 09:50	25: OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake R. Gropp ¹ , H. Jodeleit ¹ , J. Caesar ¹ , C. Villarroel Aguilera ¹ , F. Beigel ^{2,3} , S. Breiteneicher ³ , J. Stallhofer ³ , M. Siebeck ¹ ¹ Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, ² Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, ³ Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany
09:50 - 10:00	26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study K. Li , F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman Janssen Research & Development, LLC, Spring House, United States
10:00 - 10:10	27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study W. J. Sandborn ¹ , S. Schreiber ² , S. D. Lee ³ , J. O. Lindsay ⁴ , X. Hebuterne ⁵ , W. Zhou ⁶ , F. Cataldi ⁶ , A. P. Lacerda ⁶ , B. Huang ⁶ , W. Xie ⁶ , E. V. Loftus Jr ⁷ ¹ University of California San Diego, La Jolla, United States, ² University Hospital Schleswig-Holstein, Kiel, Germany, ³ University of Washington, Seattle, United States, ⁴ Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁵ Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, ⁶ AbbVie Inc., North Chicago, United States, ⁷ Mayo Clinic, Rochester, United States
10:10 - 10:30	28: Precision surgery in UC Yves Panis, Clichy, France

10:30 - 11:00 Coffee break

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

11:00 - 12:30 Scientific Session 5: IBD around the world

Toshifumi Hibi, Tokyo, Japan
Giovanni Maconi, Milan, Italy



Y-ECCO
Abstract Award

11:00 - 11:20	29: Vaccination and travelling with IBD: An update Jean-François Rahier, Yvoir, Belgium
11:20 - 11:30	30: OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy? <i>J. Burisch¹, H. Vardi², D. Schwartz³, Z. Krznaric⁴, P. L. Lakatos⁵, M. Fumery⁶, L. Kupcinskas⁷, F. Magro⁸, E. Belousova⁹, P. Oksanen¹⁰, N. Arebi¹¹, E. Langholz¹², S. Turcan¹³, R. D'Inca¹⁴, V. Hernandez¹⁵, D. Valpiani¹⁶, Z. Veghis¹⁷, M. Giannotta¹⁷, K. H. Katsanos¹⁸, D. Duricova¹⁹, K. R. Nielsen²⁰, H. A. L. Kievit²¹, P. Ellul²², R. Salupere²³, A. Goldis²⁴, I. Kaimakliotis²⁵, N. Pedersen²⁶, V. Andersen²⁷, J. Halfvarson²⁸, S. Sebastian²⁹, J. F. Dahlerup³⁰, P. Munkholm¹, S. Odes³, Epi-IBD</i> ¹ North Zealand University Hospital, Frederikssund, Denmark, ² Ben Gurion University of the Negev, Beer Sheva, Israel, ³ Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, ⁴ University Hospital Center Zagreb, Zagreb, Croatia, ⁵ Semmelweis University, Budapest, Hungary, ⁶ Amiens University and Hospital, Amiens, France, ⁷ Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁸ Hospital de São João, Porto, Portugal, ⁹ Moscow Regional Research Clinical Institute, Moscow, Russian Federation, ¹⁰ Tampere University Hospital, Tampere, Finland, ¹¹ Imperial College London, London, United Kingdom, ¹² Herlev University Hospital, Herlev, Denmark, ¹³ State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, ¹⁴ Azienda Ospedaliera di Padova, Padova, Italy, ¹⁵ Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹⁶ Morgagni Hospital, Forli, Italy, ¹⁷ Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, ¹⁸ University Hospital, Ioannina, Greece, ¹⁹ Charles University, Prague, Czech Republic, ²⁰ National Hospital of the Faroe Islands, Torshavn, Faroe Islands, ²¹ Herning Hospital, Herning, Denmark, ²² Mater Dei Hospital, Msida, Malta, ²³ Tartu University Hospital, Tartu, Estonia, ²⁴ University of Medicine 'Victor Babes', Timisoara, Romania, ²⁵ American Gastroenterology Center, Nicosia, Cyprus, ²⁶ Slagelse Hospital, Department of medicine, Denmark, ²⁷ Regional Hospital of Viborg, Viborg, Denmark, ²⁸ Örebro University, Örebro, Sweden, ²⁹ Hull and East Yorkshire NHS Trust, Hull, United Kingdom, ³⁰ Aarhus University Hospital, Aarhus, Denmark
11:30 - 11:50	31: Management of IBD outside of Europe: The example of India Rupa Banerjee, Hyderabad, India
11:50 - 12:00	32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results <i>S. Bloom¹, T. Iqbal², C. Nwokolo³, M. Smith⁴, D. O'Donoghue⁵, J. Hall⁶, Dzyngiel⁶</i> ¹ University College London Hospitals, London, United Kingdom, ² Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, ³ University Hospital Coventry & Warwickshire, Coventry, United Kingdom, ⁴ Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, ⁵ St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, ⁶ Sublimity Therapeutics, Solana Beach, United States

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

<p>12:00 - 12:10</p>	<p>33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies R. Huang¹, H. Irizar², R. Kosoy³, W.-M. Song³, A. Dinarzo³, K. Hao³, J. Rogers⁴, A. Atreja⁴, M. Mahajan³, A. Stojmirovic⁵, J. Perrigoue⁵, C. Brodmerkel⁵, S. Plevy⁶, J. Friedman⁵, J.-F. Colombel⁴, M. Dubinsky⁴, B. Sands⁴, E. Schadt³, A. Kasarskis³, B. Losic³, C. Argmann³, M. Suarez-Farinás^{1,3} ¹Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, ²University College of London, London, United Kingdom, ³Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, ⁴Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, ⁵Janssen Research & Development, Janssen Biotech, Johnson & Johnson, Spring House, United States</p>
<p>12:10 - 12:30</p>	<p>34: East meets West: Epidemiology of IBD Johan Burisch, Copenhagen, Denmark Siew Ng, Hong Kong, China</p>
<p>12:30 - 13:30 <i>Break / Guided Poster Session (Hall B)</i> See pg. 65</p>	
<p>12:40 - 13:20 <i>Educational Lunchtime Satellite Symposia LS1 & LS2 & LS3 & LS4</i> See pg. 110</p>	
<p>13:30 - 14:40 <i>Scientific Session 6: New ways of doing endoscopy and imaging in IBD</i> Hankje Escher, Rotterdam, The Netherlands Christian Maaser, Lüneburg, Germany</p>	
 <p>IIS Abstract Award</p>	<p>13:30 - 13:50 35: Assessing bowel damage in CD from adult to childhood Anne Griffiths, Toronto, Canada</p> <p>13:50 - 14:00 36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn's Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial A. Assa¹, M. Matar², D. Turner³, E. Broide⁴, B. Weiss⁵, O. Ledder⁶, A. Guz Mark⁷, F. Rinawi⁷, S. Cohen⁷, C. Topf Olivestone⁸, R. Shaoul⁹, B. Yerushalmi¹⁰, R. Shamir² ¹Schneider Children's Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, ²Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, ³Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, ⁴Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, ⁵Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, ⁶Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, ⁷Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, ⁸Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, ⁹Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, ¹⁰Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel</p> <p>14:00 - 14:20 37: Best practice in screening for dysplasia Marietta Iacucci, Birmingham, United Kingdom</p>

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center (Session 7 & 8)

	38: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis Y. Haberman ^{1, 2} , R. Karns ² , P. Dexheimer ² , M. Schirmer ³ , T. Braun ¹ , M. Collins ² , A. Mo ⁴ , M. Rosen ² , N. Gotman ⁵ , PROTECT Study group, S. Kugathasan ⁶ , T. D. Walters ⁷ , G. Gibson ⁴ , S. Davis Thomas ⁵ , C. Hutterhower ⁸ , R. J. Xavier ⁹ , J. S. Hyams ¹⁰ , L. A. Denzon ² ¹ Sheba Medical Center, Tel Hashomer, Israel, ² Cincinnati Children Hospital Medical Center, Cincinnati, United States, ³ Broad Institute of MIT and Harvard University, Cambridge, United States, ⁴ Georgia Institute of Technology, Atlanta, United States, ⁵ University of North Carolina, Chapel Hill, United States, ⁶ Emory University, Atlanta, United States, ⁷ Hospital For Sick Children, Toronto, Canada, ⁸ Harvard School of Public Health, Boston, United States, ⁹ Broad Institute of MIT and Harvard University, Boston, United States, ¹⁰ Connecticut Children's Medical Center, Hartford, United States
	39: OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn's Disease A. Lewis ¹ , R. Jeffrey ¹ , T. Kumagai ¹ , C. J. Hawkey ² , M. M. Clark ² , M. Allez ³ , J. Satangi ⁴ , G. Rogler ⁵ , A. Silver ¹ , J. O. Lindsay ⁶ ¹ Bizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, ² Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, ³ Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Paris, France, ⁴ Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ⁵ Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, ⁶ Bizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom

14:40 - 15:10 Coffee break

EITHER:

	Scientific Session 7: ECCO Fellowships and Grants (Plenary Hall, Hall A, Bella Center) Edouard Louis, Liège, Belgium Janneke van der Woude, Rotterdam, The Netherlands
--	--

	40: Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease Arie Levine, Tel Aviv, Israel
	41: Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease Sudharshan Elangovan, Thuwal, Saudi Arabia
	42: Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease Sales Ibiza, Lisbon, Portugal
	43: Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States
	44: Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease Mathieu Uzzan, Clichy, France
	45: Announcement of ECCO Fellowships & Grants 2019

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center (Session 7 & 8)

15:55 - 16:55		Scientific Session 8: IBD Horizons (Plenary Hall, Hall A, Bella Center) Dominik Bettenworth, Münster, Germany Janneke N. Samsom, Rotterdam, The Netherlands
15:55 - 16:05		46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients S. Vermeire ¹ , X. Hébuterne ² , P. Napora ³ , M. Wisniewska-Jarosinska ⁴ , G. Kiss ⁵ , A. Bourreille ⁶ , Z. Przemyslaw ⁷ , J. Nitcheu ⁸ , P. Gineste ⁸ , J.-M. Steens ⁸ , H. Ehrlich ⁸ ¹ University Hospitals Leuven, Leuven, Belgium, ² CHU Nice Hopital Archet ² , Nice, France, ³ Piotr Napora Centrum Badań Klinicznych Lekarze Sp. z o.o., Wrocław, Poland, ⁴ SANTA FAMILIA, Centrum Badań Profilaktyki i Leczenia, Łódź, Poland, ⁵ Vasútégezségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, ⁶ CHU Nantes Hotel Dieu, Nantes, France, ⁷ KO-Med, Lublin, Poland, ⁸ Abivax, Paris, France
16:05 - 16:15		47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis M. Barnhoorn ¹ , L. Plug ¹ , E. Muller-de Jonge ¹ , E. Bos ² , A. van der Meulen-de Jong ¹ , H. Verspaget ¹ , L. Hawinkels ¹ ¹ Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, ² Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands
16:15 - 16:25		48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models J. Shin ¹ , N. Ha ¹ , D. Bae ¹ , D.-h. Suh ¹ , J.-Y. Baek ¹ , J. H. Jun ¹ , Y. J. Lee ¹ , Y. I. Choi ¹ , K. H. Ryu ¹ , G. S. Youn ² , J. Park ² , S.-M. Lee ³ , S.-K. Seo ³ , J. W. Lee ⁴ , J. S. Kim ^{4,5} ¹ Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, ² Hallym University, Department of Biomedical Science, Chuncheon, South Korea, ³ Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, ⁴ Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ⁵ Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea
16:25 - 16:35		49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's Disease M. Fumery ¹ , L. Peyrin-Biroulet ² , S. Nancey ³ , R. Altwepp ⁴ , P. Veyrand ⁵ , G. Bouguen ⁶ , S. Viennot ⁷ , F. Poulleron ⁸ , J. Filippi ⁹ , A. Buisson ¹⁰ , A. Bozon ¹¹ , C. Gilletta ¹² , F. Brazier ¹³ , L. Pouillon ² , B. Flourie ¹⁴ , L. Boivineau ⁴ , L. Siproudhis ⁶ , D. Laharie ⁸ , X. Roblin ¹⁵ , X. Tretton ¹¹ ¹ Amiens University Hospital, Gastroenterology, Amiens, France, ² Nancy University Hospital, Gastroenterology, Nancy, France, ³ Lyon University Hospital, Lyon, France, ⁴ Montpellier University Hospital, Gastroenterology, Montpellier, France, ⁵ Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, ⁶ Rennes University Hospital, Gastroenterology, Rennes, France, ⁷ Caen University Hospital, Gastroenterology, Caen, France, ⁸ Bordeaux University Hospital, Gastroenterology, Bordeaux, France, ⁹ Nice University Hospital, Gastroenterology, Nice, France, ¹⁰ Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, ¹¹ Hôpital Beaujon, Gastroenterology, Clichy, France, ¹² Toulouse University Hospital, Gastroenterology, Toulouse, France, ¹³ Amiens University Hospital, Gastroenterology, Amiens, France, ¹⁴ Lyon University Hospital, Gastroenterology, Lyon, France, ¹⁵ Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center (Session 7 & 8)



IIS
Abstract Award

16:35 - 16:45	<p>50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's Disease</p> <p>E. Dreesen¹, F. Baert², D. Laharie³, P. Bossuyt⁴, Y. Bouhnik⁵, A. Buisson⁶, G. Lambrecht⁷, E. Louis⁸, B. Oldenburg⁹, B. Pariente¹⁰, M. Pierik¹¹, C. J. van der Woude¹², G. D'Haens¹³, S. Vermeire^{14, 15}, A. Gils¹</p> <p>¹University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²AZ Delta, Department of Gastroenterology, Roeselare, Belgium, ³Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, ⁴Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, ⁵Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, ⁶Estaint University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, ⁷AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, ⁸Liège University Hospital, Department of Gastroenterology, Liège, Belgium, ⁹University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ¹⁰Huriez Hospital, Lille, ¹¹University, Department of Gastroenterology and Hepatology, Lille, France, ¹²University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ¹³Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ¹⁴Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ¹⁵University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ¹⁵University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium</p>
16:45 - 16:55	<p>51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn's Disease: Final results from the GEMINI LTS study</p> <p>S. Vermeire¹, J.-F. Colombel², B. G. Feagan³, W. J. Sandborn⁴, B. E. Sands², S. Danese⁵, G. D'Haens⁶, R. Panaccione⁷, D. T. Rubin⁸, I. Shafran⁹, A. Parfionovas¹⁰, R. Rogers¹⁰, R. A. Lirio¹⁰, E. V. Loftus, Jr¹¹</p> <p>¹University Hospitals Leuven, Leuven, Belgium, ²Cahn School of Medicine at Mount Sinai, New York, United States, ³Western University, London, Canada, ⁴University of California San Diego, La Jolla, United States, ⁵Humanitas University, Milan, Italy, ⁶Academic Medical Centre, Amsterdam, Netherlands, ⁷University of Calgary, Calgary, Canada, ⁸University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, ⁹Shafran Gastroenterology Research Center, Winter Park, United States, ¹⁰Takeda Pharmaceuticals, Cambridge, United States, ¹¹Mayo Clinic College of Medicine, Rochester, United States</p>

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

C1-M4-5, Hall C, Bella Center (Session 9)

OR:

Scientific Session 9: Basic Science: Immune cells and microbes: A happy marriage?

(C1-M4-5, Hall C, Bella Center)

Tim Raine, Cambridge, United Kingdom

Raja Atreya, Erlangen, Germany

15:10 - 16:50

52: Metabolic profiling – the new player in microbiome research

Stefan Schreiber, Kiel, Germany

53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease

V. van Unen¹, N. Li¹, T. Abdelaal^{2,3}, Y. Kooy-Winkelhaar¹, L. Ouboter^{1,4}, G. Beyrend¹, T. Höltt^{5,6}, L. Mearin⁷, A. Witte⁸, H. Escher⁹, B. Lelieveldt¹⁰, F. A. van der Meulen - de Jong⁴, F. Koning¹

¹Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, ²Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, ³Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁶Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, ⁷Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, ⁸Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, ⁹Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ¹⁰Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, ¹¹Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands

15:30 - 15:40

54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis

M. Neyazi¹, N. Ilott², Oxford IBD Cohort study investigators¹, S. Travis¹, C. Arancibia¹, F. Powrie², A. Geremia¹

¹University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, ²University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom

15:40 - 15:50

55: Using mucosal immune pathways to predict disease outcome

Ahmed Hegazy, Berlin, Germany

15:50 - 16:10

56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer

L. R. Lopetuso¹, C. De Salvo², L. Di Martino², W. Goodman², F. Scaldaferri³, A. Armuzzi³, A. Gasbarrini¹, T. T. Pizarro²

¹Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrinio-Metabolical Sciences Department, Roma, Italy, ²Case Western Reserve University, Cleveland, United States, ³Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrinio-Metabolical Sciences Department, Roma, Italy

16:10 - 16:20



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

C1-M4-5, Hall C, Bella Center (Session 9)

16:20 - 16:30	<p>57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis</p> <p>K. Machiels¹, M. Ferrante^{1, 2}, N. Davani¹, A. Wolthuis³, A. D'Hoore³, S. Vermeire^{1, 2}</p> <p>¹KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, ³University Hospitals Leuven, Abdominal surgery, Leuven, Belgium</p>
16:30 - 16:50	<p>58: Resolution pathways: Next frontier to control intestinal inflammation</p> <p>Silvia D'Alessio, Milan, Italy</p>
17:05 - 18:05	<p>Digital Oral Presentations (Sessions 6 - 10)</p> <p>See pg. 41</p>
18:35-19:35	<p>Industry sponsored satellite symposia 4a & 4c & 4d</p> <p>See pg. 112</p>

OP = Oral presentation – Best abstracts



European
Crohn's and Colitis
Organisation

UR-CARE

Online
now!

United Registries for Clinical
Assessment and Research



The IBD Database for your patient records and your research studies

What to expect

- Comprehensive registry capturing demographics, environmental factors, clinical characteristics, examinations and therapeutic interventions in IBD
- Ground-breaking cross-project cooperation
- Retro- & prospective data collection and evaluation
- Autonomous data management offered to study groups
- Precise data ownership rules

Highlights

- Quality of care assessment
- High mobility & continuity of care for patients
- Different options of printable patient reports
- Sophisticated, user friendly data export
- Real-life test version
- Core paediatric & surgical variables available
- Validation study: Published in JCC

Scan and visit

www.ecco-ibd.eu/ur-care



Saturday, March 9, 2019

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

08:30 - 10:20	Scientific Session 10: The cycle of IBD life in clinical practice Glen Doherty, Dublin, Ireland Richard Russell, Glasgow, United Kingdom
08:30 - 08:50	59: Challenges in managing the elderly Guillaume Savoye, Rouen, France
08:50 - 09:00	60: OP31: TP53 mutation in human colonic organoids acquires resistance to <i>in vitro</i> long-term inflammation <i>K. Tsuchiya</i> , S. Watanabe, T. Shirasaki, R. Nishimura, N. Katsukura, S. Hibiya, R. Okamoto, T. Nakamura, M. Watanabe Tokyo Medical and Dental University and Dental University and, Tokyo, Japan
09:00 - 09:10	61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD <i>R. J. Dart</i> ^{1,2,3} , P. Vantourout ^{1,2} , P. M. Irving ³ , A. Hayday ^{1,2} ¹ King's College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, ² Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, ³ Guy's and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom
09:10 - 09:30	62: The reproductive phase: Practical recommendations Ailsa Hart, London, United Kingdom
09:30 - 09:40	63: OP33: Late-breaking Abstract
09:40 - 09:50	64: OP34: Late-breaking abstract



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

09:50 - 10:00	<p>65: OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's Disease: Long-term data from CALM</p> <p>C. Yzet¹, R. Ungaro², P. Bossuyt³, F. Baert⁴, T. Vanasek⁵, G. D'Haens⁶, V. Joustra⁶, R. Panaccione⁷, G. Novacek⁸, A. Armuzzi⁹, O. Golovchenko¹⁰, O. Prymak¹⁰, A. Goldis¹¹, S. Travis¹², X. Hébuterne¹³, M. Ferrante¹⁴, G. Rogler¹⁵, M. Fumery¹⁶, S. Danese¹⁶, G. Rydzewska¹⁷, B. Pariente¹⁸, E. Hertervig¹⁹, C. Stanciu²⁰, J.-C. Grimaud²¹, M.-M. Diculescu²², L. Peyrin-Biroulet²³, D. Laharie²⁴, J. P. Wright²⁵, F. Gomollón²⁶, I. Gubonina²⁷, S. Schreiber²⁸, S. Motoya²⁹, P. Hellström³⁰, J. Halfvarson³¹, J.-F. Colombel²</p> <p>¹Amiens University Hospital, Amiens, France, ²cahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, ³IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, ⁴AZ Delta Roeselare, Roeselare, Belgium, ⁵-nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, ⁶Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, ⁷Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁸Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ⁹Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, ¹¹Universitatea de Medicina si Farmacie, Timisoara, Romania, ¹²Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom, ¹³Gastro-Entérologie & Nutrition Clinique, Hopital de l'Archet ², Nice, France, ¹⁴University Hospitals Leuven, Leuven, Belgium, ¹⁵Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, ¹⁶Humanitas University, Istituto Clinico Humanitas, Milan, Italy, ¹⁷Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, ¹⁸Claude Huriez Hospital, Lille University, Lille, France, ¹⁹Skane University Hospital, Lund, Sweden, ²⁰Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, ²¹Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, ²²University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²³Hôpital Gastro-Entérologie, Hôpital de Brabois, Nancy, France, ²⁴Hépato-gastroentérologie et d'oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, ²⁵Kingsbury Hospital, Cape Town, South Africa, ²⁶Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain, ²⁷Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, ²⁸Department of Internal Medicine I, Kiel University, Kiel, Germany, ²⁹IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, ³⁰Uppsala University Hospital, Uppsala, Sweden, ³¹Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden</p>
10:00 - 10:20	<p>66: Cancer risk in children with IBD, an under-recognised issue</p> <p>Arie Levine, Tel Aviv, Israel</p>

10:20 - 10:50 Coffee break

OP = Oral presentation – Best abstracts

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

10:50 - 12:20	Scientific Session 11: Towards the future of IBD Nik Sheng Ding, Melbourne, Australia Marc Ferrante, Leuven, Belgium
10:50 - 11:10	67: Artificial intelligence augmenting medical management Vishal Nangalia, London, United Kingdom
11:10 - 11:20	68: OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease T. Sato ¹ , K. Li ¹ , K. Hayden ¹ , L. Tomsho ¹ , F. Baribaud ¹ , C. Brodmerkel ¹ , L. E. Greenbaum ¹ , J. R. Friedman ¹ , M. Curran ¹ , Y. Imai ² , S. Plevy ¹ , S. E. Telesco ¹ ¹ Janssen Research & Development, LLC, Spring House, United States, ² Janssen Pharmaceutical K.K., Tokyo, Japan
11:20 - 11:40	69: Robot and surgeon: How will a partnership work? Antonino Spinelli, Milan, Italy
11:40 - 11:50	70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI W. J. Sandborn ¹ , B. E. Sands ² , R. Panaccione ³ , C. D. O'Brien ⁴ , H. Zhang ⁴ , J. Johanns ⁴ , L. Peyrin-Biroulet ⁵ , G. Van Assche ⁶ , S. Danese ⁷ , S. R. Targan ⁸ , M. T. Abreu ⁹ , T. Hisamatsu ¹⁰ , P. Szapary ⁴ , C. Marano ⁴ ¹ University of California San Diego, La Jolla, United States, ² Cahn School of Medicine at Mount Sinai, New York, United States, ³ University of Calgary, Calgary, Canada, ⁴ Janssen Research & Development, LLC, Spring House, United States, ⁵ Nancy University Hospital, Université de Lorraine, Nancy, France, ⁶ University of Leuven, Leuven, Belgium, ⁷ Humanitas Research Hospital, Milan, Italy, ⁸ Cedars-Sinai Medical Center, Los Angeles, United States, ⁹ University of Miami Miller School of Medicine, Miami, United States, ¹⁰ Kyorin University, Tokyo, Japan
11:50 - 12:00	71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis G. R. D'Haens ¹ , W. J. Sandborn ² , M. Ferrante ³ , B. R. Bhandari ⁴ , E. Berliba ⁵ , T. Hib ⁶ , J. Tuttle ⁷ , J. B. Canavan ⁸ , S. Friedrich ⁸ , M. Durante ⁹ , V. Arora ⁸ , B. Feagan ⁹ ¹ Amsterdam University Medical Centers, Amsterdam, Netherlands, ² University California San Diego, La Jolla, California, United States, ³ UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ⁴ Delta Research Partners, LLC, Bastrop, LA, United States, ⁵ Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, ⁶ Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, ⁷ Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, ⁸ Eli Lilly and Company, Indianapolis, Indiana, United States, ⁹ Western University, Robarts Clinical Trials Inc, London, Ontario, Canada
12:00 - 12:20	72: Big data: Potential for transforming IBD research and care Ignacio Hernandez-Medrano, Madrid, Spain

OP = Oral presentation – Best abstracts

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)
Plenary Hall, Hall A, Bella Center

12:20 - 12:50	Scientific Session 12: ECCO Lecture Silvio Danese, Milan, Italy Laurent Peyrin-Biroulet, Vandoeuvre-Les-Nancy, France
12:20 - 12:50	73: ECCO Lecture: Inflammatory cytokines from discoveries to therapies Charles Dinarello, Denver, United States
12:50 - 12:55	74: Awards and closing remarks Silvio Danese, Milan, Italy
12:55 - 13:00	75: The ECCO Film

OP = Oral presentation – Best abstracts



European
Crohn's and Colitis
Organisation

Copenhagen
Denmark

Abstracts 2019



Contains all ECCO'19 Abstracts

ECCO Key USB Drive

- Pick up at ECCO Booth

Helmet shaped USB Drive

- Pick up at Booth #17
- Limited number only

Please be aware that upon receiving your special shaped USB key in the Exhibition hall, the sponsor will collect your name, city, country, affiliation and email address.

Scan and contact the ECCO Office
www.ecco-ibd.eu



Abstract presentation format

Oral presentations (OP)

Out of 1228 submitted abstracts the 38 best submitted abstracts have carefully been chosen by a panel of referees and selected for oral presentation during the scientific programme. For the presentation schedule, please refer to the scientific programme on pg. 19.

Note: Oral poster presentations will not be displayed as hard copy posters.

Digital oral presentations (DOP)

After the 38 selected for oral presentations in the scientific programme, the following 90 best abstracts are selected as digital oral presentations. Each author of an abstract accepted under this category is invited to hold a 5-minute oral presentation in one of ten Digital Oral Presentation sessions.

DOP sessions 1-5 run parallel on Thursday, March 7, 2019 from 17:30 to 18:30. DOP Sessions 6-10 run parallel on Friday, March 8, 2019 from 17:05-18:05. You can find a detailed schedule of all DOP sessions on pg. 41.

Note: Digital oral presentations will not be displayed as hard copy posters.

DOP award ceremony:

On Saturday, March 9, 2019 from 12:50 to 12:55 the DOP prizes will be awarded to the "Top Ten Best DOPs". One abstract of each digital oral presentation room will be nominated for this award by the chairs of the respective sessions.

Please note that this is the 9th year that the ECCO Congress hosts a separate nurse poster section in the poster exhibition area located in Hall B. Please find the link to nurse posters on pg. 68.

DOP award ceremony is chaired by:

Silvio Danese (Italy)

Laurent Peyrin-Biroulet (France)

Willem Bemelman (The Netherlands)

Janneke van der Woude (The Netherlands)

Antonio López-Sanromán (Spain)

Hard copy poster presentations

Authors of accepted abstracts which are not OPs or DOPs are invited to present their studies as hard copy poster presentations. For details regarding the poster exhibition, visit the ECCO Website at www.ecco-ibd.eu/ecco19. An overview of the abstract topics with a link to the respective hard copy posters can be found on pg. 67. Hard copy posters will be installed on poster walls in the poster exhibition area in Hall B and will be available for viewing throughout the Congress.

Reviewers

ECCO gratefully thanks the following reviewers for their valuable time and efforts in reviewing abstracts submitted to ECCO'19:

(i) Basic Science

Giorgio Bamias (Greece), Mathilde Body (France), Paula Borralho Nunes (Portugal), Gerhard Rogler (Switzerland), Azucena Salas (Spain), Franco Scaldaferri (Italy), Michael Scharl (Switzerland), Anja Schirbel (Germany), Dror Shouval (Israel), Heitor Siffert de Souza (Brazil), Monika Tripathi (United Kingdom), Holm Uhlig (United Kingdom), Dominique Velin (Switzerland), David Bernardo (Spain), Jesús Cosín (Spain), George Kolios (Greece), Elias Kouroumalis (Greece), Daniel Marks (United Kingdom), Saurabh Mehandru (United States), Luis Menchen (Spain), Marie-Alice Meuwis (Belgium), Salomé Pinho (Portugal)

(ii) Clinical: Diagnosis and Outcome

Matthieu Allez (France), Marina Aloia (Italy), Vito Annese (Italy), Raja Atreya (Germany), Oliver Bachmann (Germany), Filip Baert (Belgium), Manuel Barreiro de Acosta (Spain), Shomron Ben-Horin (Israel), Dominik Bettenworth (Germany), Bernd Bokemeyer (Germany), Yoram Bouchnik (France), Daniel Burger (Australia), Emma Calabrese (Italy), Andrea Cassinotti (Italy), Fabiana Castiglione (Italy), Cristina Cjevski (Romania), Francesco Colombo (Italy), Marilia Cravo (Portugal), Silvio Danese (Italy), Gert De Hertogh (Belgium), Lissy de Ridder (The Netherlands), Vincenza Di Leo (Italy), Mircea Diculescu (Romania), Glen Doherty (Ireland), Eugeni Domènech (Spain), Tomas Douda (Czech Republic), David Drobne (Belgium), Martin Goetz (Germany), Gwo-Tzer Ho (United Kingdom), Marietta Iacucci (United Kingdom), Njegica Jovic (Serbia), Philippe Marteau (France), Florian Rieder (United States), Jordi Rimola (Spain), Richard Russell (United Kingdom), Hagit Tulchinsky (Israel), Patrick Van Rheenen (The Netherlands), Francesca Maccioni (Italy), Giovanni Maconi (Italy), Pasquale Paolantonio (Italy), Dina Tiniakos (Greece), Christos Zavos (Greece), Francesca Rosini (United Kingdom)

(iii) Clinical: Therapy and Clinical Observation

Antonio Di Sabatino (Italy), Nick Kennedy (United Kingdom), Ioannis Papaconstantinou (Greece), Juris Pokrotnieks (Latvia), Frank Werner Seibold (Switzerland), Albert Wolthuis (Belgium), Alessandro Armuzzi (Italy), Willem Bemelman (The Netherlands), Franck Carbonnel (France), Mario Cottone (Italy), Joline de Groot (The Netherlands), Laurence Egan (Ireland), Hankje Escher (The Netherlands), Marc Ferrante (Belgium), Gionata Fiorino (Italy), Mayur Garg (Australia), Kristina Gecse (Hungary), Ann Gils (Belgium), Daniel Ginard Vicens (Spain), Paolo Gionchetti (Italy), Javier Perez Gisbert (Spain), Adrian Goldis (Romania), Dieter Hahnloser (Switzerland), Jonas Halfvarson (Sweden), Ailsa Hart (United Kingdom), Joaquin Hinjoosa (Spain), Christoph Högenauer (Austria), Samuel Huber (Germany), Peter Irving (United Kingdom), Guru lyngkaran (Australia), Laimas Jonaitis (Lithuania), Pascal Juillerat (Switzerland), Konstantinos Karmiris (Greece), Konstantinos Katsanos (Greece), Robert Koch (Austria), Pavel Kohout (Czech Republic), Uri Kopylov (Canada), Paulo Kotze (Brazil), Iskren Kotzev (Bulgaria), Ioannis Koutroubakis (Greece), Zeljko Krznaric (Croatia), David Laharie (France), Peter Lakatos (Hungary), Ebbe Langholz (Denmark), Charlie W. Lees (United Kingdom), Jimmy Limdi (United Kingdom), James Lindsay (United Kingdom), Loris Riccardo Lopetuso (Italy), Eduard Louis (Belgium), Fernando Magro (Portugal), Nitsan Mahershak (Israel), John Mansfield (United Kingdom), Gerassimos Mantzaris (Greece), Pierre Michetti (Switzerland), Paula Ministro (Portugal), Tamas Molnar (Hungary), Bjorn Moum (Norway), Pär Myrelid (Sweden), Gottfried Novacek (Austria), Tom Oresland (Norway), Julian Panes (Spain), Yves Panis (France),

Konstantinos Papadakis (Greece), Konstantinos Papamichail (Greece), Gareth Parkes (United Kingdom), Harald Peeters (Belgium), Guillaume Pineton de Chambrun (France), Valérie Pittet (Switzerland), Tim Raine (United Kingdom), Zhihua Ran (China), Catherine Reenaers (Belgium), Jonathan Rhodes (United Kingdom), Elena Ricart (Spain), Xavier Roblin (France), Simone Saibeni (Italy), Bruce Sands (United States), Shaji Sebastian (United Kingdom), Nik Sheng Ding (Australia), Britta Siegmund (Germany), Andreas Stallmach (Germany), Andreas Sturm (Germany), Dino Tarabar (Serbia), Herbert Tilg (Austria), Simon Travis (United Kingdom), John Triantafillidis (Greece), Dan Turner (Israel), Janneke van der Woude (The Netherlands), Stephan Vavricka (Switzerland), Bram Verstockt (Belgium)

(iv) Epidemiology

Nynne Nyboe Andersen (Denmark), Marte Lie Hoivik (Norway), Jonas Ludvigsson (Sweden), Ola Olén (Sweden), Marko Banic (Croatia), Johan Burisch (Denmark), Silvija Cukovic Cavka (Croatia), Hannah Gordon (United Kingdom), Tine Jess (Denmark), Richard Pollok (United Kingdom), Guillaume Savoye (France), Marco Scarpa (Italy), Morten Vatn (Norway), Gabor Veres (Hungary), Ida Vind (Denmark), David Wilson (United Kingdom)

(v) Genetics

Isabelle Cleynen (Belgium), Maria Gazouli (Greece), Debby Laukens (Belgium), Maikel Peppelenbosch (The Netherlands)

(vi) Microbiology

Christine Edwards (United Kingdom), Gwenny Fuhler (The Netherlands), Charlotte Hedin (Sweden), Kathleen Machiels (Belgium), Philippe Seksik (France), Harry Sokol (France), Markus Tschurtschenthaler (Austria)

(vii) Nurses abstracts

Wladzia Czuber-Dochan (United Kingdom), Kay Greveson (United Kingdom), Petra Hartmann (Germany), Karen Kemp (United Kingdom), Jochen Maul (Germany), Marian O'Connor (New Zealand)



European
Crohn's and Colitis
Organisation

Why submit your research to JCC?



Prompt and professional peer review

JCC publishes research that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendations by independent reviewers. The average time from submission to first decision is two weeks.

Fast publication speeds

- Fast Advance Access publication of the author manuscript version within one week of acceptance making your work discoverable faster.

High Impact Factor

- With its 2017 Impact Factor, which now stands at 6.637, JCC ranks highly among gastroenterology and hepatology journals.

Wide dissemination

- Publishing in JCC will ensure that your article will be seen, read and cited by your research community.

Scan and log in at

www.ecco-ibd.eu



Digital oral presentations (DOP)

Thursday March 7, 2019 17:30-18:30	Digital Oral Presentation Sessions 1-5	C1 Rooms, Hall C
Friday, March 8, 2019 17:05-18:05	Digital Oral Presentation Sessions 6-10	C1 Rooms, Hall C

Please find an overview of all DOP sessions below. A detailed schedule including selected abstracts for each digital oral presentation room can be found on the pages listed in the table.

Digital Oral Presentation Session 1 (please refer to page 42)	Advances in IBD pathophysiology Room: C1 M1 Javier Gisbert, Madrid, Spain Maximilian Waldner, Erlangen, Germany
Digital Oral Presentation Session 2 (please refer to page 43)	Mechanisms of intestinal inflammation Room: C1 M0 Loris Riccardo Lopetuso, Rome, Italy Britta Siegmund, Berlin, Germany
Digital Oral Presentation Session 3 (please refer to page 45)	Translational science in IBD Room: C1 M2 Peter Bossuyt, Bonheiden, Belgium Axel Dignass, Frankfurt, Germany
Digital Oral Presentation Session 4 (please refer to page 47)	Practicalities of IBD patient care Room: C1 M3 Uri Kopylov, Tel Aviv, Israel Fernando Magro, Porto, Portugal
Digital Oral Presentation Session 5 (please refer to page 50)	Old and new treatment Room: C1 M4-5 Paolo Gionchetti, Bologna, Italy Anne Strik, Amsterdam, The Netherlands
Digital Oral Presentation Session 6 (please refer to page 53)	Novel treatments Room C1 M4-5 Marc Ferrante, Leuven, Belgium Gionata Fiorino, Rome, Italy
Digital Oral Presentation Session 7 (please refer to page 55)	Recent advances of biologic therapies Room: C1 M3 Filip Baert, Roeselare, Belgium Shomron Ben-Horin, Ramat Gan, Israel
Digital Oral Presentation Session 8 (please refer to page 57)	Intestinal healing Room: C1 M2 Raja Atreya, Erlangen, Germany Marietta Iacucci, Birmingham, United Kingdom
Digital Oral Presentation Session 9 (please refer to page 59)	Surgery and IBD Room: C1 M1 Paulo Kotze, Curitiba, Brazil Andre D'Hoore, Leuven, Belgium
Digital Oral Presentation Session 10 (please refer to page 62)	Clinical epidemiology Room: C1 M0 Stefanos Bonovas, Milan, Italy Johan Burisch, Copenhagen, Denmark

Digital oral presentations

Please find the detailed schedule for each session on the following pages:

Thursday, March 7, 2019

17:30 - 18:30	Digital Oral Presentation Session 1 – Advances in IBD pathophysiology Room: C1 M1 Javier Gisbert, Madrid, Spain Maximilian Waldner, Erlangen, Germany
17:30 - 17:36	DOP01: Extracellular nicotinamide phosphoribosyltransferase (eNAMPT): possible new target and biomarker in Inflammatory Bowel Diseases G. Colombo ¹ , C. Travelli ¹ , C. Porta ¹ , G. Stocco ² , F. Malavasi ³ , A. A. Genazzani ¹ ¹ Università del Piemonte Orientale, Department of Pharmaceutical Sciences UNIUPO, Novara, Italy, ² Università degli studi di Trieste, Department of Chemical and Pharmaceutical Sciences, Trieste, Italy, ³ Università degli Studi di Torino, Department of Medical Science, Torino, Italy
17:36 - 17:42	DOP02: Supplementation with butyrate producing bacteria reduces tumor load in a mouse model of Colitis associated cancer A. Montalban Arques ¹ , I. Olivares Rivas ¹ , K. Attrott ¹ , C. Gottier ¹ , S. Lang ¹ , G. Leventhal ² , T. DeWouters ³ , M. Scharl ¹ , M. Spalinger ¹ ¹ University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, ² Massachusetts Institute of Technology, Department of Civil and Environmental Engineering, Cambridge, United States, ³ Pharmabiome, Zurich, Switzerland
17:42 - 17:48	DOP03: The correlation of regulatory miRNAs with cytokine serum levels and cytokine genes' polymorphisms A. Surowiecka-Pastewka ^{1,2} , M. Zagozda ² , E. Zakościelna ² , M. Durlik ^{1,2} ¹ CSK Ms wiia, Department of Gastroenterological Surgery and Transplantation, Warsaw, Poland, ² Mossakowski Medical Research Centre of the Polish Academy of Sciences, Department of Surgical Research and Transplantology, Warsaw, Poland
17:48 - 17:54	DOP04: The ability of epithelial regeneration is reduced in the Crohn's Disease patient-derived organoids, especially in TNF-α enriched condition J. H. Song, S. N. Hong , G. Seong, T. J. Kim, E. R. Kim, D. K. Chang, Y.-H. Kim, C. Lee, C. Lee Samsung Medical Center, Seoul, South Korea
17:54 - 18:00	DOP05: Adipose-derived stem cells from Crohn's Disease patients show antigen presenting cell-like properties C. Serena ¹ , M. Terrón-Puig ¹ , M. Ejárque ¹ , F. Algabe-Chueca ¹ , E. Maymó-Masip ¹ , M. Millan ² , M. Menacho ³ , E. Espín ⁴ , M. Martí ⁴ , S. Fernández-Veleido ¹ , J. Vendrell ¹ ¹ Health Institute Pere Virgili, Hospital Joan XXIII, Tarragona, Spain, ² Hospital Joan XXIII, Colorectal Surgery Unit, Tarragona, Spain, ³ Hospital Joan XXIII, Digestive Unit, Tarragona, Spain, ⁴ Hospital Vall Hebrón, Colorectal Surgery Unit, General Surgery Service, Barcelona, Spain
18:00 - 18:06	DOP06: Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in Ulcerative Colitis and may predict response to vedolizumab therapy S. Hermangild Kottoor ¹ , Z. Kassam ¹ , P. Pavlidis ^{1,2} , E. Alberts ¹ , H. Ibraheim ^{1,2} , L. Constable ¹ , J. Digby-Bell ¹ , D. Warren ² , S. Odukwe ² , M. Samaan ² , P. Irving ² , J. Sanderson ² , N. Powell ^{1,2} ¹ King's College London, School of Immunology and Microbial Sciences, London, United Kingdom, ² Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
18:06 - 18:12	DOP07: IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases M. Angin , C. Brignone, F. Triebel Immutep, Orsay, France

Thursday, March 7, 2019, cont.

18:12 - 18:18	<p>DOP08: The regulatory landscape of intestinal cells – investigating the transcriptional effect of autophagy impairment observed in Crohn's Disease using organoid and network biology approaches</p> <p>A. Treveil^{1,2}, P. Sudhakar^{1,3}, Z. Matthews⁴, T. Wrzesinski⁴, E. Jones^{1,2}, P. Powell⁴, T. Wileman^{2,4}, I. Hautefort¹, L. Hall², F. Di Palma¹, W. Haerty¹, T. Korcsmaros^{1,2}</p> <p>¹Earlham Institute, Norwich, United Kingdom, ²Quadram Institute, Norwich, United Kingdom, ³Catholic University of Leuven, Translational Research in Gastrointestinal Disorders, Leuven, Belgium, ⁴University of East Anglia, Norwich Medical School, Norwich, United Kingdom</p>
18:18 - 18:24	<p>DOP09: Interleukin-20 subfamily cytokines in controlling intestinal inflammation and epithelial barrier integrity</p> <p>M. Moniruzzaman^{1,2}, R. Wang², K. Wong², H. Tong², M. McGuckin³, S. Hasnain^{1,2}</p> <p>¹Faculty of Medicine, The University of Queensland, Brisbane, Australia, ²Immunopathology Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia</p>

17:30 - 18:30 Digital Oral Presentation Session 2 – Mechanisms of intestinal inflammation Room: C1 M0 Loris Riccardo Lopetuso, Rome, Italy Britta Siegmund, Berlin, Germany	
17:30 - 17:36	<p>DOP10: Serum N-glycomic biomarkers predict treatment escalation in Inflammatory Bowel Disease</p> <p>A. Shubhakar¹, B. Jansen¹, A. Adams², K. Reiding³, N. Ventham⁴, D. Bergmalm⁵, P. Urbanowicz¹, R. Gardner¹, IBD-BIOM Consortium, J. Halfvarson⁶, J. Satsangi², D. Fernandes¹, M. Wuhrer¹, D. Spencer¹</p> <p>¹Ludger Ltd, Abingdon, United Kingdom, ²University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, ³Utrecht University, Division of Biomolecular Mass Spectrometry, Utrecht, Netherlands, ⁴University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, ⁵Orebro University, Department of Gastroenterology, Örebro, Sweden, ⁶Örebro University, Örebro, Sweden, ⁷Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, Netherlands</p>
17:36 - 17:42	<p>DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in Ulcerative Colitis</p> <p>S. Slevin¹, M. Tan¹, C. Lahiff¹, L. M. Wang², B. Greenaway¹, K. Lynch¹, A. Geremia¹, S. Hughes³, K. Leavens³, K. Nevin³, D. J. B. Marks³, R. Tarzi³, N. Srinivasan³, S. Travis¹, C. Arancibia¹, S. Keshav¹</p> <p>¹University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, ²Changi General Hospital, SingHealth, Department of Laboratory Medicine, Singapore, Singapore, ³GlaxoSmithKline, Experimental Medicine Unit, Stevenage, United Kingdom</p>
17:42 - 17:48	<p>DOP12: Mutations in the X-linked inhibitor of apoptosis protein promote susceptibility to microbiota-induced intestinal inflammation</p> <p>S. Gopalakrishnan^{1,2}, Y. Zeissig², A. Strigli¹, M. Basic³, J. Hartwig², J. Wang⁴, M. Muders⁵, G. Barreton⁵, J. F. Baines⁴, A. Bleich³, J. Hampe^{1,5}, S. Zeissig^{1,2,5}</p> <p>¹Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany, ²University Hospital Schleswig-Holstein, Kiel, Germany, ³Hannover Medical School, Hannover, Germany, ⁴Max-Planck Institute for Evolutionary Biology, Kiel, Germany, ⁵University Hospital Carl-Gustav Carus, Dresden, Germany</p>

Thursday, March 7, 2019, cont.

17:48 - 17:54	DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD) M. Letizia ¹ , Y. Rodriguez Sillke ¹ , F. Schmidt ¹ , C. Günther ² , D. Kunkel ³ , R. Glauben ¹ , B. Siegmund ¹ , C. Weidinger ¹ ¹ Charité - Universitätsmedizin Berlin, Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany, ² Universitätsklinikum Erlangen, Gastroenterologie, Erlangen, Germany, ³ Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
17:54 - 18:00	DOP14: TiO₂ nanoparticles abrogate the protective effect of the autoimmunity-associated PTPN22^{R61Q/W} variant during acute DSS Colitis M. Schwarzfischer , L. Hering, E. Katkeviciute, A. Niechcial, K. Atrott, K. Bäbler, P. Busenhart, G. Rogler, M. Scharl, M. Spalinger University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland
18:00 - 18:06	DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naïve Ulcerative Colitis patients J. Diab ¹ , T. Hansen ¹ , R. Goll ² , E. Jensen ¹ , T. Moritz ³ , J. Florholmen ⁴ , G. Forsdahl ¹ ¹ Natural Products and Medicinal Chemistry Research Group, Department of pharmacy, University of Tromsø The Arctic University of Norway, Tromsø, Norway, ² Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Tromsø, Norway, ³ Swedish Metabolomics Center, Swedish University of Agricultural Sciences, Umeå, Sweden, ⁴ Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, Tromsø, Norway
18:06 - 18:12	DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn's Disease C. Li , J. Kuemmerle Virginia Commonwealth University, Internal Medicine, Richmond, United States
18:12 - 18:18	DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD) M. Wang ¹ , T. John ² , L. Zhang ¹ , L. Zhu ¹ , Y. Xu ¹ , K. Chen ¹ , S. Han ¹ , J. Li ¹ , F. Wang ¹ , C. Deceneux ^{3,4} , A. Behren ^{3,4} , Z. Yang ¹ ¹ Dizal (Jiangsu) Pharmaceutical Co., Ltd, Shanghai, China, ² Austin Health, Heidelberg, Australia, ³ Olivia Newton-John Cancer Research Institute, Heidelberg, Australia, ⁴ La Trobe University, School of Cancer Medicine, Heidelberg, Australia
18:18 - 18:24	DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production A. Vossenkamper ¹ , K. Foster ² , K. Nevin ² , G. Tannahill ² , S. Flint ² , T.T. McDonald ¹ ¹ Blizard Institute, Barts and the London School of Medicine and Dentistry, Immunobiology, London, United Kingdom, ² GlaxoSmithKline, Immunoinflammation Unit, Stevenage, United Kingdom

Thursday, March 7, 2019, cont.

Digital Oral Presentation Session 3 – Translational science in IBD

17:30 - 18:30

Room: C1 M2

 Peter Bossuyt, Bonheiden, Belgium
 Axel Dignass, Frankfurt, Germany

17:30 - 17:36	DOP19: Spermidine treatment ameliorates experimental Colitis in vivo A. Niechcial¹, E. Katkeviciute¹, L. Hering¹, M. Wawrzyniak¹, M. Schwarzfischer¹, K. Bäbler¹, K. Attrrot¹, M. Scharl^{1,2}, M. R. Spalinger¹ ¹ University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, ² University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland
17:36 - 17:42	DOP20: Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of structuring Crohn's Disease A. Lewis¹, A. Nijhuis¹, G. Bertl¹, C. Felice², R. Jeffrey¹, S. Iqbal¹, A. B. Pomeranc¹, S. Aldelemi³, S. Mehta¹, E. Giannoulatou³, R. Feakins¹, A. Armuzzi², J. O. Lindsay³, A. Silver¹ ¹ Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, ² IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ³ Victor Chang Cardiac Research Institute and ⁴ St Vincent's Clinical School, University of New South Wales, Sydney, Australia, ⁴ Department of Histopathology, The Royal London Hospital, London, United Kingdom, ⁵ Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom
17:42 - 17:48	DOP21: This abstract has been withdrawn.
17:48 - 17:54	DOP22: UC-related and segment-specific properties of patient-derived colonic organoids K. Suzuki¹, H. Shimizu¹, M. Kawai¹, J. Takahashi¹, S. Anzai¹, A. Kawamoto¹, S. Nagata¹, Y. Hiraguri¹, S. Yui¹, K. Tsuchiya¹, T. Nakamura¹, K. Ohtsuka¹, R. Okamoto¹, M. Watanabe¹ ¹ Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan
17:54 - 18:00	DOP23: Myenteric plexitis and post-operative recurrence in Crohn's Disease: The role of enteric glial cells and ICAM-1 C. Le Berre¹, J. Pabois¹, T. Durand¹, E. Durieu¹, M. Rolli-Derkinderen¹, C. Bossard², J. Podevin³, M. Neunlist¹, I. Neveu¹, P. Naveilhan¹, A. Bourreille^{1,4} ¹ Nantes University Hospital, UMR Inserm 1235 - TENS, Gastroenterology department, Institut des Maladies de l'Appareil Digestif, Nantes, France, ² Nantes University Hospital, Pathology department, Nantes, France, ³ Nantes University Hospital, Digestive surgery department, Institut des Maladies de l'Appareil Digestif, Nantes, France, ⁴ Nantes University Hospital, CIC, INSERM 1413, Nantes, France
18:00 - 18:06	DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis B. Weder¹, W. T. Van Haften², K. Baebler¹, G. Rogler³, G. Dijkstra⁴, P. H. Imenez Silva⁵, Y. Wang⁵, C. De Vallière³, C. Wagner⁵, I. Frey-Wagner³, K. Seuwen⁶, P. Ruiz³, M. Hausmann³ ¹ University of Zurich, Zurich, Switzerland, ² University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ³ University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, ⁴ University of Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ⁵ University of Zurich, Institute of Physiology, Zurich, Switzerland, ⁶ Novartis Institutes for Biomedical Research, Basel, Switzerland

Thursday, March 7, 2019, cont.

18:06 - 18:12	<p>DOP25: Unravelling vedolizumab mechanism of action in Ulcerative Colitis</p> <p>M. Veny¹, A. Garrido¹, H. Bassolas-Molina¹, M. C. Masamunt¹, M. Esteller¹, M. Arroyes¹, A. M. Corraliza¹, E. Tristán², A. Fernández-Clotet¹, I. Ordás¹, E. Ricart¹, M. Esteve², J. Panés¹, A. Salas¹</p> <p>¹IDIBAPS, Hospital Clínic, CIBERehd, Department of Gastroenterology, Barcelona, Spain, ²Hospital Universitari Mutua Terrassa, Department of Gastroenterology, Terrassa, Spain</p>
18:12 - 18:18	<p>DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients</p> <p>B. Creyns^{1,2}, B. Verstockt^{2,3}, J. Cremer^{1,2}, V. Ballet³, M. Ferrante^{2,3}, S. Vermeire^{2,3}, J. Ceuppens¹, G. Van Assche^{2,3}, C. Breyneert¹</p> <p>¹KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium, ²KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium</p>
18:18 - 18:24	<p>DOP27: Late-breaking Abstract</p>

Thursday, March 7, 2019, cont.

Digital Oral Presentation Session 4 – Practicalities of IBD patient care
17:30 - 18:30

 Room: C1 M3
 Uri Kopylov, Tel Aviv, Israel
 Fernando Magro, Porto, Portugal

DOP28: Maternal obstetric outcomes in women with IBD compared to the general population
G. Lever¹, T. Glanville¹, C. Selinger²
¹Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom

17:30 - 17:36

DOP29: Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF or conventional therapy
A. Moens^{1,2}, C. van der Woude³, M. Julsgaard⁴, S. Sebastian^{5,6}, N. Arebi⁷, M. Alzinaty⁸, E. Humblet⁸, K. B. Kok⁹, J. Sheridan¹⁰, C. Gillette De Saint-Joseph¹¹, S. Nancey¹², J.-F. Rahier¹³, P. Bossuyt¹⁴, A. Cremer¹⁵, S. Dewit¹⁶, C. Eriksson¹⁷, F. Hoentjen¹⁸, T. Krause¹⁹, E. Louis²⁰, E. Macken²¹, Z. Milenkovic²², J. Nijs²³, A. Posen²⁴, A. Van Hootegem²⁵, W. Van Moerkerke²⁶, S. Vermeire^{1,2}, A. Bar-Gil Shitrit²⁷, M. Ferrante^{1,2}
¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²Catholic University Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ³Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ⁴Aarhus University Hospital, Department of Gastroenterology and Hepatology, Aarhus, Denmark, ⁵Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom, ⁶University of Hull & York, Hull York Medical School, Hull, United Kingdom, ⁷St. Marks Hospital, Department of Gastroenterology, London, United Kingdom, ⁸Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, ⁹Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom, ¹⁰St. Vincent's University Hospital, Department of Gastroenterology, Dublin, Ireland, ¹¹Hôpital Rangueil, Department of Gastroenterology, Toulouse, France, ¹²CHU Lyon, Department of Gastroenterology and Hepatology, Lyon, France, ¹³CHU UCL Namur, Université catholique de Louvain, Department of Gastroenterology, Yvoir, Belgium, ¹⁴Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, ¹⁵Hôpital Erasme, Université Libre de Bruxelles, Department of Gastroenterology, Brussels, Belgium, ¹⁶Mariaziekenhuis Noord-Limburg, Department of Gastroenterology, Overpelt, Belgium, ¹⁷Faculty of Medicine and Health Orebro University, Department of Gastroenterology, Örebro, Sweden, ¹⁸Radboud UMC, Department of Gastroenterology, Nijmegen, Netherlands, ¹⁹Opernstrasse, Department of Gastroenterology, Kassel, Germany, ²⁰CHU Liège, Department of Gastroenterology, Liège, Belgium, ²¹Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, ²²Military Medical Academy Belgrade, Department of Gastroenterology, Belgrade, Serbia, ²³Sint-Trudo Ziekenhuis, Department of Gastroenterology, St-Truiden, Belgium, ²⁴AZ Vesalius, Department of Gastroenterology, Tongeren, Belgium, ²⁵AZ Klinika, Department of Gastroenterology, Brasschaat, Belgium, ²⁶AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, ²⁷Shaare Zedek Medical Center, Hebrew University Jerusalem, Digestive diseases institute, Jerusalem, Israel

17:36 - 17:42

DOP30: Factors associated with life satisfaction in people with Crohn's Disease and Ulcerative Colitis: Results from the national 2018 Crohn's and Colitis UK Inflammatory Bowel Disease Quality of Life Survey
G. Rowse¹, S. Hollobone², S. Afhim², P. Oliver³
¹University of Sheffield, Clinical Psychology Unit, Sheffield, United Kingdom, ²Crohn's and Colitis UK, St Albans, United Kingdom,

³University of Sheffield, Academic Unit of Primary Medical Care, Sheffield, United Kingdom

17:42 - 17:48

Thursday, March 7, 2019, cont.

17:48 - 17:54	<p>DOP31: Development and validation of the IBD-REFER criteria: When should a general practitioner or paediatrician refer a patient for suspected IBD?</p> <p>O. Atia¹, G. Focht¹, A. Assa², B. Yerushalmi³, R. Shaoul⁴, D. S. Shouval⁵, A. Bar-Gil Shitrit⁶, B. Koslowsky⁶, I. Dotan⁷, R. Kariv⁸, E. Lavon⁸, D. Turner¹</p> <p>¹Institute of Pediatric Gastroenterology, The Hebrew University of Jerusalem, Jerusalem, Israel, ²Schneider Children's Hospital, Petach Tikva, Israel, ³Soroka University Medical Center and Faculty of Pediatric Gastroenterology Unit, Health Sciences, Beer-Sheva, Israel, ⁴Pediatric Gastroenterology Institute, Ruth Children's Hospital, Rambam Medical Center, Haifa, Israel, ⁵Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat gan, Israel, ⁶Digestive diseases institute, Shaare Zedek Medical Center, Jerusalem, Israel, ⁷Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Petach Tikva, Israel, ⁸Health Division, Maccabi Healthcare Services, Jerusalem, Israel</p>
17:54 - 18:00	<p>DOP32: Withdrawal of thiopurines in Crohn's Disease treated with scheduled adalimumab maintenance: A prospective randomised clinical trial (DIAMOND2)</p> <p>T. Hisamatsu¹, S. Kato², R. Kunisaki³, M. Matsuura⁴, M. Nagahori⁵, S. Motoya⁶, M. Esaki⁷, N. Fukata⁸, S. Inoue⁹, T. Sugaya¹⁰, H. Sakuraba¹¹, F. Hirai¹², K. Watanabe^{13,14}, T. Kanai¹⁵, M. Naganuma¹⁵, H. Nakase¹⁶, Y. Suzuki¹⁷, M. Watanabe⁵, T. Hibi¹⁸, M. Nojima¹⁹, T. Matsumoto²⁰, DIAMOND² Study Group</p> <p>¹Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, ²Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, ³Yokohama City University Medical Center, Inflammatory Bowel Disease Centre, Kanagawa, Japan, ⁴Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, ⁵Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ⁶Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, ⁷Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, ⁸Kansai Medical University, Third Department of Internal Medicine, Osaka, Japan, ⁹Kobe City Medical Center General Hospital, Departments of Gastroenterology, Hyogo, Japan, ¹⁰Japan Red Cross Ashikaga Hospital, Department of Internal Medicine, Tochigi, Japan, Japan, ¹¹Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan, ¹²Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ¹³Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, ¹⁴Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, ¹⁵Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, ¹⁶Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, ¹⁷Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ¹⁸Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, ¹⁹Institute of Medical Science Hospital, University of Tokyo, Center for Translational Research, Tokyo, Japan, ²⁰Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan</p>

Thursday, March 7, 2019, cont.

	DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn's Disease: A multi-centre Belgian cohort study C. Liefferinckx¹, B. Verstockt², A. Gils³, M. Noman², C. Van Kemseke⁴, E. Macken⁵, M. De Vos⁶, W. Van Moerkercke⁷, J.-F. Rahier⁸, P. Bossuyt⁹, J. Dutré¹⁰, E. Humblet¹¹, D. Staessens¹², H. Peters¹³, P. Van Hoetegem¹⁴, E. Louis¹⁴, D. Franchimont¹, F. Baert¹⁵, S. Vermeire² ¹ Hôpital Erasme - ULB, Department of Gastroenterology, Brussels, Belgium, ² University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ³ KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ⁴ Centre Hospitalier Universitaire Sart-Tilman - ULG, Department of Gastroenterology, Liège, Belgium, ⁵ Universiteit ziekenhuis Antwerpen - UZA, Department of Gastroenterology, Antwerpen, Belgium, ⁶ Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, ⁷ AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, ⁸ Centre Hospitalier Universitaire Mont-Godinne - UCL, Department of Gastroenterology, Yvoir, Belgium, ⁹ Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, ¹⁰ Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, ¹¹ Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, ¹² GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, ¹³ Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, ¹⁴ Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, ¹⁵ AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium
18:00 - 18:06	DOP34: Disease activity patterns during the first 5 years after diagnosis in children with Ulcerative Colitis: A population-based study M. Aloj¹, M. Bramuzzo², L. Norsa³, S. Arrigo⁴, M. Distante⁵, E. Miele⁶, A. Agrusti², C. Romano⁷, C. Giobbi⁸, R. Panceri⁸, L. D'Antiga⁹, S. Cucchiara⁵, P. Alvisi⁹, SIGENP IBD Working Group ¹ Sapienza University of Rome, Department of Pediatrics, Pediatric Gastroenterology Unit, Rome, Italy, ² Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ³ Ospedale Papa Giovanni XXIII, Pediatric Gastroenterology Hepatology and Nutrition, Bergamo, Italy, ⁴ Istituto Giannina Gaslini, Department of Gastroenterology and Endoscopy, Genoa, Italy, ⁵ Sapienza University of Rome, Department of Pediatric Gastroenterology, Rome, Italy, ⁶ University of Naples „Federico II”, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, ⁷ University of Messina, Department of Pediatric Gastroenterology and Endoscopy, Messina, Italy, ⁸ San Gerardo Hospital, Monza, Italy, ⁹ Maggiore Hospital, Bologna, Italy
18:06 - 18:12	DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn's Disease, is significantly amplified in patients with a complicated phenotype R. S. Choung¹, F. Petralia², J. Torres^{3, 4}, T. Sato⁵, X.-J. Li⁶, P. Wang², S. Telesco⁵, C. Porter⁷, R. Laird⁷, R. Gutierrez⁷, F. Princen⁶, S. Plevy², R. Strauss⁵, M. Riddle⁷, J. Murray¹, J. F. Colombel³, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) study group ¹ Mayo Clinic, Gastroenterology and Hepatology, Rochester, United States, ² Icahn School of Medicine, Genetics and Genomic Sciences, New York, United States, ³ Icahn School of Medicine at Mount Sinai, New York, United States, ⁴ Hospital Beatriz Ángelo, Lisbon, Portugal, ⁵ Janssen R&D, Spring House, United States, ⁶ Prometheus Laboratories Inc., San Diego, United States, ⁷ Naval Medical Research Center, Silver Spring, United States

Thursday, March 7, 2019, cont.

<p>18:18 - 18:24</p>	<p>DOP36: Gut microbial variations in patients with quiescent Crohn's Disease predict subsequent disease flare</p> <p>T. Braun¹, A. Di Segni¹, M. BenShoshan¹, S. Neuman¹, O. Picard¹, K. Sosnovski¹, G. Efroni¹, B. Weiss¹, D. Yablecovitch¹, A. Lahat¹, R. Eliakim¹, U. Kopylov¹, S. Ben-Horin¹, Y. Haberman^{1,2}, On behalf of Israeli IBD Research Nucleus (IIRN) ¹Sheba Medical Center, Tel Hashomer, Israel, ²Cincinnati Children Hospital Medical Center, Cincinnati, United States</p>
<p>17:30 - 18:30</p> <p>Digital Oral Presentation Session 5 – Old and new treatment</p> <p>Room: C1 M4-5 Paolo Giunchetti, Bologna, Italy Anne Strik, Amsterdam, The Netherlands</p>	<p>DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: A large single centre experience</p> <p>B. Verstockt^{1,2}, E. Mertens¹, A. Outtiger¹, G. Van Assche^{1,2}, S. Vermeire^{1,2}, M. Ferrante^{1,2} ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium</p>
 <p>Y-ECCO Abstract Award</p>	<p>DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with Inflammatory Bowel Disease</p> <p>B. Verstockt^{1,2}, S. Verstockt³, P. Sudahakar^{2,4,5}, J. Dehairs⁶, H. Blevi², G. Van Assche^{1,2}, S. Vermeire^{1,2}, M. Ferrante^{1,2} ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, ⁴Earlham Institute, Norwich, United Kingdom, ⁵Quadram Institute, Norwich, Belgium, ⁶Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium</p>
<p>17:36 - 17:42</p>	<p>DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with Inflammatory Bowel Disease: London Ontario experience</p> <p>S. Al Draiweesh^{1,2}, C. Ma^{3,4}, M. Alkhattabi^{1,4}, N. Chande¹, B. G. Feagan^{1,5}, J. C. Gregor¹, R. Khanna¹, P. Marotta¹, A. Sandhu¹, K. Qumosani¹, A. Teriaky¹, M. Brahmania¹, V. Jairath^{1,5} ¹Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, ²King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, ³University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, ⁴King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, ⁵Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada</p>
<p>17:42 - 17:48</p>	<p>DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn's Disease: A French equivalence study</p> <p>A. Meyer¹, J. Rudant², J. Drouin², A. Weill³, F. Carbonnel³, J. Coste² ¹Caisse Nationale Assurance Maladie, Paris, France, ²Caisse Nationale de l'Assurance Maladie, Paris, France, ³Hôpital Bicêtre, Le Kremlin Bicêtre, France</p>
<p>17:48 - 17:54</p>	<p>DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn's Disease: A French equivalence study</p> <p>A. Meyer¹, J. Rudant², J. Drouin², A. Weill³, F. Carbonnel³, J. Coste² ¹Caisse Nationale Assurance Maladie, Paris, France, ²Caisse Nationale de l'Assurance Maladie, Paris, France, ³Hôpital Bicêtre, Le Kremlin Bicêtre, France</p>

Thursday, March 7, 2019, cont.

17:54 - 18:00	<p>DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with Ulcerative Colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studies</p> <p>M. Chiorean¹, C. Su², K. Matsuoka³, A. Orlando⁴, A. J. Thorpe², C. I. Nduaka², D. S. Chapman⁵, D. A. Woodworth⁶, N. Lawendy², G. S. Friedman², R. D. Cohen⁶</p> <p>¹Virginia Mason Medical Center, Seattle, WA, United States, ²Pfizer Inc, Collegeville, PA, United States, ³Toho University Sakura Medical Center, Sakura, Chiba, Japan, ⁴University of Palermo, IBD Unit, Palermo, Italy, ⁵Pfizer Inc, New York, NY, United States, ⁶University of Chicago Medicine, Chicago, IL, United States</p>
18:00 - 18:06	<p>DOP42: Dietary therapies induce rapid response and remission in Active Paediatric Crohn's Disease</p> <p>R. Sigall Boneh^{1,2}, J. Van Limbergen³, A. Assa⁴, R. Shaoul⁵, E. Wine⁶, P. Milman⁷, S. Cohen⁸, M. Kori⁹, S. Peleg¹⁰, A. On¹¹, H. Shamaly¹², L. Abrams¹, A. Levine^{1,2}</p> <p>¹Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³Dalhousie University, Halifax, Canada, ⁴Schneider Hospital, Petach Tikva, Israel, ⁵Meyer Hospital, Haifa, Israel, ⁶University of Alberta, Edmonton, Canada, ⁷Hadassah Hospital, Jerusalem, Israel, ⁸Tel Aviv Medical Center, Tel Aviv, Israel, ⁹Kaplan Hospital, Rehovot, Israel, ¹⁰HaEmek Hospital, Afula, Israel, ¹¹Poriah hospital, Tiberias, Israel, ¹²French Hospital, Nazareth, Israel</p>
18:06 - 18:12	<p>DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed responders</p> <p>D. T. Rubin¹, M. C. Dubinsky², M. Lukas³, D. Quirk⁴, C. I. Nduaka⁴, E. Maller⁴, N. Lawendy⁴, C. Kayhan⁴, H. Fan⁴, D. A. Woodworth⁴, G. Chan⁴, C. Su⁴</p> <p>¹University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States, ²Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, United States, ³Charles University, Prague, Czech Republic, ⁴Pfizer Inc, Collegeville, PA, United States</p>

Thursday, March 7, 2019, cont.



Y-ECCO
Abstract Award

18:12 - 18:18

DOP44: Efficacy and safety of tacrolimus in Ulcerative Colitis: A nationwide, multicentric study from GETECCU

I. Rodriguez-Lago¹, J. Castro-Poceiro², A. Fernández-Clotet², F. Mesonero³, A. López-Sanromán³, A. López-García⁴, L. Márquez⁴, A. Clos-Parale⁵, F. Cañete⁵, M. Vicuña⁶, Ó. Nantes⁶, O. Merino⁷, V. Matallana Royo⁷, J. Gordillo⁸, A. Elorza⁹, R. Vicente¹⁰, M. J. Casanova^{11, 12}, R. Ferreiro-Iglesias¹³, P. Pérez-Galindo¹⁴, J. M. Benítez^{15, 16}, C. Taxonera¹⁷, M. J. García García¹⁸, E. Martín Arranz¹⁹, M. Calafat²⁰, A. Martín-Cardona^{21, 22}, F. Muñoz Núñez²³, J. O. Miquel-Cusachs²⁴, E. Sáinz Arnau²⁵, J. P. Gisbert¹¹, Young IBD Group from GETECCU

¹Hospital de Galdakao, Gastroenterology, Galdakao, Spain, ²Hospital Clinic, Gastroenterology, Barcelona, Spain, ³Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, ⁴Hospital del Mar, Gastroenterology, Barcelona, Spain, ⁵Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ⁶Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, ⁷Hospital de Cruces, Gastroenterology, Bilbao, Spain, ⁸Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, ¹⁰Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, ¹¹Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, ¹²Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, ¹³Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain, ¹⁴Hospital Montecelo, Gastroenterology, Pontevedra, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶IMIBIC, Córdoba, Spain, ¹⁷Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, ¹⁹Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, ²⁰Hospital Son Llàtzer, Gastroenterology, Palma, Spain, ²¹Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain, ²²Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas (CIBERehd), Terrassa, Spain, ²³Hospital de Salamanca, Gastroenterology, Salamanca, Spain, ²⁴Hospital Universitario de Girona, Gastroenterology, Girona, Spain, ²⁵Hospital Arnau de Vilanova, Gastroenterology, Lérida, Spain

18:18 - 18:24

DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with Fistulising Crohn's Disease: A post-hoc analysis of the ACCENT-2 trial

N. Vandecasteele^{1, 2}, K. Papamichael³, J. Jeyarajah², M. T. Osterman⁴, A. S. Cheifetz³

¹University of California San Diego, Department of Medicine, La Jolla, United States, ²Robarts Clinical Trials, Inc., London, Canada, ³Beth-Israel Deaconess Medical Center, Harvard Medical School, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Boston, United States, ⁴University of Pennsylvania, Department of Medicine, Perelman School of Medicine, Philadelphia, United States

Friday, March 8, 2019

Digital Oral Presentation Session 6 – Novel treatments**17:05 - 18:05**

Room: C1 M4-5

Marc Ferrante, Leuven, Belgium
Gionata Fiorino, Rome, Italy**DOP46: Extended induction treatment with mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis: Results from a phase 2 trial**

W. J. Sandborn¹, M. Ferrante², B. R. Bhandari³, E. Berliba⁴, T. Hibi⁵, G. Geert R. D'Haens⁶, J. Tuttle⁷, K. Krueger⁸, S. Friedrich⁸, M. Durante⁸, V. Arora⁸, B. Feagan⁹

¹University California San Diego, La Jolla, California, United States, ²UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ³Delta Research Partners, LLC, Bastrop, LA, United States, ⁴Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, ⁵Kitasono Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, ⁶Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, ⁸Eli Lilly and Company, Indianapolis, Indiana, United States, ⁹Western University, Robarts Clinical Trials Inc, London, Ontario, Canada

DOP47: Sustained remission in patients with Moderate to Severe Ulcerative Colitis: Results from the phase 3 UNIFI maintenance study

G. Van Assche¹, S. R. Targan², T. Baker³, C. D. O'Brien³, H. Zhang³, J. Johanns³, P. Szapary³, C. Marano³, R. W. Leong^{4,5}, D. Rowbotham^{6,7}, T. Hisamatsu⁸, S. Danese⁹, B. E. Sands¹⁰, **L. Peyrin-Biroulet**¹¹

¹University of Leuven, Leuven, Belgium, ²Cedars-Sinai Medical Center, Los Angeles, United States, ³Janssen Research and Development, Spring House, United States, ⁴Concord Hospital, Sydney, Australia, ⁵Macquarie University Hospital, Sydney, Australia, ⁶Auckland City Hospital, Auckland, New Zealand, ⁷University of Auckland, Auckland, New Zealand, ⁸Kyorin University, Tokyo, Japan, ⁹Humanitas Research Hospital, Milan, Italy, ¹⁰Cahn School of Medicine at Mount Sinai, New York, United States, ¹¹Nancy University Hospital, Vandœuvre-lès-Nancy, France

DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's Disease patients: A proof of concept study

G. D'Haens¹, S. Danese², M. Davies³, M. Watanabe⁴, T. Hibi⁵

¹Academic Medical Centre, Amsterdam, Netherlands, ²Humanitas Research Hospital, Gastroenterology, Milano, Italy, ³Mitsubishi Tanabe Europe Ltd, London, United Kingdom, ⁴Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan, ⁵University Kitasato Hospital, Gastroenterology, Tokyo, Japan

Friday, March 8, 2019, cont.

17:23 - 17:29	DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in Ulcerative Colitis: Results from the open-label extension study TURANDOT II W. Reinisch ¹ , W. J. Sandborn ² , S. Danese ³ , X. Hébuterne ⁴ , M. Klopocka ⁵ , D. Tarabar ⁶ , T. Vaňásek ⁷ , M. Greguš ⁸ , P. A. Hellstern ⁹ , J. S. Kim ¹⁰ , M. Sparrow ¹¹ , K. J. Gorelick ¹² , M. Goetsch ¹³ , C. Bliss ¹⁴ , C. Gupta ¹⁵ , F. Cataldi ¹⁴ , S. Vermeire ¹⁶ ¹ Medical University of Vienna, Vienna, Austria, ² University of California San Diego, La Jolla, CA, United States, ³ Humanitas University, Milan, Italy, ⁴ University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, ⁵ Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, ⁶ Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, ⁷ Charles University Hospital, Hradec Králové, Czech Republic, ⁸ Gastroenterology Center, Nitra, Slovakia, ⁹ Nature Coast Clinical Research, Inverness, FL, United States, ¹⁰ Seoul National University College of Medicine, Seoul, South Korea, ¹¹ Alfred Hospital, Melbourne, VIC, Australia, ¹² Zymo Consulting Group, Newtown Square, PA, United States, ¹³ Shire, Zug, Switzerland, ¹⁴ Shire, Lexington, MA, United States, ¹⁵ Cytel Inc., Cambridge, MA, United States, ¹⁶ University Hospitals Leuven, Leuven, Belgium
17:29 - 17:35	DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with Moderate to Severe Crohn's Disease: Data from the CELEST study L. Peyrin-Biroulet ¹ , S. Danese ² , E. Louis ³ , P. D.R. Higgins ⁴ , M. Dubinsky ⁵ , F. Cataldi ⁶ , Q. Zhou ⁶ , W.-J. Lee ⁶ , K. Kligys ⁶ , A. P. Lacerda ⁶ ¹ University of Lorraine, Nancy, France, ² Istituto Clinico Humanitas, Milan, Italy, ³ CHU de Liège et Université de Liège, Liège, Belgium, ⁴ University of Michigan, Ann Arbor, United States, ⁵ ICahn School of Medicine at Mount Sinai, New York, United States, ⁶ AbbVie Inc, North Chicago, United States
17:35 - 17:41	DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with Ulcerative Colitis W. Reinisch ¹ , W. J. Sandborn ² , S. Danese ³ , X. Hébuterne ⁴ , M. Klopocka ⁵ , D. Tarabar ⁶ , T. Vaňásek ⁷ , M. Greguš ⁸ , P. A. Hellstern ⁹ , J. S. Kim ¹⁰ , M. Sparrow ¹¹ , K. J. Gorelick ¹² , M. Goetsch ¹³ , C. Bliss ¹⁴ , C. Gupta ¹⁵ , F. Cataldi ¹⁴ , S. Vermeire ¹⁶ ¹ Medical University of Vienna, Vienna, Austria, ² University of California San Diego, La Jolla, CA, United States, ³ Humanitas University, Milan, Italy, ⁴ University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, ⁵ Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, ⁶ Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, ⁷ Charles University Hospital, Hradec Králové, Czech Republic, ⁸ Gastroenterology Center, Nitra, Slovakia, ⁹ Nature Coast Clinical Research, Inverness, FL, United States, ¹⁰ Seoul National University College of Medicine, Seoul, South Korea, ¹¹ Alfred Hospital, Melbourne, VIC, Australia, ¹² Zymo Consulting Group, Newtown Square, PA, United States, ¹³ Shire, Zug, Switzerland, ¹⁴ Shire, Lexington, MA, United States, ¹⁵ Cytel Inc., Cambridge, MA, United States, ¹⁶ University Hospitals Leuven, Leuven, Belgium

Friday, March 8, 2019, cont.

17:41 - 17:47	<p>DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with Moderately to Severely Active Ulcerative Colitis</p> <p>W. J. Sandborn¹, B. Sands², T. Kobayashi³, J. Tuttle⁴, J. Schmitz⁵, M. Durante⁶, R. Higgs⁵, J. B. Canavan⁵, R. Siegel⁵, M. Ferrante⁶</p> <p>¹University California San Diego, La Jolla, California, United States, ²Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York, United States, ³Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan, ⁴Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, ⁵Eli Lilly and Company, Indianapolis, Indiana, United States, ⁶UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium</p>
17:47 - 17:53	<p>DOP53: Clinical, endoscopic, histologic and biomarker activity following treatment with the gut-selective, pan-JAK Inhibitor TD-1473 in Moderately to Severely Active Ulcerative Colitis</p> <p>W. Sandborn¹, D. Nguyen², B. Ferslew², L.-Y. Hao³, T. Kanno³, L. Tomsho³, D. Boyle¹, R. Graham², B. Abhyankar², J. Panes⁴</p> <p>¹University of California San Diego, Medicine, San Diego, United States, ²Theravance Biopharma US, Inc, South San Francisco, United States, ³Janssen R&D, Springhouse, United States, ⁴Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain</p>
17:53 - 17:59	<p>DOP54: Efficacy and safety of ustekinumab through week 16 in patients with Moderate to Severe Ulcerative Colitis randomised to ustekinumab: Results from the UNIFI induction trial</p> <p>S. Danese¹, B. E. Sands², C. D. O'Brien³, H. Zhang³, J. Johanns³, S. Sloan³, J. Izanec⁴, P. Szapary³, C. Marano³, R. W. Leong^{5,6}, D. Rowbotham^{7,8}, S. R. Targan⁹, G. Van Assche¹⁰</p> <p>¹Humanitas Research Hospital, Milan, Italy, ²Icahn School of Medicine at Mount Sinai, New York, United States, ³Janssen Research & Development, LLC, Spring House, United States, ⁴Janssen Scientific Affairs, LLC, Horsham, United States, ⁵Concord Hospital, Sydney, Australia, ⁶Macquarie University Hospital, Sydney, Australia, ⁷Auckland City Hospital, Auckland, New Zealand, ⁸University of Auckland, Auckland, New Zealand, ⁹Cedars-Sinai Medical Center, Los Angeles, United States, ¹⁰University of Leuven, Leuven, Belgium</p>
17:05 - 18:05 Room: C1 M3 Filip Baert, Roeselare, Belgium Shomron Ben-Horin, Ramat Gan, Israel	<p>Digital Oral Presentation Session 7 – Recent advances of biologic therapies</p>
17:05 - 17:11	<p>DOP55: ZNF133 is associated with infliximab responsiveness in patients with Inflammatory Bowel Diseases using whole-exome sequencing</p> <p>E. S. Jung^{1,2}, K.-W. Choi³, S. W. Kim², M. Hübenthal¹, S. Mucha¹, J. Park², Z. Park², D. Ellinghaus¹, S. Schreiber¹, A. Franke¹, W. Y. Oh³, J. H. Cheon²</p> <p>¹Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, ²Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, ³National Institute of Food and Drug Safety Evaluation, Clinical Research Division, Cheongju, South Korea</p>

Friday, March 8, 2019, cont.

17:11 - 17:17	<p>DOP56: Dashboard driven versus conventional dosing of infliximab in Inflammatory Bowel Disease patients: The PRECISION trial A. Strik^{1,2}, S. Berends³, D. Mould⁴, R. Mathôt³, C. Ponsioen², J. van den Brande⁵, J. Jansen⁶, D. Hoekman⁷, J. Brandse⁸, M. Löwenberg², G. D'Haens² ¹Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Amsterdam UMC, location AMC, Gastroenterology and Hepatology, Amsterdam, Netherlands, ³Amsterdam UMC, location AMC, Hospital Pharmacy, Amsterdam, Netherlands, ⁴Projections Research Inc., Phoenixville, United States, ⁵Tergooi Hospital, Blaricum, Netherlands, ⁶Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁷Amsterdam UMC, location AMC, Clinical Genetics, Amsterdam, Netherlands, ⁸Amsterdam UMC, location VuMc, Gastroenterology and Hepatology, Amsterdam, Netherlands</p>
17:17 - 17:23	<p>DOP57: Monitoring response to anti-TNF therapy in Ulcerative Colitis patients by gastrointestinal ultrasound: Sub-analysis from TRUST&UC C. Maaser¹, F. Petersen¹, U. Helwig², I. Fischer³, S. Rath⁴, S. Kolterer⁴, D. Lang⁴, T. Kucharzki¹ ¹University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany, ²Gastroenterology Practice, Oldenburg, Germany, ³Biostatistik Tuebingen, Tuebingen, Germany, ⁴AbbVie Deutschland GmbH & Co.KG, Medical Department Gastroenterology, Wiesbaden, Germany</p>
17:23 - 17:29	<p>DOP58: IDEAL – a multi-center prospective infliximab dose to level pharmacokinetic study during induction in Paediatric Crohn's Disease G. H. Huynh¹, M. W. Carroll¹, A. M. Griffiths², W. El-Matary³, A. Petrova⁴, C. Prosser⁵, C. Kluthe⁶, J. C. deBruyn⁷, D. Tomalty², D. R. Mould⁸, E. Wine⁴, H. Q. Huynh⁴ ¹University of Alberta, Paediatrics, Edmonton, Canada, ²Hospital for Sick Children, University of Toronto, Paediatrics, Toronto, Canada, ³The Children's Hospital University of Manitoba, Paediatrics, Winnipeg, Canada, ⁴Stollery Children's Hospital University of Alberta, Paediatrics, Edmonton, Canada, ⁵Alberta Health Services, Biochemistry, Edmonton, Canada, ⁶Alberta Health Services, Paediatrics, Edmonton, Canada, ⁷Alberta Children's Hospital University of Calgary, Paediatrics and Community Health Sciences, Calgary, Canada, ⁸Projections Research, Phoenixville, United States</p>
17:29 - 17:35	<p>DOP59: Proactive infliximab drug monitoring is superior to conventional management in Inflammatory Bowel Disease S. Raimundo Fernandes, S. Bernardo, C. Simões, L. Correia, P. Moura Santos, A. Rita Gonçalves, A. Valente, C. Baldaia, R. Tato Marinho Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastroenterology and Hepatology Unit, Lisbon, Portugal</p>
17:35 - 17:41	<p>DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non response in Crohn's P. Pavlidis¹, A. Tsakmaki¹, U. Niazi², J. Digby-Bell¹, G. Lombardi¹, B. Hayee¹, G. Bewick¹, N. Powell¹ ¹King's College London, London, United Kingdom, ²BRC Bioinformatics core, London, United Kingdom, ³King's College Hospital, London, United Kingdom</p>

Friday, March 8, 2019, cont.

	DOP61: A nationwide cohort study of colectomy rates for Ulcerative Colitis during the introduction of biologic therapy G. Worley ^{1,2} , A. Almoudaris ^{1,2} , P. Bassett ^{3,7} , J. Segal ^{1,2} , A. Akbar ^{2,4} , P. Aylin ⁵ , O. Faiz ^{1,2} ¹ St Mark's Hospital and Academic Institute, Surgical Epidemiology Trials and Outcome Centre, London, United Kingdom, ² Imperial College London, Department of Surgery and Cancer, London, United Kingdom, ³ Statsconsultancy Ltd, Buckinghamshire, United Kingdom, ⁴ St Mark's Hospital and Academic Institute, London, United Kingdom, ⁵ Imperial College London, Dr Foster Unit, Department of Primary Care and Public Health, London, United Kingdom
17:41 - 17:47	DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with Active Crohn's Disease W. Reinisch ¹ , B. I. Jang ² , V. Borzan ³ , A. Lahat ^{4,5} , A. Pukitis ⁶ , M. Osipenko ⁷ , Y. Mostovoy ⁸ , S. Schreiber ⁹ , S. Ben-Horin ¹⁰ , S. J. Lee ¹¹ , J. H. Suh ¹¹ , S. G. Lee ¹¹ , J. H. Lee ¹¹ , B. D. Ye ¹² ¹ Medical University Vienna, Vienna, Austria, ² Yeungnam University Hospital, Daegu, South Korea, ³ Clinical Hospital Center Osijek, Osijek, Croatia, ⁴ Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, ⁵ Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶ Pauls Stradiņš Clinical University Hospital, Riga, Latvia, ⁷ Novosibirsk State Medical University, Novosibirsk, Russian Federation, ⁸ Private Small-Scale Enterprise Medical Centre „Pulse“, Vinnytsya, Ukraine, ⁹ University Hospital Schleswig-Holstein, Kiel, Germany, ¹⁰ Sheba Medical Center, Tel Hashomer, Israel, ¹¹ Celltrion, Inc., Incheon, South Korea, ¹² Asan Medical Center, Seoul, South Korea
17:47 - 17:53	DOP63: Late-breaking Abstract
17:53 - 17:59	Digital Oral Presentation Session 8 – Intestinal healing Room: C1 M2 Raja Atreya, Erlangen, Germany Marietta Iacucci, Birmingham, United Kingdom
17:05 - 18:05	DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with Inflammatory Bowel Disease L.-Y. Mak ¹ , L. Chen ² , T. Tong ² , S. Lau ² , W.-K. Leung ² ¹ Queen Mary Hospital, Medicine, Hong Kong, Hong Kong, ² The University of Hong Kong, Medicine, Hong Kong, Hong Kong
17:05 - 17:11	DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn's Disease S. Noh ¹ , E. H. Oh ¹ , S. H. Park ^{2,3} , J. B. Lee ⁴ , J. Y. Kim ¹ , J. C. Park ¹ , J. Kim ¹ , N. Ham ¹ , E. M. Song ¹ , S. H. Park ^{1,5} , S. W. Hwang ^{1,3} , D. H. Yang ¹ , J. S. Byeon ¹ , S. J. Myung ¹ , S. K. Yang ^{1,3} , B. D. Ye ^{1,3} ¹ Asan medical center, Gastroenterology, Seoul, South Korea, ² Asan medical center, Radiology, Seoul, South Korea, ³ Asan medical center, Inflammatory Bowel Disease Center, Seoul, South Korea, ⁴ Asan medical center, Clinical Epidemiology & Biostatistics, Seoul, South Korea
17:11 - 17:17	DOP66: Surveillance colonoscopies are associated with improved prognosis and survival in patients with Ulcerative Colitis A. Hu ¹ , G. Nguyen ² , J. Rangrej ³ , J. Marshall ^{1,1} , N. Narula ¹ ¹ McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, Canada, ² University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada, ³ Ministry of Health and Long-Term Care, Health Analytics Branch, Toronto, Canada
17:17 - 17:23	

Friday, March 8, 2019, cont.

	DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with Inflammatory Bowel Disease E. Klencke ¹ , R. Atreya ¹ , A. Hartmann ² , S. Fischer ¹ , S. Hirschmann ¹ , S. Zundler ¹ , M. Iacucci ³ , M. Neurath ¹ , T. Rath ¹ ¹ University Hospital of Erlangen, Department of Medicine 1, Division of Gastroenterology, Erlangen, Germany, ² University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany, ³ University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom
17:23 - 17:29	DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse free survival in patients with Ulcerative Colitis in clinical and endoscopic remission H. Wang ¹ , I. Fewings ² , L. Bornman ¹ , B. Shadbolt ³ , M. Fadia ² , K. Subramaniam ^{1,4} ¹ Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia, ² ACT Pathology, Canberra Hospital, Canberra, Australia, ³ Health Analytics Research Centre, Canberra Hospital, Canberra, Australia, ⁴ ANU Medical School, Australian National University, Canberra, Australia
17:29 - 17:35	DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with Ulcerative Colitis: A sub-analysis of the Navigator Study K. Watanabe ^{1,2} , M. Esaki ³ , S. Oká ⁴ , F. Shimamoto ⁵ , M. Nishishita ² , T. Fukuchi ⁶ , S. Fujii ⁷ , F. Hirai ⁸ , K. Kamimoto ⁹ , T. Inoue ⁹ , H. Kashida ¹⁰ , K. Takeuchi ¹¹ , N. Ohmiya ¹² , M. Saruta ¹³ , S. Saito ¹⁴ , Y. Saito ¹⁵ , S. Tanaka ¹⁶ , Y. Ajioka ¹⁷ , H. Tajiri ¹³ ¹ Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan, ² Nishishita GI Hospital, Osaka, Japan, ³ Saga University, Saga, Japan, ⁴ Hiroshima University, Hiroshima, Jamaica, ⁵ Prefectural University of Hiroshima, Hiroshima, Japan, ⁶ Osakafu Saiseikai Nakatsu Hospital, Osaka, Japan, ⁷ Kyoto Katsura Hospital, Kyoto, Japan, ⁸ Fukuoka University Chikushi Hospital, Fukuoka, Japan, ⁹ Osaka Medical College, Osaka, Japan, ¹⁰ Kinki University, Osaka, Japan, ¹¹ Toho University Sakura Medical Center, Chiba, Japan, ¹² Fujita Medical University, Aichi, Japan, ¹³ The Jikei University School of Medicine, Tokyo, Japan, ¹⁴ The Cancer Institute Hospital Of JFCR, Tokyo, Japan, ¹⁵ National Cancer Center Hospital, Tokyo, Japan, ¹⁶ Hiroshima University, Hiroshima, Japan, ¹⁷ Niigata University, Niigata, Japan
17:35 - 17:41	DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's Disease B. Verstockt ^{1,2} , P. Sudahakar ^{2,3,4} , B. Creyns ⁵ , S. Verstockt ⁶ , J. Cremer ⁵ , W.-J. Wollants ⁵ , S. Organe ² , T. Korcsmaros ^{3,4} , M. Madgwick ³ , G. Van Assche ^{1,2} , C. Breynaert ⁵ , S. Vermeire ^{1,2} , M. Ferrante ^{1,2} ¹ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ² KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³ Earlham Institute, Norwich, United Kingdom, ⁴ Quadram Institute, Norwich, Belgium, ⁵ KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium, ⁶ KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium
17:41 - 17:47	

Friday, March 8, 2019, cont.

17:47 - 17:53	<p>DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis K. Li¹, J. R. Friedman¹, C. Marano¹, H. Zhang¹, F. Yang¹, B. G. Feagan², L. Peyrin-Biroulet³, G. De Hertogh⁴ ¹Janssen Research & Development, LLC, Spring House, United States, ²Robarts Research Institute, Robarts Clinical Trials, London, Canada, ³Nancy University Hospital, Université de Lorraine, Nancy, France, ⁴University Hospitals KU, Leuven, Belgium</p>
17:53 - 17:59	<p>DOP72: Increased risk of advanced neoplasia in Inflammatory Bowel Disease patients with recurrent low-grade dysplasia M. de Jong¹, H. Kanne¹, L. Nissen², I. Nagtegaal³, J. Drent¹, L. Derikx^{1,2}, F. Hoentjen¹ ¹ Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, Netherlands, ² Jeroen Bosch Hospital, Gastroenterology and Hepatology, s'Hertogenbosch, Netherlands, ³ Radboud University Medical Center, Pathology, Nijmegen, Netherlands</p>
17:05 - 18:05	<p>Digital Oral Presentation Session 9 – Surgery and IBD Room: C1 M1 Paulo Kotze, Curitiba, Brazil Andre D'Hoore, Leuven, Belgium</p>
17:05 - 17:11	<p>DOP73: Treatment of perianal fistulas in Crohn's Disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): A randomised controlled trial K. Wasemann¹, E. J. de Groot², M. Stellingwerf¹, G. D'Haens³, C. Ponsioen³, K. Gecse³, M. Dijkgraaf⁴, W. Bemelman², C. Buskens² ¹ Amsterdam UMC, Department of Surgery and Gastroenterology, Amsterdam, Netherlands, ² Amsterdam UMC, Department of Surgery, Amsterdam, Netherlands, ³ Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁴ Amsterdam UMC, Clinical Research Unit & Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam, Netherlands</p>

Friday, March 8, 2019, cont.

	DOP74: Efficacy of ustekinumab in perianal Crohn's Disease: The BioLAP multicentre observational study C. Biron ¹ , P. Seksik ² , M. Nachury ³ , Y. Bouhnik ⁴ , A. Amiot ⁵ , S. Viennot ⁶ , M. Serrero ⁷ , M. Fumerly ⁸ , M. Allez ⁹ , L. Siproudhis ¹⁰ , A. Buisson ¹¹ , G. Pineton de Chambrun ¹² , V. Abitbol ¹³ , S. Nancey ¹⁴ , L. Caillol ¹⁵ , L. Plastaras ¹⁶ , L. Armengol-Debeir ¹⁷ , E. Chanteloup ¹⁸ , M. Simon ¹⁹ , N. Dib ²⁰ , S. Rajca ²¹ , M. Amil ²² , L. Peyrin-Biroulet ²³ , L. Vuitton ²⁴ ¹ CHU Jean Minjoz, Gastroenterology, Besançon, France, ² Hôpital Saint-Antoine, Gastroentérologie, Paris, France, ³ CHRU Lille, Gastroentérologie, Lille, France, ⁴ Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, ⁵ Hôpital Henri-Mondor, Gastroentérologie, Paris, France, ⁶ CHRU Caen, Gastroentérologie, Caen, France, ⁷ APHM Hôpital Nord, Gastroentérologie, Marseille, France, ⁸ CHRU Amiens, Gastroentérologie, Amiens, France, ⁹ Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, ¹⁰ CHRU Rennes, Gastroentérologie, Rennes, France, ¹¹ CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, ¹² CHRU Montpellier, Gastroentérologie, Montpellier, France, ¹³ Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, ¹⁴ Groupeement Hospitalier Sud' Hospices Civils de Lyon, Gastroentérologie, Lyon, France, ¹⁵ CHU Nîmes, Gastroentérologie, Nîmes, France, ¹⁶ Hôpital Pasteur, Gastroentérologie, Colmar, France, ¹⁷ CHRU Rouen, Gastroentérologie, Rouen, France, ¹⁸ Hôpital Saint-Joseph, Gastroentérologie, Paris, France, ¹⁹ Institut Mutualiste Monsouris, Gastroentérologie, Paris, France, ²⁰ CHRU Angers, Gastroentérologie, Angers, France, ²¹ Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, ²² CHD Vendée, Gastroentérologie, La Roche-sur-Yon, France, ²³ CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, ²⁴ CHRU Jean Minjoz, Gastroentérologie, Besançon, France
17:11 - 17:17	DOP75: Surgery and hospitalisations rates in Inflammatory Bowel Disease patients in the Québec provincial database from 1996 - 2015 C. Verdon ¹ , J. Reinglas ¹ , J. Coulombe ² , L. Gonczi ³ , T. Bessissow ¹ , W. Afif ¹ , M. Vutcovici ⁴ , G. Wild ¹ , E. Seidman ¹ , A. Bitton ¹ , P. Brassard ^{5,6} , P. Lakatos ¹ ¹ McGill University Health Center, Division of Gastroenterology, Montreal, Canada, ² Lady Davis Research Institute, Jewish General Hospital, Centre for Clinical Epidemiology, Montreal, Canada, ³ Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, ⁴ McGill University Health Centre, Division of Gastroenterology, Montreal, Canada, ⁵ Biostatistics and Occupational Health, Department Of Epidemiology, Montreal, Canada, ⁶ McGill University, Department of Medicine, Montreal, Canada
17:17 - 17:23	DOP76: Prevalence and health-care costs of perianal fistulas in Crohn's Disease in a nationwide cohort A. Nordholm-Carstensen ¹ , N. Qvist ² , B. Høgaard ³ , C. Halling ³ , M. Carstensen ⁴ , N.-P. Ipland ⁴ , J. Burisch ⁵ ¹ Zéland University Hospital, Department of Surgery, Roskilde, Denmark, ² Odense University Hospital, Department of Surgery, Odense, Denmark, ³ VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark, ⁴ Takeda Pharma A/S, Taastrup, Denmark, ⁵ Danish Centre for eHealth & Epidemiology, Frederiksund, Denmark
17:23 - 17:29	DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's Disease O. Knyazev, A. Kagramanova , A. Lishchinskaya, M. Zvyaglova, D. Kulakov, A. Parfenov Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation
17:29 - 17:35	

Friday, March 8, 2019, cont.

	DOP78: Efficacy of vedolizumab in perianal Crohn's Disease: The BioLAP multicentre observational study C. Biron ¹ , P. Seksik ² , M. Nachury ³ , S. Nancey ⁴ , Y. Bouhnik ⁵ , M. Serrero ⁶ , L. Armengol-Debeir ⁷ , A. Buisson ⁸ , M.-L. Tran Minh ⁹ , C. Zallot ¹⁰ , M. Fumery ¹¹ , G. Bouguen ¹² , V. Abitbol ¹³ , S. Viennot ¹⁴ , É. Chanteloup ¹⁵ , S. Rajca ¹⁶ , N. Dib ¹⁷ , L. Peyrin-Biroulet ¹⁰ , L. Vuitton ¹⁸
17:35 - 17:41	¹ CHU Jean Minjoz, Gastroenterology, Besançon, France, ² Hôpital Saint-Antoine, Gastroentérologie, Paris, France, ³ CHRU Lille, Gastroentérologie, Lille, France, ⁴ Groupeum Hospitalier Sud Hospices Civils de Lyon, Gastroentérologie, Lyon, France, ⁵ Hôpital Beaujon, AP-HP, Gastroentérologie, Paris, France, ⁶ APHM Hôpital Nord, Gastroentérologie, Marseille, France, ⁷ CHRU Rouen, Gastroentérologie, Rouen, France, ⁸ CHRU Clermont-Ferrand, Gastroentérologie, Clermont-Ferrand, France, ⁹ Hôpital Saint-Louis, AP-HP, Gastroentérologie, Paris, France, ¹⁰ CHRU Nancy, hôpitaux de Brabois, Gastroentérologie, Nancy, France, ¹¹ CHRU Amiens, Gastroentérologie, Amiens, France, ¹² CHRU Rennes, Gastroentérologie, Rennes, France, ¹³ Hôpital Cochin, AP-HP, Gastroentérologie, Paris, France, ¹⁴ CHRU Caen, Gastroentérologie, Caen, France, ¹⁵ Hôpital Saint-Joseph, Gastroentérologie, Paris, France, ¹⁶ Hôpital Louis-Mourier, AP-HP, Gastroentérologie, Paris, France, ¹⁷ CHRU Angers, Gastroentérologie, Angers, France, ¹⁸ CHRU Jean Minjoz, Gastroentérologie, Besançon, France
17:41 - 17:47	DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trials B. G. Feagan ¹ , B. E. Sands ² , R. Lirio ³ , T. Lissoos ³ , J. Wang ³ , D. Feng ³ , K. Lasch ³ ¹ Robarts Clinical Trials, Western University, London, Ontario, Canada, ² Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, United States, ³ Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, United States
17:47 - 17:53	DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's Disease treated with concomitant thiopurines: The POPCUR trial A. Buisson ¹ , D. Laharie ² , S. Nancey ³ , X. Hébuterne ⁴ , X. Roblin ⁵ , M. Nachury ⁶ , L. Peyrin-Biroulet ⁷ , M. Fumery ⁸ , F. Goutorbe ¹ , D. Coban ¹ , C. Allimant ¹ , M. Reymond ¹ , E. Vazeille ¹ , B. Pereira ¹ , M. Goutte ¹ , G. Bommeelaer ¹ ¹ University Hospital Estaing, IBD unit, Clermont-Ferrand, France, ² CHU Bordeaux, Bordeaux, France, ³ HCL Lyon-Sud, Lyon, France, ⁴ CHU Nice, Nice, France, ⁵ CHU Saint-Etienne, Saint-Etienne, France, ⁶ CHU Lille, Lille, France, ⁷ CHU Nancy, Nancy, France, ⁸ CHU Amiens, Amiens, France
17:53 - 17:59	DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn's Disease A. L. Hamilton ¹ , P. P. De Cruz ^{1,2} , E. K. Wright ³ , L. Okada ⁴ , M. Hale ⁴ , L. Mims ⁴ , A. Jain ⁴ , M. A. Kamm ¹ ¹ The University of Melbourne and St Vincent's Hospital, Melbourne, Department of Medicine and Department of Gastroenterology, Melbourne, Australia, ² Austin Health, Department of Gastroenterology, Melbourne, Australia, ³ St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia, ⁴ Prometheus Laboratories Inc, San Diego, United States

Friday, March 8, 2019, cont.

Digital Oral Presentation Session 10 – Clinical Epidemiology 17:05 - 18:05 Room: C1 M0 Stefanos Bonovas, Milan, Italy Johan Burisch, Copenhagen, Denmark	
17:05 - 17:11	<p>DOP82: Direct and indirect costs of Inflammatory Bowel Disease in the biological era; ten years of follow up in a Danish population-based inception cohort</p> <p>B. Lo¹, I. Vind¹, M. K. Vester-Andersen^{1,2}, F. Bendtsen¹, J. Burisch¹ ¹Copenhagen University Hospital Hvidovre, The Gastro Unit, Hvidovre, Denmark, ²Zealand University Hospital, Medical Department, Koegé, Denmark</p>
17:11 - 17:17	<p>DOP83: Association of FUT2 and ABO with Crohn's Disease in Koreans</p> <p>H.-S. Lee^{1,2}, B. M. Kim², S. Jung², M. Hong², K. Kim², J. W. Moon², J. Baek², S. W. Hwang³, S. H. Park³, S.-K. Yang³, K. Song², B. D. Ye³ ¹KU Leuven, Department of Human Genetics, Laboratory of Complex Genetics, Leuven, Belgium, ²University of Ulsan College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, South Korea, ³Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, South Korea</p>
17:17 - 17:23	<p>DOP84: Nationwide incidence and prevalence of Paediatric Inflammatory Bowel Disease in Scotland 2015-2017 demonstrates the highest paediatric prevalence rate recorded worldwide</p> <p>C. Burgess^{1,2}, P. Henderson^{1,2}, I. Chalmers³, R. Harris⁴, R. Hansen⁴, R. Russell⁴, D. Wilson^{1,2} ¹University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, ²Royal Hospital for Sick Children, Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom, ³Royal Aberdeen Children's Hospital, Paediatric Gastroenterology and Nutrition, Aberdeen, United Kingdom, ⁴Royal Hospital for Children, Paediatric Gastroenterology and Nutrition, Glasgow, United Kingdom</p>
17:23 - 17:29	<p>DOP85: Rising depression and antidepressant use amongst Inflammatory Bowel Disease patients</p> <p>J. Blackwell¹, S. Saxena², C. Alexakis¹, E. Cecil², A. Bottle², I. Petersen^{3,4}, M. Hotopf², R. Pollak¹ ¹St George's Healthcare NHS Trust, Gastroenterology, London, United Kingdom, ²Imperial College London, School of Public Health, London, United Kingdom, ³University College London, Epidemiology and Health Informatics, London, United Kingdom, ⁴Aarhus University, Biostatistics, Aarhus, Denmark, ⁵King's College London, Institute of Psychiatry, London, United Kingdom</p>
17:29 - 17:35	<p>DOP86: Risk for development of Inflammatory Bowel Disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis: A review and meta-analysis</p> <p>W. Eigner¹, J. Burisch², W. Reinisch¹ ¹Medical University of Vienna, Medicine III, Division Gastroenterology and Hepatology, Vienna, Austria, ²Danish Centre for eHealth & Epidemiology, Department of Gastroenterology, Frederiksund, Denmark</p>
17:35 - 17:41	<p>DOP87: Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)</p> <p>G.-R. Jones^{1,2}, M. Lyons², N. Plevris¹, P. Jenkinson¹, C. Bisset¹, J. Fulforth¹, C. S. Chuah¹, S. Minnis¹, S.-L. Gillespie¹, W. Brindle¹, C. Burgess³, P. Henderson³, D. Wilson³, C. Lees¹ ¹Western General Hospital, Gastroenterology, Edinburgh, United Kingdom, ²University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ³Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, United Kingdom</p>


Friday, March 8, 2019, cont.

	<p>DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in Inflammatory Bowel Disease patients: A nationwide Danish cohort study.</p> <p>S. B. Thomsen¹, K. H. Allin², J. Burisch², C. B. Jensen², S. Hansen², L. L. Gluud¹, K. Theede¹, M. Kiszka-Kanowitz¹, A. M. Nielsen¹, T. Jess²</p> <p>¹Copenhagen University Hospital Hvidovre, Gastronut, Medical Division, Copenhagen, Denmark, ²Bispebjerg and Frederiksberg Hospital, Center for Clinical Research and Prevention, Copenhagen, Denmark</p>
17:41 - 17:47	<p>DOP89: Final growth in Paediatric Crohn's Disease is impaired also in the era of biologics: A population based analysis from the epilIRR administrative cohort</p> <p>A. Assa¹, S. Cohen², N. Asayag³, N. Dan⁴, G. Focht⁴, O. Ledder⁴, N. Lederman⁵, E. Matz⁶, A. Cahan⁷, R. Balicer⁸, B. Feldman⁸, I. Brufman⁸, D. Turner⁴</p> <p>¹Schneider Children's Medical Center of Israel Hospital for Children, Petah Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, ⁴Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel, ⁵Meuhedet Health Services, Tel Aviv, Israel, ⁶Leumit Health Services, Tel Aviv, Israel, ⁷Maccabi Healthcare Services, Tel Aviv, Israel, ⁸Clalit Research Institute, Chief's Office, Clalit Health Services, Tel Aviv, Israel, Tel Aviv, Israel</p>
17:47 - 17:53	<p>DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD. Results after 20 years of follow-up in the IBSEN study</p> <p>A. Ossum^{1,2}, Ø. Palm³, M. Cvancarova⁴, B. Moum^{1,2}, M. L. Høivik¹, The IBSEN study group</p> <p>¹Oslo University Hospital, Ullevaal, Gastroenterology, Oslo, Norway, ²University of Oslo, Faculty of Medicine, Oslo, Norway, ³Oslo University Hospital, Rikshospitalet, Rheumatology, Oslo, Norway, ⁴OsloMet, Faculty of Public Health, Oslo, Norway</p>



European
Crohn's and Colitis
Organisation

New ECCO Guidelines & Topical Reviews



Stay tuned with JCC online 2019

ECCO Guidelines

- ECCO - ESGAR Consensus Guidelines on Diagnostic Techniques and Monitoring

ECCO Topical Reviews

- Complementary Medicine and Psychotherapy
- Perioperative Dietary Therapy

ECCO is looking forward to your visit to JCC online, which also provides free access to all Guideline and Topical Review publications!

Christian Maaser
ECCO GuiCom Chair

Laurence Egan
JCC Editor-in-Chief

Scan and contact the ECCO Office
www.ecco-ibd.eu



Hard copy poster presentations/Poster exhibition

Opening Hours

Industry and Poster exhibition	
Wednesday, March 6, 2019	Closed
Thursday, March 7, 2019	13:00 - 19:00
Friday, March 8, 2019	08:30 - 19:00
Saturday, March 9, 2019	08:00 - 13:00

Guided poster session

The guided poster session is on Friday, March 8, 2019 from 12:30 to 13:30 in Hall B.

In pairs, poster session chairs will guide groups through the poster exhibition and presenting authors will have the opportunity to share the major findings of their abstracts in 1-2 minutes. In that time, delegates will have the chance to engage with the abstract authors and directly ask any questions.

To join the guided poster session, please choose one of poster groups listed below and find the respective poster chairs near the poster exhibition at 12:30 on Friday, March 8, 2019. All poster chairs carry an "ECCO Poster Chair" button and also hold a sign that states the poster group number as well as the scientific category.

Guided poster sessions are chaired by:

(i) Basic Science:

- Group 1** (starts at P001): Franco Sculdaferri, Rome, Italy
Michael Scharl, Zurich, Switzerland
- Group 2** (starts at P026): Azucena Salas, Barcelona, Spain
Gerhard Rogler, Zurich, Switzerland
- Group 3** (starts at P051): Jesús Cosín-Roger, Valencia, Spain
Monika Tripathi, Cambridge, United Kingdom
- Group 4** (starts at P076): Charlotte Hedin, Solna, Sweden
Dror Shouval, Ramat-Gan, Israel

(ii) Clinical: Diagnosis & outcome:

- Group 5** (starts at P100): Laurent Beaugerie, Paris, France
Christianne Buskens, Amsterdam, The Netherlands
- Group 6** (starts at P131): Lissy de Ridder, Rotterdam, The Netherlands
David Wilson, Edinburgh, United Kingdom
- Group 7** (starts at P161): Janneke van der Woude, Rotterdam, The Netherlands
Gert De Hertogh, Leuven, Belgium
- Group 8** (starts at P191): Marina Alois, Rome, Italy
Jimmy Limdi, Manchester, United Kingdom

- Group 9** (starts at P221): Arie Levine, Tel Aviv, Israel
Giulia Roda, Milan, Italy
- Group 10** (starts at P251): Roger Feakins, London, United Kingdom
Tim Raine, Cambridge, United Kingdom
- Group 11** (starts at P281): Gerassimos Mantzaris, Athens, Greece
Patrick van Rheenen, Groningen, The Netherlands
- (iii) **Clinical: Therapy and observation:**
- Group 12** (starts at P311): Loris Riccardo Lopetuso, Rome, Italy
John Mansfield, Newcastle, United Kingdom
- Group 13** (starts at P342): Willem Bemelmann, Amsterdam, The Netherlands
Yves Panis, Clichy, France
- Group 14** (starts at P373): Raja Atreya, Erlangen, Germany
Janindra Warusavitarne, London, United Kingdom
- Group 15** (starts at P404): Ailsa Hart, London, United Kingdom
Fabrizio Michelassi, New York, United States
- Group 16** (starts at P435): Dominik Bettenworth, Münster, Germany
Ebbe Langholz, Copenhagen, Denmark
- Group 17** (starts at P466): Boris Vucelic, Zagreb, Croatia
Ran Zhihua, Shanghai, China
- Group 18** (starts at P497): Fernando Magro, Porto, Portugal
Sophie Restellini, Geneva, Switzerland
- Group 19** (starts at P528): Jaroslaw Kierkus, Warsaw, Poland
Shaji Sebastian, Hull, United Kingdom
- Group 20** (starts at P558): Mark Löwenberg, Amsterdam, The Netherlands
Bram Verstockt, Leuven, Belgium
- Group 21** (starts at P588): Krisztina Gecse, Amsterdam, The Netherlands
Piotr Eder, Poznan, Poland
- Group 22** (starts at P618): Javier Gisbert, Madrid, Spain
Nik Sheng Ding, Melbourne, Australia
- Group 23** (starts at P648): Uri Kopylov, Tel Aviv, Israel
Pascal Juillerat, Bern, Switzerland
- Group 24** (starts at P678): David Laharie, Pessac, France
Valerie Pittet, Lausanne, Switzerland
- Group 25** (starts at P708): Pierre Michetti, Lausanne, Switzerland
Pär Myrelid, Linköping, Sweden
- (iv) **Epidemiology:**
- Group 26** (starts at P738): Nynne Nyboe Andersen, Copenhagen, Denmark
Naila Arebi, London, United Kingdom
- Group 27** (starts at P777): Julien Kirchgesner, Paris, France
Peter Lakatos, Budapest, Hungary
- (v) **Genetics:**
- Group 28** (starts at P815): Richard Russell, Glasgow, United Kingdom
Magali Svrcek, Paris, France
- (vi) **Microbiology:**
- Group 29** (starts at P829): James Lindsay, London, United Kingdom
TBD

Poster exhibition

In order to view the list with abstracts presented at ECCO'19 as hard copy posters, please follow the links stated or scan the QR-codes in each category.

(i) **Basic Science**

Poster P001-P099

ecco-ibd.eu/bs



(ii) **Clinical: Diagnosis and outcome**

Poster P100-P310

ecco-ibd.eu/cd



(iii) **Clinical: Therapy and observation**

Poster P311-P737

ecco-ibd.eu/ct



(iv) **Epidemiology**

Poster P738-P814

ecco-ibd.eu/epi



(v) **Genetics**

Poster P815-P828

ecco-ibd.eu/gen



(vi) **Microbiology**

Poster P829-P861

ecco-ibd.eu/mb



(vii) **Nurses abstracts**

Poster N01-N24

ecco-ibd.eu/np



Educational programme

ECCO aims to promote education and improve the quality of care for IBD patients throughout Europe. Thus, ECCO offers the following educational activities prior to as well as during the 14th Congress of ECCO in Copenhagen.

17th IBD Intensive Advanced Course

Date:	Wednesday-Thursday, March 6-7, 2019
Time:	Wednesday, March 6: 08:00-16:45 Thursday, March 7: 07:30-12:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation only. No onsite registration.
CME accreditation:	10 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

*Programme overview (as of February 1, 2019)
HB4 M1-2, Hall B, Bella Center*

08:00 - 08:15	Arrival & distribution of voting pads
08:15 - 08:30	1: Welcome Silvio Danese, Milan, Italy James Lindsay, London, United Kingdom
08:30 - 09:15	Session 1: Pathogenesis Lead discussant: Yehuda Chowers, Haifa, Israel
	2: Exposome Jonas Halfvarson, Örebro, Sweden
	3: Genetics Siew Ng, Hong Kong, China
	4: Inflammatory pathways Yehuda Chowers, Haifa, Israel
09:15 - 09:35	Coffee break
09:35 - 11:20	Session 2: Part I: Case-based management of IBD therapies Lead discussant: Peter Irving, London, United Kingdom
	5: 5-ASA compounds Gerhard Rogler, Zurich, Switzerland
	6: Thiopurines Peter Irving, London, United Kingdom
	7: Methotrexate Pascal Juillerat, Bern, Switzerland
	8: Steroids Fernando Gomollón García, Zaragoza, Spain
	9: Anti-TNF agents Filip Baert, Roeselare, Belgium
	10: Anti-integrines James Lindsay, London, United Kingdom

Wednesday, March 6, 2019, cont.

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

11:20 - 12:05 Session 2: Part II: New biologics and small molecules

Lead discussant: Axel Dignass, Frankfurt, Germany

11:20 - 11:35	11: Ustekinumab Marc Ferrante, Leuven, Belgium
11:35 - 11:50	12: Tofacitinib Florian Rieder, Cleveland, United States
11:50 - 12:05	13: Other small molecules (apremilast/ozanimod) Laurent Peyrin Birolet, Vandoeuvre-lès-Nancy, France

12:05 - 13:25 Lunch break

13:25 - 14:55 Session 3: Seminars: Part I: Special clinical situations

EITHER:

14a. Managing IBD and pregnancy
(HB4 M1-2, Hall B, Bella Center)

Iris Dotan, Petah Tikva, Israel

Janneke van der Woude, Rotterdam, The Netherlands

OR:

14b. Managing extraintestinal manifestations of IBD
(B4 M10, Hall B, Bella Center)

Peter Lakatos, Budapest, Hungary; Montreal, Canada

Stephan Vavricka, Zurich, Switzerland

EITHER:

14a. Managing IBD and pregnancy
(B4 M10, Hall B, Bella Center)

Iris Dotan, Petah Tikva, Israel

Janneke van der Woude, Rotterdam, The Netherlands

OR:

14b. Managing extraintestinal manifestations of IBD
(HB4 M1-2, Hall B, Bella Center)

Peter Lakatos, Budapest, Hungary; Montreal, Canada

Stephan Vavricka, Zurich, Switzerland

14:55 - 15:15 Coffee break

15:15 - 16:45 Session 3: Seminars: Part II : Long term management

EITHER:

15a. Managing complications associated with anti-TNF therapy
(HB4 M1-2, Hall B, Bella Center)

Shomron Ben-Horin, Ramat Gan, Israel

Joana Torres, Lisbon, Portugal

OR:

15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation
(B4 M10, Hall B, Bella Center)

Pierre Michetti, Lausanne, Switzerland

Henit Yanai, Petah Tikva, Israel

EITHER:

15a. Managing complications associated with anti-TNF therapy
(B4 M10, Hall B, Bella Center)

Shomron Ben-Horin, Ramat Gan, Israel

Joana Torres, Lisbon, Portugal

OR:

15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation
(HB4 M1-2, Hall B, Bella Center)

Pierre Michetti, Lausanne, Switzerland

Henit Yanai, Petah Tikva, Israel

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

07:30 - 09:30	Session 4: Interactive case discussions Lead discussants: Pascal Juillerat, Bern, Switzerland Antonio López-Sanromán, Madrid, Spain
07:30 - 08:00	16: Investigation and management of early Mild/Moderate Crohn's Disease Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Larry Egan, Galway, Ireland
08:00 - 08:05	Discussion
08:05 - 08:40	17: Management of perianal CD Paulo Kotze, Curitiba, Brazil Antonio López-Sanromán, Madrid, Spain
08:40 - 08:45	Discussion/Questions
08:45 - 09:30	18: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents Case presentation: Dominik Bettenworth, Münster, Germany Discussion: Pascal Juillerat, Bern, Switzerland Paulo Kotze, Curitiba, Brazil
09:30 - 09:45	Coffee break
09:45 - 11:45	Session 5: Special case scenarios Lead discussant: Gerassimos Mantzaris, Athens, Greece
09:45 - 10:15	19: Medical management of Acute Severe Ulcerative Colitis David Laharie, Bordeaux, France
10:15 - 10:45	20: Pre- and postoperative management of Crohn's Disease Glen Doherty, Dublin, Ireland
10:45 - 11:15	21: Management of refractory pouchitis Iris Dotan, Petah Tikva, Israel
11:15 - 11:45	Discussion / Q&A Session
11:45- 12:00	22: Feedback and closing remarks Pascal Juillerat, Bern, Switzerland

3rd School for Clinical Trialists

Date:	Wednesday, March 6, 2019
Time:	08:00-11:30
Organisation:	ClinCom
Target audience:	Clinical trial coordinators, IBD Nurses and Allied health professionals
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

Auditorium 15, Hall A, Bella Center

3rd School for Clinical Trialists: Clinical Trial Evolution and Recruitment in IBD	
08:00 - 08:15	1: Welcome & Introduction Marc Ferrante, Leuven, Belgium
08:15 - 09:30	Session 1: Evolution of trial design Javier Gisbert, Madrid, Spain
08:15 - 08:45	2: What did we achieve with the past IBD trials until now? Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France
08:45 - 09:15	3: What are the unmet needs and how can new type/innovative trials meet these? Gert van Assche, Leuven, Belgium
09:15 - 09:30	4: General Discussion
09:30 - 10:00	Coffee break
10:00 - 11:20	Session 2: How to optimise recruitment Uri Kopylov, Tel Aviv, Israel
10:00 - 10:20	5: Clinical trial coordinator's view Martin Thomas, Cambridge, United Kingdom
10:20 - 10:40	6: Patient's view / IBD nurse's view (together) Carina Blixt, Hvidovre, Denmark Annette Munk Happel, Hvidovre, Denmark (IBD Patient)
10:40 - 11:00	7: PI's view Laurent Beaugerie, Paris, France
11:00 - 11:20	7: Group Discussion Laurent Beaugerie, Paris, France Carina Blixt, Hvidovre, Denmark Krisztina Gecse, Amsterdam, The Netherlands Martin Thomas, Cambridge, United Kingdom Annette Munk Happel, Hvidovre, Denmark (IBD Patient) Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim)
11:20 - 11:30	9: Summary & closing remarks John Mansfield, Newcastle upon Tyne, United Kingdom

10th N-ECCO School

Date:	Wednesday, March 6, 2019
Time:	08:30-16:15
Organisation:	N-ECCO
Target audience:	IBD Nurses, Dietitians
Registration:	Upon invitation only. No onsite registration.
CME accreditation:	N/A

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

B3 M5-6, Hall B, Bella Center

08:30 - 08:45	1: Welcome & Introduction Petra Hartmann, Minden, Germany
08:45 - 12:15	Session 1: Diagnosis and assessment Marjo Campmäns-Kuijpers, Groningen, The Netherlands Petra Hartmann, Minden, Germany
	08:45 - 09:30 2: Diagnosis, anatomy and physiology in IBD Marc Ferrante, Leuven, Belgium
	09:30 - 10:00 3: Psychosocial implications of living with IBD Kay Greveson, London, United Kingdom
	10:00 - 10:30 4: Nutritional assessment in IBD Konstantinos Gerasimidis, Glasgow, United Kingdom
10:30 - 10:45	Coffee break
	10:45 - 11:15 5: Surgery in IBD Michel Adamina, Winterthur, Switzerland
	11:15 - 11:45 6: Medical treatment Dominik Bettenworth, Münster, Germany
	11:45 - 12:15 7: Adherence Susanna Jähgult, Stockholm, Sweden
12:15 - 13:15	Lunch break

Wednesday, March 6, 2019, cont.

Programme overview (as of February 1, 2019)

B3 M5-6, Hall B, Bella Center

13:15 - 14:45	Session 2: Case studies – Disease management Władysława Czuber-Dochan, London, United Kingdom Catherine Wall, London, United Kingdom
13:15 - 14:00	EITHER: 8a: Workshop 1 – UC Management (Group A) (B3 M5-6, Hall B, Bella Center) Nik Sheng Ding, Melbourne, Australia OR: 8b: Workshop 2 – CD Management (Group B) (B3 M9-10, Hall B, Bella Center) Marieke Pierik, Maastricht, The Netherlands
14:00 - 14:45	EITHER: 8a: Workshop 1 – UC Management (Group B) (B3 M9-10, Hall B, Bella Center) Nik Sheng Ding, Melbourne, Australia OR: 8b: Workshop 2 – CD Management (Group A) (B3 M5-6, Hall B, Bella Center) Marieke Pierik, Maastricht, The Netherlands
14:45 - 15:00	Coffee break
15:00 - 16:05	Session 3: Multidisciplinary management in IBD Władysława Czuber-Dochan, London, United Kingdom Catherine Wall, London, United Kingdom
15:05 - 15:35	9: Nutritional management in IBD Catherine Wall, London, United Kingdom
15:35 - 16:05	10: Nursing roles in IBD management Susanna Jäghult, Stockholm, Sweden
16:05 - 16:15	11: Closing remarks Petra Hartmann, Minden, Germany

6th ECCO-ESGAR Ultrasound Workshop – Advanced



Date: Wednesday, March 6, 2019
Time: 09:30-13:40
Organisation: EduCom in collaboration with ESGAR
Target audience: Physicians, Radiologists, Surgeons, Paediatricians
Registration: For registered participants only. No onsite registration.
CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

*Programme overview (as of February 1, 2019)
B3 M1-2, Hall B, Bella Center*

09:30 - 09:40	1: Welcome & Introduction Antonio López-Sanromán, Madrid, Spain Giovanni Maconi, Milan, Italy
09:40 - 11:40	Session 1: Assessment of IBD activity Antonio López-Sanromán, Madrid, Spain Jordi Rimola, Barcelona, Spain
	2: How to monitor activity in Crohn's Disease Torsten Kucharzik, Lüneburg, Germany
	3: Interactive video presentation 1 Torsten Kucharzik, Lüneburg, Germany
	4: Assessing and grading postoperative recurrence Stephan Vavricka, Zurich, Switzerland
	5: Interactive video presentation 2 Stephan Vavricka, Zurich, Switzerland
	6: The contribution of ultrasound in Ulcerative Colitis Christian Maaser, Lüneburg, Germany
	7: Interactive video presentation 3 Christian Maaser, Lüneburg, Germany
11:40 - 12:10	Light lunch
12:10 - 13:20	Session 2: Assessment of complications in Crohn's Disease Giovanni Maconi, Milan, Italy
	8: Elastography and CEUS to characterize strictures and abdominal masses in Crohn's Disease Rune Wilkens, Copenhagen, Denmark
	9: Interactive video presentation Rune Wilkens, Copenhagen, Denmark
	10: Transperineal ultrasound to detect, assess and monitor perianal Crohn's Disease Giovanni Maconi, Milan, Italy
	11: Interactive video presentation Giovanni Maconi, Milan, Italy
13:20 - 13:40	12: Post course test Summary and closing remarks Giovanni Maconi, Milan, Italy

4th Advanced ECCO:

EduCational COurse for Industry

Date:	Wednesday, March 6, 2019
Time:	14:00-18:00
Organisation:	ClinCom
Target audience:	Corporate Members & Non-Corporate Members
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	N/A

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

Auditorium 15, Hall A, Bella Center

14:00 - 14:05	1: Welcome & Introduction Silvio Danese, Milan, Italy
14:05 - 14:55	2: Session 1: Individualised therapy: The role of prognostic biomarkers Shomron Ben-Horin, Ramat Gan, Israel Panel discussion and interaction with the audience: Shomron Ben-Horin, Ramat Gan, Israel Silvio Danese, Milan, Italy Brihad Abhyankar, Dublin, Ireland (Theravance) Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Swati Tole, San Francisco, United States (Roche)
14:55 - 15:45	3: Session 2: From phase 3 to first-line use Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France Panel discussion and interaction with the audience: Brian Feagan, London, Canada Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France Fabio Cataldi, Cambridge, United States (AbbVie) Scott Plevy, Spring House, United States (Johnson & Johnson) Elmer Schabel, Bonn, Germany (Federal Institute of Drugs and Medical Products)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: Challenges in paediatric study design Anne Griffiths, Toronto, Canada Panel discussion and interaction with the audience: Lissy de Ridder, Rotterdam, The Netherlands Anne Griffiths, Toronto, Canada Laurence D'Agay, Boudry, Switzerland (Celgene) Peter Szitanyi, Prague, Czech Republic (Charles University) William Treem, Cambridge, United States (Takeda)
17:05 - 17:55	5: Session 4: EMA recommendations for clinical trial design in IBD Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Panel discussion and interaction with the audience: Mark Ainsworth, Copenhagen, Denmark John Mansfield, Newcastle Upon Tyne, United Kingdom Julián Panés, Barcelona, Spain Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim) Freddy Cornillie, Kriens, Switzerland (MSD International)
17:55 - 18:00	6: Closing remarks Krisztina Gecse, Amsterdam, The Netherlands

5th Y-ECCO Basic Science Workshop

Date:	Wednesday, March 6, 2019
Time:	12:30-16:30
Organisation:	Y-ECCO
Target audience:	Basic scientists, Physicians, Paediatricians, Surgeons, IBD Nurses
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)
 B3 M7-8, Hall B, Bella Center

12:30 - 12:35	1: Welcome & Introduction Demystifying complex molecular techniques Nuha Yassin, Birmingham, United Kingdom
12:35 - 13:50	Session 1: Complex genetics and functional epigenetics Charlotte Hedin, Stockholm, Sweden Dermot McGovern, Los Angeles, United States
	12:35 - 13:05 2: Complex genetics and functional epigenetics Dermot McGovern, Los Angeles, United States
	13:05 - 13:20 3: Abstract 1: Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients Sare Verstockt, Leuven, Belgium Presented as P821 in the poster exhibition
	13:20 - 13:35 4: Abstract 2: Signalling and transcriptional network propagation uncovers novel Ulcerative Colitis pathogenetic pathways from single nucleotide polymorphisms Dezso Modos, Cambridge, United Kingdom Presented as P011 in the poster exhibition
	13:35 - 13:50 5: Abstract 3: The regulatory landscape of intestinal cells – investigating the transcriptional effect of autophagy impairment observed in Crohn's disease using organoid and network biology approaches Agatha Treveil, Norwich, United Kingdom Presented as DOP08 in DOP Session 1
13:50 - 14:15	Meet the speakers break
14:15 - 15:30	Session 2: Understanding and integrating the 'omics' in IBD Elaine Holmes, London, United Kingdom Nuha Yassin, Birmingham, United Kingdom
	14:15 - 14:45 6: Understanding and integrating the 'omics' in IBD Elaine Holmes, London, United Kingdom
	14:45 - 15:00 7: Abstract 4: Supplementation with butyrate producing bacteria reduces tumor load in a mouse model of colitis associated cancer Ana Montalbar-Arques, Zurich, Switzerland
	15:00 - 15:15 8: Abstract 5: Myenteric plexitis and post-operative recurrence in Crohn's disease: the role of enteric glial cells and ICAM-1 Catherine Le Berre, Nantes, France
	15:15 - 15:30 9: Abstract 6: The cytokine milieu in patients with Inflammatory Bowel Disease impacts the phenotype of mesenchymal stromal cells Marieke Barnhoorn, Leiden, The Netherlands
15:30 - 16:25	Session 3: Group session – Which methods should you choose? Moderators: Dominik Bettenworth, Münster, Germany Johan Burisch, Copenhagen, Denmark Nik Sheng Ding, Melbourne, Australia Expert panel: Isabelle Cleynen, Leuven, Belgium Elaine Holmes, London, United Kingdom Dermot McGovern, Los Angeles, United States
16:25 - 16:30	10: Closing remarks and Y-ECCO best abstract awards Nuha Yassin, Birmingham, United Kingdom

11th Y-ECCO Career Workshop

Date: Wednesday, March 6, 2019
Time: 17:00-19:00
Organisation: Y-ECCO
Target audience: Physicians, Paediatricians, Surgeons, IBD Nurses
Registration: For registered participants only. No onsite registration.
CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

*Programme overview (as of February 1, 2019)
B3 M7-8, Hall B, Bella Center*

Modern career enhancing skills		
17:00 - 17:05	1: Welcome & Introduction Johan Burisch, Copenhagen, Denmark	
17:05 - 18:00	Session 1: Keys to the IBD kingdom – fellowships and beyond Dominik Bettenworth, Münster, Germany Charlotte Hedin, Stockholm, Sweden	
	17:05 - 17:30 2: The view of the fellow Pieter Hindryckx, Ghent, Belgium	
	17:30 - 18:00 3: The view of the host Siew Ng, Hong Kong, China	
18:00 - 19:00	Session 2: Optimising your career using modern technology Nik Sheng Ding, Melbourne, Australia Nuha Yassin, Birmingham, United Kingdom	
	18:00 - 18:30 4: Science and social media – why bother? Charlie Lees, Edinburgh, United Kingdom	
	18:30 - 19:00 5: Living like an academic athlete Florian Rieder, Cleveland, United States	
19:00	6: Closing remarks Johan Burisch, Copenhagen, Denmark	

1st ECCO-ESGAR Basic Imaging Workshop



Date:	Wednesday-Thursday, March 6-7, 2019
Time:	Wednesday, March 6: 14:30-19:00 Thursday, March 7: 07:30-12:00
Organisation:	EduCom in collaboration with ESGAR
Target audience:	Physicians, Radiologists, Surgeons, Paediatricians
Registration:	For registered participants only. No onsite registration.
CME accreditation:	7 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

B3 M1-2, Hall B, Bella Center

14:30 - 14:45	1: Day 1. Welcome & pre-course test Marietta Iacucci, Birmingham, United Kingdom James Lindsay, London, United Kingdom
14:45 - 16:30	Session 1: Endoscopy – Endoscopic assessment and scoring systems in IBD: "The simpler the better" Krisztina Gecse, Amsterdam, The Netherlands Marietta Iacucci, Birmingham, United Kingdom
14:45 - 15:05	2a: Presentation: Endoscopic scoring systems in IBD: When and How can I EXIT? Raf Bisschops, Leuven, Belgium
15:05 - 15:20	2b: Video case: Endoscopic scoring systems in IBD: When and How can I EXIT? Krisztina Gecse, Amsterdam, The Netherlands
15:20 - 15:45	2c: Panel discussion: Endoscopic scoring systems in IBD: When and How can I EXIT? Filip Baert, Roeselare, Belgium Raf Bisschops, Leuven, Belgium James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom
15:45 - 16:05	3a: Presentation: How to write a great IBD endoscopy report? Matt Rutter, North Tees, United Kingdom
16:05 - 16:30	3b: Panel discussion: How to write a great IBD endoscopy report? Filip Baert, Roeselare, Belgium Raf Bisschops, Leuven, Belgium James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom

16:30 - 17:00 Coffee break

Wednesday, March 6, 2019, cont.

Programme overview (as of February 1, 2019)

B3 M1-2, Hall B, Bella Center

17:00 - 18:30	Session 2: Endoscopy – Surveillance and dysplasia management in IBD Matt Rutter, North Tees, United Kingdom Raf Bisschops, Leuven, Belgium
17:00 - 17:20	4a: Presentation: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom
17:20 - 17:35	4b: Video case: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? Federica Furfaro, Milan, Italy Paulo Kotze, Curitiba, Brazil
17:35 - 18:00	4c: Panel discussion: Surveillance colonoscopy and dysplasia characterisation: How do I do and manage it? Raf Bisschops, Leuven, Belgium James East, Oxford, United Kingdom Marietta Iacucci, Birmingham, United Kingdom Taku Kobayashi, Tokyo, Japan Matt Rutter, North Tees, United Kingdom Henit Yanai, Petah Tikva, Israel
18:00 - 18:30	5: Small bowel Crohn's Disease – is MRE enough? Do we still need enteroscopy? Taku Kobayashi, Tokyo, Japan
18:30 - 19:00	6: Day 1: Post-course test and Closing remarks Marietta Iacucci, Birmingham, United Kingdom

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)

B3 M3-4, Hall B, Bella Center

07:30 - 07:40	7: Day 2: Welcome & Introduction Andrea Laghi, Rome, Italy Giovanni Maconi, Milan, Italy
07:40 - 08:30	Session 3: Ultrasound and MRI – Introductory Lectures Giovanni Maconi, Milan, Italy
	07:40 - 08:05 8: Intestinal Ultrasound Christian Maaser, Lüneburg, Germany
	08:05 - 08:30 9: Enterico-MRI Jordi Rimola, Barcelona, Spain
08:30 - 11:30	Session 4: Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations
	10: Management of suspected IBD Torsten Kucharzik, Lüneburg, Germany Francesca Maccioni, Rome, Italy
	11: Assessment of Crohn's Disease activity Stephan Vavricka, Zurich, Switzerland Pasquale Paolantonio, Rome, Italy
08:30 - 11:30	12: Intestinal complications of Crohn's Disease Rune Wilkens, Copenhagen, Denmark Arun Gupta, London, United Kingdom
	13: Post-operative recurrence of Crohn's Disease Britta Siegmund, Berlin, Germany Cristiana Bonifacio, Rozzano, Italy
	14: Perianal Crohn's Disease Giovanni Maconi, Milan, Italy Giuseppe Lo Re, Palermo, Italy
	15: Ulcerative Colitis Christian Maaser, Lüneburg, Germany Michael Torkzad, London, United Kingdom
11:30 - 12:00	16: Day 2: Post-course test and Closing remarks Andrea Laghi, Rome, Italy Giovanni Maconi, Milan, Italy



ECCO IBD Curriculum



ECCO's Framework of Education

- Concise yet complete: What gastroenterologists need to know to develop expertise in the IBD field
- Developed in part by ECCO Officers and ECCO National Representatives
- Provides a future framework for ECCO Educational Activities
- Close to 500 items from the e-CCO Learning Platform are already mapped to the ECCO IBD Curriculum
 - e-Courses
 - Talking Heads
 - Educational Podcasts
 - Skills Videos
 - Webcasts from the ECCO Congress Scientific Programme and Educational Activities



Scan and visit
www.e-learning.ecco-ibd.eu



7th SciCom Workshop: Mechanisms and therapeutic modulation of mucosal healing in IBD

Date:	Thursday, March 7, 2019
Time:	08:45-12:00
Organisation:	SciCom
Target audience:	Basic scientists and interested clinicians
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	2 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)
B3 M9-10, Hall B, Bella Center

<i>Mechanisms and therapeutic modulation of mucosal healing in IBD</i>		
08:45 - 10:10	Session 1: Intestinal regeneration and its disruption in IBD	
	Jesús Rivera-Nieves, San Diego, United States	
	Janneke Van der Woude, Rotterdam, The Netherlands	
	08:45 - 08:55 1: Welcome & Introduction Shomron Ben-Horin, Ramat Gan, Israel	
	08:55 - 09:20 2: Epithelial barrier defects in the pathogenesis of IBD Sebastian Zeissig, Dresden, Germany	
	09:20 - 09:45 3: Intestinal immunity – friend or foe in regeneration? Michael Scharl, Zurich, Switzerland	
	09:45 - 10:10 4: The extracellular matrix as a central regulator of intestinal regeneration TBD	
10:10 - 10:30	Coffee break	
10:30 - 11:45	Session 2: Clinical assessment and therapeutic modulation of intestinal regeneration in IBD	
	Gerhard Rogler, Zurich, Switzerland	
	Sebastian Zeissig, Dresden, Germany	
	10:30 - 10:55 5: Epithelial transplantation to facilitate mucosal healing Mamoru Watanabe, Tokyo, Japan	
	10:55 - 11:20 6: Novel endoscopic approaches for the assessment of mucosal healing Maximilian Waldner, Erlangen, Germany	
	11:20 - 11:45 7: New drugs to support tissue healing – insights from other fields Florian Rieder, Cleveland, United States	
11:45 - 12:00	8: Closing remarks	
	Sebastian Zeissig, Dresden, Germany	

1st Guideline Methodology and GRADE Workshop

Date:	Thursday, March 7, 2019
Time:	08:00-12:00
Organisation:	GuiCom
Target audience:	All health care professionals interested in guidelines and guideline development
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, March 7, 2019

*Programme overview (as of February 1, 2019)
B3 M7-8, Hall B, Bella Center*

08:00 - 10:15	Session 1 Gionata Fiorino, Milan, Italy Joana Torres, Lisbon, Portugal
08:00 - 08:15	1: Welcome & Introduction Gionata Fiorino, Milan, Italy
08:15 - 09:45	2: What you need to know to understand the GRADE methodology Stefanos Bonovas, Milan, Italy
09:45 - 10:05	3: Patient perspectives of guidelines – why should patients be involved Ciara Drohan, Dublin, Ireland (EFCCA patient representative) Evelyn Groß, Graz, Austria (EFCCA patient representative) Sanna Lönnfors, Pyhtää, Finland (EFCCA patient representative) Marko Perovic, Belgrade, Serbia (EFCCA patient representative)
10:05 - 10:15	4: What is the role of patients in the GRADE methodology Stefanos Bonovas, Milan, Italy
10:15 - 10:45	Coffee break
10:45 - 12:00	Session 2 Gionata Fiorino, Milan, Italy Tim Raine, Cambridge, United Kingdom
10:45 - 11:00	5: How to perform a scientifically sound literature research – the new ECCO SOP Joana Torres, Lisbon, Portugal
11:00 - 11:45	6: The pros and cons of using the GRADE vs. Oxford methodology Marién González Lorenzo, Milan, Italy Theodore Lytras, Athens, Greece
11:45 - 12:00	7: Discussion and conclusion Gionata Fiorino, Milan, Italy Joana Torres, Lisbon, Portugal

6th P-ECCO Educational Course

Date:	Thursday, March 7, 2019
Time:	08:00-10:00
Organisation:	P-ECCO in collaboration with N-ECCO
Target audience:	Advanced IBD Nurses; Paediatricians, Physicians, Surgeons
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	2 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)

C1 M0, Hall C, Bella Center

08:00 - 10:00 Dealing with challenging adolescents with IBD		
08:00 - 08:05	1: Welcome David Wilson, Edinburgh, United Kingdom	
08:05 - 08:35	2: I am not a challenging patient: I want to live a normal life! Rosie Campbell, London, United Kingdom	
08:35 - 09:05	3: Non-adherence and motivational interviewing Ailsa Hart, London, United Kingdom	
09:05 - 09:30	4: Helping adolescents to thrive Vikki Garrick, Glasgow, United Kingdom	
09:30 - 10:00	5: Transitional care and sexuality Patrick van Rheenen, Groningen, The Netherlands	

13th N-ECCO Network Meeting

Date:	Thursday, March 7, 2019
Time:	10:30-16:45
Organisation:	N-ECCO
Target audience:	IBD Nurses - advanced level
Registration:	For registered participants only. No onsite registration.
CME accreditation:	N/A

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)

C1 M0, Hall C, Bella Center

10:30 - 10:45	1: Welcome & Introduction Announcement of the N-ECCO Research Grant Award 2019 Kay Greveson, London, United Kingdom
10:45 - 12:00	Session 1: New research and developments in IBD Wladyslawa Czuber-Dochan, London, United Kingdom Susanna Jäghult, Stockholm, Sweden
10:45 - 11:15	2: New model of e-health – “IBD Home” Susanna Jäghult, Stockholm, Sweden
11:15 - 11:30	3: Nurse Abstract 1: Fatigue and physical activity in individuals with Inflammatory Bowel Disease: A feasibility cross-sectional, correlational study Dawn Farrell, Tralee, Ireland Presented as N01 in poster exhibition
11:30 - 11:45	4: Nurse Abstract 2: Inflammatory Bowel Disease and pregnancy: The impact of education in knowledge and attitude of women in reproductive age. One-year follow-up study Triantafyllia Tsavdaroglou, Athens, Greece Presented as N02 in poster exhibition
11:45 - 12:00	5: Nurse Abstract 3: Can post biologic infusion monitoring be reduced? A multi-centred retrospective study Lisa Younge, London, United Kingdom Presented as N03 in poster exhibition
12:00 - 13:30	Lunch break
12:15 - 13:15	N-ECCO Network Meeting Lunch Satellite Symposium See page 113.

Thursday, March 7, 2019, cont.

Programme overview (as of February 1, 2019)

C1 M0, Hall C, Bella Center

13:30 - 15:00	Session 2: Clinical and practical IBD – how to work together with the patient Petra Hartmann, Minden, Germany Else Mikkelsen, Herning, Denmark
13:30 - 14:00	6: How to implement biosimilars Kay Greveson, London, United Kingdom
14:00 - 15:00	7: The importance of shared care in IBD – a tandem talk Anne Carol Elisabeth Jørgensen, Herlev, Denmark Büsra Nergiz, Søborg, Denmark (IBD Patient)
15:00 - 15:30 <i>Coffee break</i>	
15:30 - 16:30	Session 3: Different views of IBD care Kay Greveson, London, United Kingdom
15:30 - 16:30	8: Different ways to work with IBD patients – Descriptions from South Africa, Germany, Denmark, Sweden Palle Bager, Aarhus, Denmark Karin Davidson, Cape Town, South Africa Petra Hartmann, Minden, Germany Susanna Jäghult, Stockholm, Sweden
16:30 - 16:45	9: Closing remarks, N-ECCO in 2019 and beyond Kay Greveson, London, United Kingdom

8th S-ECCO IBD Masterclass in collaboration with ESCP

Date: Thursday, March 7, 2019
Time: 08:00-17:15
Organisation: S-ECCO in collaboration with ESCP
Target audience: Surgeons, Physicians, IBD Nurses
Registration: For online registered participants only. No onsite registration.
CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form.



Thursday, March 7, 2019

Programme overview (as of February 1, 2019)
C1 M2, Hall C, Bella Center

08:00 - 08:10	1: Welcome Willem Bemelman, Amsterdam, The Netherlands
08:10 - 10:00	Session 1: Hot debates in IBD surgery Geert D'Haens, Amsterdam, The Netherlands André D'Hoore, Leuven, Belgium
08:10 - 08:55	Debate 1: Perforating form of ileal Crohn's Disease
	08:10 - 08:20 2: What about the radiology? Andrea Laghi, Rome, Italy
	08:20 - 08:30 3: Only medical treatment can solve the problem! Julián Panés, Barcelona, Spain
	08:30 - 08:40 4: No! Surgery is the only solution! Antonino Spinelli, Milan, Italy
	08:40 - 08:55 Discussion
08:55 - 09:40	Debate 2: The failed pouch
	08:55 - 09:05 5: Diverting stoma is enough! Dieter Hahnloser, Lausanne, Switzerland
	09:05 - 09:15 6: Pouch excision and definitive stoma is much better! Pär Myrelid, Linköping, Sweden
	09:15 - 09:25 7: No! Redo pouch is fantastic! Conor Delaney, Cleveland, United States
	09:25 - 09:40 Discussion
09:40 - 10:00	8: Tandem talk: Outcome measures in IBD surgery Michel Adamina, Winterthur, Switzerland Laurent Beaugerie, Paris, France
10:00 - 10:30	Coffee break

Thursday, March 7, 2019, cont.

Programme overview (as of February 1, 2019)

C1 M2, Hall C, Bella Center

10:30 - 12:00	Session 2: The scientific IBD surgeon: Trial updates and free papers Michel Adamina, Winterthur, Switzerland Conor Delaney, Cleveland, United States
Trial updates	
10:30 - 10:40	9: Rectal stump or not after laparoscopic subtotal colectomy: Results of a 5-center European study Diane Mège, Clichy, France
10:40 - 10:50	10: Stoma rates in the biological era Paulo Kotze, Curitiba, Brazil
10:50 - 11:00	11: Early biomarkers for surgical complications in 250 CD patients Michele Carvello, Milan, Italy
Free papers	
11:00 - 11:10	12: Abstract 1: Iterative ileocolonic resection for Crohn's Disease: A prospective multicentric cohort study of the GETAID Chirurgie Sofalah Abdalla, Paris, France Presented as P558 in the poster exhibition
11:10 - 11:20	13: Abstract 2: Treatment of perianal fistulas in Crohn's Disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): A randomised controlled trial Karin Wasmann, Amsterdam, The Netherlands Presented as DOP73 in DOP Session 9
11:20 - 11:30	14: Abstract 3: Long-term function after transanal versus transabdominal ileal pouch-anal anastomosis for Ulcerative Colitis: A multicenter cohort study Antonino Spinelli, Milan, Italy Presented as P468 in the poster exhibition
11:30 - 11:45	15: Pregnancy and delivery in IBD patients Hagit Tulchinsky, Tel Aviv, Israel
11:45 - 12:00	16: Faecal diversion in severe anoperineal Crohn's Disease: Does it really work? Yves Panis, Clichy, France
12:00 - 13:25	Lunch break
12:15 - 13:15	Lunchtime Satellite Symposium (see pg. 113)
13:25 - 15:25	Session 3: Difficult decisions in IBD surgery Fabrizio Michelassi, New York, United States Yves Panis, Clichy, France
13:25 - 13:55	Debate 3: Can we prevent recurrence after surgery for CD?
13:25 - 13:35	17: Postoperative medical prevention after ileocecal resection for CD Pierre Michetti, Lausanne, Switzerland
13:35 - 13:45	18: Prevention by surgery is possible Christianne Buskens, Amsterdam, The Netherlands
13:45 - 13:55	Discussion

Thursday, March 7, 2019, cont.

Programme overview (as of February 1, 2019)

C1 M2, Hall C, Bella Center

13:55 - 14:45	Surgery is not always easy – Session
13:55 - 14:05	19: Open surgery for IBD patients: Never? Fabrizio Michelassi, New York, United States
14:05 - 14:15	20: Upper GI CD: What are the surgical options? Paulo Kotze, Curitiba, Brazil
14:15 - 14:25	21: Subtotal colectomy first for all UC patients? André D'Hoore, Leuven, Belgium
14:25 - 14:35	22: Oncologic decisions in IBD surgery Phillip Fleshner, Los Angeles, United States
14:35 - 14:45	Discussion
14:45 - 15:25	Surgical technique video session
14:45 - 14:55	23: Laparoscopic subtotal colectomy for Acute Colitis Janindra Warusavitarne, London, United Kingdom
14:55 - 15:05	24: Long side-to-side stricturoplasty Fabrizio Michelassi, New York, United States
15:05 - 15:15	25: Flap for anoperineal fistula complicating CD Phil Tozer, London, United Kingdom
15:15 - 15:25	26: Gracilis muscle interposition for rectovaginal fistula complicating CD Oded Zmora, Tel Aviv, Israel
15:25 - 15:45	Coffee break
15:45 - 16:15	Session 4: Surgery in the era of biologics André D'Hoore, Leuven, Belgium Paulo Kotze, Curitiba, Brazil
15:45 - 16:00	27: Good news! Less surgery Jean-Frédéric Colombel, New York, United States
16:00 - 16:15	28: No! Biologics only delay surgery Willem Bemelman, Amsterdam, The Netherlands
16:15 - 17:00	Session 5: Consultants' corner on challenging cases Willem Bemelman, Amsterdam, The Netherlands Jean-Frédéric Colombel, New York, United States Conor Delaney, Cleveland, United States André D'Hoore, Leuven, Belgium Dieter Hahnloser, Lausanne, Switzerland
	Challenging cases
16:15-16:30	29: A refractory proctitis complicating CD Laura Beyer-Berjot, Marseille, France
16:30-16:45	30: A rectovaginal fistula complicating CD Diane Mège, Clichy, France
16:45-17:00	31: A chronic fistula after IPAA for UC Michele Carvello, Milan, Italy
17:00 - 17:15	Closing remarks Yves Panis, Clichy, France

4th ECCO-AOCC Forum: East meets West

Date:	Thursday, March 7, 2019
Time:	08:50-11:40
Organisation:	ECCO Governing Board
Target audience:	Physicians, Surgeons
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	N/A

Thursday, March 7, 2019


Programme overview (as of February 1, 2019)
C1 M3, Hall C, Bella Center

Session 1		
08:50 - 10:00	Glen Doherty, Dublin, Ireland Jiaming Qian, Beijing, China	
08:50 - 09:00	1: Welcome & Introduction Silvio Danese, Milan, Italy	
09:00 - 10:00	2: Tandem Talk: Surgical and medical approach for Fistulising Crohn's Disease Christianne Buskens, Amsterdam, The Netherlands Byong Duk Ye, Seoul, Korea	
10:00 - 10:30 Coffee break		
Session 2		
10:30 - 11:40	Peter Irving, London, United Kingdom Yoon Tae Jeen, Seoul, Korea	
10:30 - 11:30	3: Tandem Talk: When to start and when to stop biologics Taku Kobayashi, Tokyo, Japan Edouard Louis, Liège, Belgium	
11:30 - 11:40	4: Closing remarks Akira Andoh, Shiga, Japan	



European
Crohn's and Colitis
Organisation

We keep you informed at all times!



More reasons to join the ECCO Family!

JCC

- 2017 Impact Factor: 6.637
- ECCO Guidelines and Topical Reviews
- ECCO Scientific Workshop Reviews
- ECCO Position statements
- JCC online only (website)
- Printed copies to be purchased at OUP

ECCO Website

- ECCO Activities & Events
- Congress abstracts

ECCO News

- All the inside stories of ECCO
- ECCO Calls, Elections and Activities
- Literature Reviews

e-CCO Learning

- ECCO IBD Curriculum
- e-Courses and e-Library
- Congress abstracts
- Scientific articles
- Congress webcasts
- Educational Audio Podcasts
- Skills videos

Scan and contact the ECCO Office
www.ecco-ibd.eu



4th H-ECCO IBD Masterclass

Date:	Thursday-Friday, March 7-8, 2019
Time:	Thursday, March 7: 13:30-17:15 Friday, March 8: 08:00-12:00
Organisation:	H-ECCO, endorsed by ESP
Target audience:	Histopathologists, Clinicians
Registration:	For registered participants only. No onsite registration.
CME accreditation:	6 CME Credits; prerequisite: completion of the online evaluation form.



Thursday, March 7, 2019

Programme overview (as of February 1, 2019)
B3 M9-10, Hall B, Bella Center

13:30 - 13:35	1: Welcome & Introduction Roger Feakins, London, United Kingdom
13:35 - 15:15	Session 1: Basic Paula Borrallo Nunes, Lisbon, Portugal James Lindsay, London, United Kingdom
	13:35 - 13:55 2: Clinical diagnosis of IBD James Lindsay, London, United Kingdom
	13:55 - 14:15 3: Biopsy diagnosis and classification of IBD Gert de Hertogh, Leuven, Belgium
	14:15 - 14:35 4: How to deal with an IBD resection specimen Monika Tripathi, Cambridge, United Kingdom
	14:35 - 14:55 5: Histological differential diagnosis of IBD Roger Feakins, London, United Kingdom
	14:55 - 15:15 6: Acute and fulminant colitis Francesca Rosini, London, United Kingdom
15:15 - 15:45	Coffee break
15:45 - 17:15	Session 2: Treatment and its effects Roger Feakins, London, United Kingdom Francesca Rosini, London, United Kingdom
	15:45 - 16:05 7: Specific effects of IBD drugs on the mucosa Gert de Hertogh, Leuven, Belgium
	16:05 - 16:25 8: Diversion proctocolitis Monika Tripathi, Cambridge, United Kingdom
	16:25 - 16:50 9: Pouch and pre-pouch pathology: Does it matter? Shaun Walsh, Dundee, United Kingdom
	16:50 - 17:15 10: Hot topics in IBD Magali Svrcek, Paris, France

Friday, March 8, 2019

Programme overview (as of February 1, 2019)
B3 M9-10, Hall B, Bella Center

08:00 - 09:45

Session 3: Age and demographics

Gert de Hertogh, Leuven, Belgium

Magali Svrcek, Paris, France

08:00 - 08:15	11: Demographics of IBD Johan Burisch, Copenhagen, Denmark
08:15 - 08:35	12: Paediatric IBD – clinical aspects Patrick van Rheenen, Groningen, The Netherlands
08:35 - 08:55	13: Paediatric IBD – pathological features Paula Borralho Nunes, Lisbon, Portugal
08:55 - 09:15	14: Older onset IBD – clinical aspects Guillaume Savoye, Rouen, France
09:15 - 09:35	15: Histology of IBD and related colitides in older patients Vincenzo Villanacci, Brescia, Italy
09:35 - 09:45	16: Slide seminar case 1 Roger Feakins, London, United Kingdom

09:45 - 10:15 Coffee break

10:15 - 11:55

Session 4: Tumours

Monika Tripathi, Cambridge, United Kingdom

Vincenzo Villanacci, Brescia, Italy

10:15 - 10:35	17: Serrated lesions in IBD Roger Feakins, London, United Kingdom
10:35 - 10:55	18: Clinical features of IBD-related tumours Laurent Beaugerie, Paris, France
10:55 - 11:15	19: Pathology of colorectal cancer in IBD Magali Svrcek, Paris, France
11:15 - 11:35	20: Other tumours in IBD Paula Borralho Nunes, Lisbon, Portugal
11:35 - 11:55	21: Slide seminar cases 2 and 3 Paula Borralho Nunes, Lisbon, Portugal Monika Tripathi, Cambridge, United Kingdom

11:55 - 12:00

22: Closing remarks

Roger Feakins, London, United Kingdom



European
Crohn's and Colitis
Organisation

ECCO Educational Workshops 2019

ECCO Workshops



61st ECCO Workshop
Lancara, **Cyprus** - June 15, 2019



62nd ECCO Workshop
Tel Aviv, **Israel** - June 19, 2019



63rd ECCO Workshop
Santiago, **Chile** - July 3, 2019



64th ECCO Workshop
New Delhi, **India** - November 9, 2019



65th ECCO Workshop
Riga, **Latvia** - December 6, 2019



LATVIA



Spreading standards in IBD:
Your presence counts!

Scan and contact the ECCO Office
www.ecco-ibd.eu



4th D-ECCO Workshop

Date:	Friday, March 8, 2019
Time:	08:15-12:25
Organisation:	D-ECCO
Target audience:	Dietitians, IBD Nurses, Physicians
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Friday, March 8, 2019

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

08:15 - 08:20	1: Welcome Marjo Campmans-Kuijpers, Groningen, The Netherlands
08:20 - 09:30	Session 1: Science, diet and IBD Rotem Sigall-Boneh, Tel Aviv, Israel Catherine Wall, London, United Kingdom
	08:20 - 08:38 2: Breastfeeding and risk of IBD Joana Torres, Lisbon, Portugal
	08:38 - 08:56 3: Diet and microbiome in IBD Marjo Campmans-Kuijpers, Groningen, The Netherlands
	08:56 - 09:15 4: Immunological effects of nutritional interventions in IBD Dror Shouval, Tel Hashomer, Israel
	09:15 - 09:30 5: Growth and bone health in patients with IBD David Wilson, Edinburgh, United Kingdom
09:30 - 09:50	Coffee break
09:50 - 10:50	Session 2: Practical clinical nutrition in IBD Marjo Campmans-Kuijpers, Groningen, The Netherlands Arie Levine, Tel Aviv, Israel
	09:50 - 10:10 6: Patients' and carers' perception about the role of diet in IBD Konstantinos Gerasimidis, Glasgow, United Kingdom
	10:10 - 10:30 7: Novel dietary treatments for IBD – how to advise the patient Rotem Sigall-Boneh, Tel Aviv, Israel
	10:30 - 10:50 8: Tandem talk: The future IBD clinic – the role of dietitian and nurse in the management of IBD patients Kay Greveson, London, United Kingdom Catherine Wall, London, United Kingdom
10:50 - 11:10	Coffee break

Friday, March 8, 2019, cont.

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

Session 3: Panel discussion – Cases & questions from the audience Konstantinos Gerasimidis, Glasgow, United Kingdom (Moderator) Jackie Falconer, London, United Kingdom Arie Levine, Tel Aviv, Israel James Lindsay, London, United Kingdom Miranda Lomer, London, United Kingdom Lisa Younge, London, United Kingdom	
11:10 - 12:20	
	Abstract presentations
11:10 - 11:20	9: Abstract 1: Development of an inflammatory bowel disease specific nutrition screening tool (IBD-NST) Catherine Wall, London, United Kingdom Presented as P599 in the poster exhibition
11:20 - 11:30	10: Abstract 2: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with Inflammatory Bowel Disease mimicking prebiotic activity and proving effects on the treatment of the disease Sonia Facchin, Padova, Italy Presented as P655 in the poster exhibition
Case presentations and panel discussion	
11:30 - 11:37	11: Nutritional factors in transitional IBD Shameer Mehta, London, United Kingdom
11:37 - 11:47	Panel discussion
11:47 - 11:54	12: Pre-operative nutritional optimisation in stricturing Crohn's Disease Dearbhla O'Hanlon, London, United Kingdom
11:54 - 12:04	Panel discussion
12:04 - 12:11	13: Complications secondary to intravenous iron infusion in PIBD patient Richard Russell, Glasgow, United Kingdom
12:11 - 12:20	Panel discussion
12:20 - 12:25	14: Closing remarks Konstantinos Gerasimidis, Glasgow, United Kingdom

Congress information

Badges

Keep your badge visible at all times throughout the entire Congress and social events. The coloured stripes on your name badge represent the following:

- Congress delegates, Faculty members, Press
- Exhibitors, Participants of educational activities only
- Congress day ticket holders
- Congress Organiser, Staff

Banks and ATM

Most banks in Copenhagen are open from Monday to Friday from 10:00 to 16:00. There are ATMs (Automatic Teller Machine) at Bella Center and all over the city of Copenhagen. At the airport and main station and along the main streets, you will find currency exchange offices as well.

Certificate of attendance

After the Congress, registered delegates can download and print their certificates of attendance from the online registration system's individual user area.

Cloakroom

The cloakroom is located in Hall E of Bella Center. Neither Bella Center nor the congress organisers are liable for any loss of belongings dropped off at the cloakroom.

Coffee breaks

Coffee breaks are always served in the Exhibition Hall (Hall C) at Bella Center. ECCO invites delegates to enjoy coffee and pastries free of charge. Water fountains are available throughout the congress venue. Lunch and other snacks are also available at cash catering stations. Delegates attending Satellite Symposia may be offered food and beverages prior to or after the symposium.

Congress bags

Registered delegates with a badge indicating eligibility, excluding exhibitors, can collect an ECCO'19 congress bag produced by Township. ECCO fully supports Township's mission of creating sustainable economic opportunity for women in South Africa's township communities and their production of fair trade, environmentally-friendly products.



Congress documentation

Abstract USB drives

Claim your USB drive by presenting your personal USB drive voucher, which you have received by email. If you have not received the USB drive voucher, please visit the Registration desk for assistance.

Abstracts – Online access

All abstracts of the ECCO'19 Congress can also be found online at www.ecco-ibd.eu and the online editions of the Journal of Crohn's and Colitis. Alternatively, delegates can also look up abstracts online at the Internet Lounge in Hall B.

Online streaming (post-event)

Members of ECCO can access the presentations of the 14th Congress of ECCO after the event – online at www.ecco-ibd.eu in the e-Library of the e-CCO Learning platform. Presentation availability is subject to speaker authorisation.

Congress organiser

OCEAIN – Organisation, Congress, Emotion, Association, iNnovation GmbH*

ECCO Office

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0) 1-710 22 42

Fax: +43-(0) 1-710 22 42-001

E-mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu/ecco19



European
Crohn's and Colitis
Organisation

*service provider fully owned by European Crohn's and Colitis Organisation

Congress venue

Bella Center

Center Boulevard 5

DK-2300 Copenhagen, Denmark

www.bellacentercopenhagen.dk



Credit cards and cheques

All major credit cards, including Visa, MasterCard, Diners and American Express are accepted in most of the establishments as restaurants, hotels and shopping-centres and stores. Travel checks can be cashed in most of the banks and exchange offices. When paying by credit card for your shopping, you will be asked to show identification or your pin code. Please have your ID card or passport with you all the time, otherwise they may refuse to accept your credit card as payment.

Currency

The official currency in Denmark is the Danish Krone (DKK). The exchange rate is approximately 1.5 Kroner to 1 Euro. You can exchange your currency at all banks as well as many exchange offices in Copenhagen. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency. Payment at cash catering onsite is also possible in Euro.

Disclaimer

Please note that in the event of a cancellation of the congress by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organiser at that time. You may wish to insure yourself directly against such a risk.

ECCOlogical

Congresses and exhibitions are commonly known for producing excessively high volumes of waste. ECCO believes that continued commitment to eco-friendly and sustainable meetings benefits host destinations and elevates the delegate experience.



At the 14th Congress of ECCO, we are dedicated in our commitment to leaving a minimal ecological footprint as we strive for greener meetings. For details, visit the ECCO Congress website at www.ecco-ibd.eu/ecco19.

Face-to-face with ECCO

Following its success in past congresses, the Congress will again hold the "Face-to-face with ECCO" during the coffee breaks at the ECCO Booth in the entrance hall. You are welcome to stop by to have a chat with ECCO Officers in an informal atmosphere. Engage in lively discussions about IBD and ECCO's Initiatives!

Floor plans

Please refer to page 119-121.

General regulations

Visitors of the 14th Congress of ECCO must fully comply with the following regulations:

- Entrance to the 14th Congress of ECCO and affiliated events is granted only with the congress badge.
- Entrance to the "ECCO Interaction: Hearts and Minds" is only granted with an entrance ticket which needs to be collected at the Registration desk.
- The congress organiser may not be held liable for any theft and/or loss of a visitor's individual property. It is the visitor's sole responsibility to keep their belongings safe.

Industry exhibition

Please refer to pg. 117.

Information on Copenhagen

For information on Copenhagen, such as tours, restaurants, museums, churches/synagogues/mosques, stop by the "Copenhagen information" desk at the Registration area in Hall E.

Insurance and liability

Neither the congress organiser nor Bella Center will assume any responsibility whatsoever for damage or injury to persons or property during the Congress. Participants are recommended to arrange their personal travel and health insurance.

Internet access

Use the network "ECCO2019", no password required, to access free WiFi throughout the congress venue. Internet access is also provided in the Internet Lounge located in Hall B. The ECCO Office asks delegates to respect the viewing time of max. 5 minutes per person.

Language

The official language of the Congress is English. No simultaneous translation will be provided.

Lost and found

For lost and found service at Bella Center, please stop by the ECCO Booth in Hall E.

For help in locating property lost outside Bella Center, please inform the registration desk.

Medical facilities

Medical assistance can be provided by qualified staff onsite. If you need immediate assistance with first aid, please contact the security/first aid personnel found in every hall.

Members' Lounge

Exclusive for ECCO Members, the Members' Lounge is located in the Exhibition Hall (Hall C), and is ideal for delegates who want to hold private meetings, or even just sit and relax. All electronic devices can be charged here, and Members can enjoy an open buffet to fuel the busy day.

Members' Lounge opening hours:

Thursday, March 7, 2019	10:30 - 19:45
Friday, March 8, 2019	07:15 - 19:45
Saturday, March 9, 2019	08:00 - 13:00

Photos, Filming and Recording

The recording of any sort of a presentation without the consent of the organiser, including but not limited to audio/video recording and photography, is strictly prohibited at the ECCO'19 Scientific programme, Educational programme and all hard copy poster presentations. This regulation encompasses the use of (smartphones) mobile devices and any professional recording device.

The entire scientific programme and selected educational activities are officially recorded by the organiser and will be published open access on the ECCO e-Learning platform after the Congress accessible to the entire IBD Community for a limited period of time. All ECCO Members however can view these official recordings at no cost throughout the entire year. All abstracts and presentations (subject to speaker authorisation) are archived in the e-Library.

Poster exhibition

Please refer to pg. 65.

Programme changes

ECCO cannot assume liability for any changes in the ECCO'19 Congress programme and programmes of the educational activities due to external or unforeseen circumstances.

Public transportation

The congress center is well served by Copenhagen's metro system with the station "Bella Center" on the green line M1.



To get to Øksnehallen, take the green metro line M1 from "Bella Center st. (Metro)" headed towards "Vestamager st." and get off at "Ørestad st.". From there, take the regional train headed towards "Helsingør st.", and get off at "Hovedbanegården København H" (Copenhagen Central Station). Then, continue straight ahead walking via Reventlowsgade to Halmtorvet until you reach Øksnehallen. (Time travel: approx. 29 min)

Visit www.rejseplanen.dk to plan your travel in detail.

Registration and accommodation

All registration procedures for the 14th Congress of ECCO have been conducted online. Should you wish to register onsite, visit the registration desk in Hall E for assistance.

Registration desk and ECCO Congress Office

The Registration Area is located in Hall E of Bella Center.

You will find the ECCO Congress Office in Office 18-19 on the 1st floor of Bella Center.

ECCO Congress Office and the Registration desk opening hours:

Wednesday, March 6, 2019	07:00 - 19:00
Thursday, March 7, 2019	07:00 - 19:00
Friday, March 8, 2019	07:00 - 19:00
Saturday, March 9, 2019	08:00 - 13:00

Registration fees

Fee in EURO (including 25% Danish VAT)	Early registration until November 14, 2018	Late registration until February 19, 2019	Onsite registration after February 19, 2019
ECCO Member Congress registration fees:			
Regular/Regular (Y-ECCO) Member Congress fee	250.-	320.-	400.-
Nurse Member Congress fee	55.-	95.-	145.-
Affiliate Member Congress fee ¹	55.-	95.-	145.-
Non-Member Congress registration fees:			
Non-Member Congress fee	605.-	685.-	770.-
Nurse Non-Member Congress fee ²	355.-	395.-	545.-
Affiliate Non-Member Congress fee ³	355.-	395.-	545.-
Patient Advocate Congress fee ⁴	55.-	55.-	55.-

¹Students/PhD Students registering at the Affiliate Member Congress fee must upload a certificate of their Student/PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

²Nurses registering at the Nurse Non-Member Congress fee must upload a certificate of their current nurse status and registration number during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

³Students/PhD Students and delegates with the following professions may register for the Affiliate Non-Member Congress fee: Dietitian, Pharmacist, Psychologist. All delegates registering at this fee must upload a certificate of their professional status/Student or PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

⁴Patient Advocates registering at this fee must upload a proof of their membership of a Patient Advocate Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.

Registration fee for delegates includes:

- Access to all scientific sessions
- Access to poster exhibition
- Access to industry exhibition (HCP only)
- Free copy of all congress documentation
- Certificate of attendance
- Access to congress abstracts
- Congress bag
- Coffee breaks

In order to pick-up a pre-paid ticket, the delegate must present a passport or ID at the Registration Area.

Speakers' Centre

The Speakers' Centre is located in Hall E of Bella Center. **Three hours** prior to the presentation, speakers must submit their PowerPoint presentations at the Speakers' Centre. The submitted presentation is saved on our central congress server and then made available on a provided congress notebook in each presentation hall respectively. For technical reasons, speakers may not use their own notebook for presentations. Specialised technical staff onsite will gladly assist delegates and answer all pertinent questions.

All conflicts are to be disclosed on the 2nd slide of each PowerPoint presentation. To facilitate and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential Conflicts of Interest in their presentation in line with UEMS regulations.

A draft Col slide has been prepared for each speaker based on the submitted Col form, and will be available in the Speakers' Centre to include in the presentation. Please be reminded that if the respective presentation does not yet include a disclosure form, the slide draft should be checked and amended before it is inserted into the presentation.

All speakers are kindly asked to personally sign the publication consent form on their talks directly at the Speakers' Centre. If you are participating in a tandem talk or panel discussion, both/all speaking are asked to visit the Speaker Center onsite in order to sign off their respective publication consent forms.

Speakers' Centre opening hours:

Wednesday, March 6, 2019	07:30 - 18:00
Thursday, March 7, 2019	07:00 - 19:30
Friday, March 8, 2019	06:30 - 19:45
Saturday, March 9, 2019	08:00 - 13:00



European
Crohn's and Colitis
Organisation

Copenhagen
Denmark

UR-CARE Training Centre

Stop by for a
try in Hall E



The IBD Database for your patient
records and your research studies

- Visit the UR-CARE Training Centre in Hall E
- Test the database and discover all of the functionalities
- Open during Congress opening hours on Wednesday through Saturday
- Ask questions and get answers directly from the UR-CARE team

Scan and visit

www.ecco-ibd.eu/ur-care



Industry sponsored satellite symposia

Industry sponsored satellite symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.

ECCO has scheduled parallel satellite symposia on:
Thursday, March 7, 2019 at 11:00-12:00 and 18:45-19:45
Friday, March 8, 2019 at 07:15-08:15 and 18:35-19:35

Parallel lunchtime satellite symposia will take place on:
Friday, March 8, 2019 at 12:40-13:20.

Kindly note that satellite symposia take place in various halls on the Ground Floor of Bella Center.
Please be advised that due to Danish compliance laws, access may be restricted to health care professionals only.

Industry sponsored satellite symposia – Scientific programme

Thursday, March 7, 2019

Satellite symposium 1a – Organiser: Meeting room:	Takeda Plenary hall, Hall A, Bella Center
11:00 - 12:00	Treatment decisions with advanced therapies: Comparative evidence in Ulcerative Colitis Jean-Frédéric Colombel, New York, United States
11:00 - 11:10	Introduction Jean-Frédéric Colombel, New York, United States
11:10 - 11:25	Key learnings from indirect comparisons of randomised controlled trials William J. Sandborn, California, United States
11:25 - 11:40	What do real-world comparative effectiveness studies tell us? Parambir S. Dulai, California, United States
11:40 - 11:55	Our evolving understanding of gut-selective vs advanced systemic therapy Jean-Frédéric Colombel, New York, United States
11:55 - 12:00	Panel Discussion/Q&A All

**Industry sponsored satellite symposia – Scientific programme****Thursday, March 7, 2019, cont.**

Satellite symposium 1b – Organiser: Meeting room:	AbbVie Hall C, C1 M4-5, Bella Center
---	--

11:00 - 12:00	Future targets and endpoints in IBD – an informed discussion Brian Feagan, London, Canada
abbvie	Welcome and Introduction Brian Feagan, London, Canada
	Evolving endpoints in clinical trials Brian Feagan, London, Canada
	Exploring the value of biomarkers and endoscopic targets Peter Bossuyt, Bonheiden, Belgium
	Interpreting patient-reported outcomes Reena Khanna, London, Canada
	Concluding remarks and close Brian Feagan, London, Canada

Satellite symposium 1c – Organiser: Meeting room:	Celltrion Auditorium 15, Bella Center
---	---

11:00 - 12:00	Redesigning the Future of IBD Treatment with Infliximab SC Walter Reinisch, Vienna, Austria
	Welcome remarks Walter Reinisch, Vienna, Austria
	Personalised Anti-TNF therapy in Crohn's Disease (PANTS) Tariq Ahmad, Exeter, United Kingdom
	Clinical findings on Infliximab SC Shomron Ben-Horin, Ramat Gan, Israel
	Earlier introduction of biologics Iris Dotan, Petah Tikva, Israel
	Future of IBD treatment with Infliximab SC Stefan Schreiber, Kiel, Germany
	Panel discussion All

Satellite symposium 2a – Organiser: Meeting room:	Pfizer Plenary hall, Hall A, Bella Center
---	---

18:45 - 19:45	Tofacitinib in Ulcerative Colitis: A practical guide Simon Travis, Oxford, United Kingdom
	Welcome and Introduction Simon Travis, Oxford, United Kingdom
	Tofacitinib: An effective option for moderate-to-severe Ulcerative Colitis Simon Travis, Oxford, United Kingdom
	Exploring the Tofacitinib safety profile Axel Dignass, Frankfurt am Main, Germany
	The practicalities of using Tofacitinib in the clinic Peter Irving, London, United Kingdom
	Q&A All

Industry sponsored satellite symposia – Scientific programme
Thursday, March 7, 2019, cont.

Satellite symposium 2b – Organiser: Meeting room:	Amgen Hall C, C1 M4-5, Bella Center
18:45 - 19:45	IBD management puzzle: Do we have all the pieces? Stefan Schreiber, Kiel, Germany
	18:45 - 18:50 Welcome and Introduction Stefan Schreiber, Kiel, Germany
	18:50 - 19:05 Putting the pieces together: When should anti-TNFs be introduced? Stefan Schreiber, Kiel, Germany
	19:05 - 19:20 Solving the riddle: How do we implement TDM to maximise treatment success? Walter Reinisch, Vienna, Austria
	19:20 - 19:35 Unravelling the problem: How can biomarkers be used to guide clinical management? Gionata Fiorino, Milan, Italy
	19:35 - 19:45 Summary and close Stefan Schreiber, Kiel, Germany

Satellite symposium 2c – Organiser: Meeting room:	Janssen Auditorium 15, Bella Center
18:45 - 19:45	IL-12/23 in IBD: Making the best use of available evidence Alessandro Armuzzi, Rome, Italy
	18:45 - 18:50 Welcome and Introduction Alessandro Armuzzi, Rome, Italy
	18:50 - 19:00 Current developments in IBD Subrata Gosh, Birmingham, United Kingdom
	19:00 - 19:30 Clinical insights in IBD Moderator: Tim Raine, Cambridge, United Kingdom Speakers: Alessandro Armuzzi, Rome, Italy Subrata Gosh, Birmingham, United Kingdom
	19:30 - 19:35 Future treatment options in IBD Alessandro Armuzzi, Rome, Italy
	19:35 - 19:45 Conclusion and close of meeting Tim Raine, Cambridge, United Kingdom

Industry sponsored satellite symposia – Scientific programme

Friday, March 8, 2019

Satellite symposium 3b – Organiser: Meeting room:	Nestle Health Science Hall C, C1 M4-5, Bella Center
07:15 - 08:15	Why do we need dietary therapy in Crohn's Disease? Iris Dotan, Petah Tikva, Israel Michael Kamm, Melbourne, Australia
 NestleHealthScience	07:15 - 07:30 Why do we need nutrition therapy in an era of biologics? Michael Kamm, Melbourne, Australia
	07:30 - 07:45 What are the targets for dietary therapy? Arie Levine, Tel Aviv, Israel
	07:45 - 08:00 Present state of the art on dietary management in Crohn's Disease Johan van Limbergen, Halifax, Canada
	08.00 - 08:15 The new kid on the block: The Crohn's Disease Exclusion Diet for induction of remission Rotem Sigall-Boneh, Tel Aviv, Israel
Satellite symposium 3c – Organiser: Meeting room:	Pfizer Auditorium 15, Bella Center
07:15 - 08:15	The Psychology of Change in IBD: Working with the mind when the gut needs a change David Rubin, Chicago, United States
	07:15 - 07:20 Welcome and Introductions David Rubin, Chicago, United States
	07:20 - 07:35 Understanding the psychological drivers of decision making in IBD Lyndsay Hughes, London, United Kingdom
	07:35 - 07:50 The psychology of IBD management: Challenging ourselves to change David Rubin, Chicago, United States
	07:50 - 08:05 Preparing our patients when the gut needs a change Tariq Ahmad, Exeter, United Kingdom
	08:05 - 08:15 Q&A

Lunchtime Satellite symposia – Scientific programme

Friday, March 8, 2019

Satellite symposium LS1 – Organiser: Meeting room:	AbbVie Plenary hall, Hall A, Bella Center
12:40 - 13:20	Rapid control of Ulcerative Colitis: Can we optimise treatment? Jean-Frédéric Colombel, New York, United States
	12:40-12:45 Welcome and Introduction Jean-Frédéric Colombel, New York, United States
	12:45-12:55 Understanding the inflammatory and symptomatic picture of Ulcerative Colitis Johan Burisch, Copenhagen, Denmark
	12:55-13:05 Timely management of Ulcerative Colitis Jean-Frédéric Colombel, New York, United States
	13:05-13:15 Optimising therapy – approaches to enhance clinical outcomes Edouard Louis, Liège, Belgium
	13:15-13:20 Concluding remarks and close Jean-Frédéric Colombel, New York, United States
Lunch symposium LS2 – Organiser: Meeting room:	Celgene Hall C, C1 M4-5, Bella Center
12:40 - 13:20	How will evolving therapies illuminate your practice?
	12:40 - 13:20 How will evolving therapies illuminate your practice? Remo Panaccione, Calgary, Canada Jonas Halfvarsson, Örebro, Sweden
Lunch symposium LS3 – Organiser: Meeting room:	Tillotts Auditorium 15, Bella Center
12:40 - 13:20	Smart Simplicity - Simplifying treatment options and processes Geert D'Haens, Amsterdam, The Netherlands
	12:40 - 12:45 Welcome and Introduction Geert D'Haens, Amsterdam, The Netherlands
	12:45 - 13:00 Difference between textbook and reality in IBD Ala Sharara, Beirut, Lebanon
	13:00 - 13:15 Confusing terminology in IBD Hugh Mulcahy, Dublin, Ireland
	13:15 - 13:20 Closing remarks All
Lunch symposium LS4 – Organiser: Meeting room:	MSD Hall C, C1 M1, Bella Center
12:40 - 13:20	Treat-to-Target in Ulcerative Colitis: Challenges in real-life practice Glen Doherty, Dublin, Ireland
	12:40 - 12:55 Targets and outcome measures in Ulcerative Colitis: IOIBD consensus vs real-life practice Alexander Moschen, Innsbruck, Austria
	12:55 - 13:10 Effective early control of inflammation in patients with active Ulcerative Colitis Glen Doherty, Dublin, Ireland
	13:10 - 13:20 Summary and Q&A All

International Symposia and Workshops

scientific Dialogue
in the Interest of
Therapeutic Progress



Workshop
**From Viral Hepatitis to Chronic
Inflammation and Liver Cancer**

Heidelberg, Germany
February 21–22, 2019



Symposium 216
Building Bridges in IBD
Brussels, Belgium
September 13–14, 2019



Symposium 214
**IBD: From Pathophysiology
to Personalized Medicine**

Oxford, Great Britain
March 29–30, 2019



Symposium 217
**West Meets East:
Functional Meets Organic
Gastrointestinal Diseases**
Singapore
November 29–30, 2019



Symposium 215
IBD: From Diagnosis to Therapy
St. Petersburg, Russia
July 5–6, 2019

FALK FOUNDATION e.V.



Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Tel.: +49 (0)761/1514-125
Fax: +49 (0)761/1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

2019

Industry sponsored satellite symposia – Scientific programme**Friday, March 8, 2019**

Satellite symposium 4a – Organiser: Meeting room:	Takeda Plenary Hall, Hall A, Bella Center
18:35 - 19:35	Evolving models of care in Crohn's disease: Identifying and treating patients at risk of disease progression Remo Panaccione, Alberta, Canada
	18:35 - 18:40 Introduction Remo Panaccione, Alberta, Canada
	18:40 - 18:55 Early disease control: Identifying patients at risk of disease progression Edouard Louis, Liège, Belgium
	18:55 - 19:15 Practical approaches for the management of Crohn's Disease according to risk stratification Remo Panaccione, Alberta, Canada
	19:15 - 19:35 Challenging patient cases: Low risk or high risk – what would you do? (panel discussion) Subrata Ghosh, Birmingham, United Kingdom

Satellite symposium 4c – Organiser: Meeting room:	Biogen and Samsung Bioepis Auditorium 15, Bella Center
18:35 - 19:35	The IBD pathway – from a patient perspective Geert D'Haens, Amsterdam, The Netherlands
 	18:35 - 18:45 Welcome and Introduction Geert D'Haens, Amsterdam, The Netherlands
	18:45 - 19:30 Patient perspectives, such as their expectations and concerns as they experience a switch in treatment, will be discussed with the audience by a multidisciplinary team: Raja Atreya, Erlangen, Germany Luisa Avedano, Brussels, Belgium Yoram Bouhnik, Paris, France Maria de Jong, Amsterdam, The Netherlands Geert D'Haens, Amsterdam, The Netherlands
	19:30 - 19:35 Closing Remarks Geert D'Haens, Amsterdam, The Netherlands

Satellite symposium 4d – Organiser: Meeting room:	Sandoz Hall C, C1 M1, Bella Center
18:35 - 19:35	Defining the future of IBD care: The pivotal role of personalised treatment Peter Irving, London, United Kingdom
	18:35 - 18:40 The myth of the typical IBD patient (introduction) Peter Irving, London, United Kingdom
	18:40 - 19:00 IBD subgroups: The secret of hitting the mark Chair: Peter Irving, London, United Kingdom Speakers: Marieke Pierik, Maastricht, The Netherlands Jonas Halfvarson, Örebro, Sweden
	19:00 - 19:15 Hidden gems of rheumatology Frank Behrens, Frankfurt, Germany
	19:15 - 19:30 Personalised treatment for IBD: Of course, but why and how? Claudio Fiocchi, Cleveland, United States
	19:30 - 19:35 Closing remarks Peter Irving, London, United Kingdom

*Industry sponsored satellite symposia – Educational programme***Thursday, March 7, 2019 – N-ECCO Network Meeting**

Satellite symposium Organiser: Meeting room:	Takeda Hall C, C1 M0, Bella Center
12:15 - 13:15 Bon voyage! Preparing our patients for confident travel with IBD	
	Stepping out of your comfort zone: You can travel with IBD! Video from Hannah Witton (Vlogger with IBD)
12:15 - 13:15	Welcome and Introductions Stephan Vavricka, Zurich, Switzerland
	Travelling with IBD, from research to reality Stephan Vavricka, Zurich, Switzerland
	How to advise patients: Practical tips to help travellers with IBD Shomron Ben-Horin, Ramat Gan, Israel Kay Greveson, London, United Kingdom
	Q&A Moderator: Stephan Vavricka, Zurich, Switzerland All
	Summary of key learning points and closing Shomron Ben-Horin, Ramat Gan, Israel

Thursday, March 7, 2019 – S-ECCO IBD Masterclass

Satellite symposium Organiser: Meeting room:	Takeda Hall C, C1 M2, Bella Center
12:45 - 13:15 The future is now: Improved management of complex perianal fistulas in Crohn's disease	
	Welcome and speaker introductions Antonino Spinelli, Milan, Italy
12:15 - 13:15	Discussion and introduction to the cases: Goal-setting in complex perianal fistula Antonino Spinelli, Milan, Italy Henit Yanai, Petah Tikva, Israel
	Matching the patient to the procedure choice for complex perianal fistula Antonino Spinelli, Milan, Italy
	Optimising long-term strategies for complex perianal fistula in Crohn's Disease Henit Yanai, Petah Tikva, Israel
	Discussion: Key learnings Antonino Spinelli, Milan, Italy Henit Yanai, Petah Tikva, Israel

Highlights of ECCO'19



The ECCO'19 Congress in a nutshell

Take-home messages from the Scientific Programme:

- Watch a summary of selected top abstracts
- Recorded just for you and your colleagues at home
- Available in the eLibrary right after the Congress

Scan and visit

www.ecco-ibd.eu/highlights



ECCO Interaction: Hearts and Minds

ECCO Interaction: Hearts and Minds is THE event at ECCO to see and be seen, to network and engage. Anyone who has been to a previous ECCO Congress knows that it is a must and everyone is welcome, but places are limited.

This year's edition of the ECCO Interaction: Hearts and Minds will be held at the famous Øksnehallen in Copenhagen.

Date: Friday, March 8, 2019

Start time: 20:30

Venue: Øksnehallen, Halmtorvet 11, 1700 Copenhagen

How to get to Øksnehallen from Bella Center using public transportation

From "Bella Center St. (Center Østvej)", take bus 250S headed towards "Buddinge st." and get off at "Hovedbanegården København H" (Copenhagen Central Station). From there you can continue walking straight ahead on Bernstorffsgade via Halmtoeret until you reach Øksnehallen. (Time travel: approx. 34 min)

Alternatively, take the green metro line M1 from "Bella Center st. (Metro)" headed towards "Vestamager st." and get off at "Ørestad st.". From there, take the regional train headed towards "Helsingør st.", and get off at "Hovedbanegården København H" (Copenhagen Central Station). Then, continue straight ahead walking via Reventlowsgade to Halmtoeret until you reach Øksnehallen. (Time travel: approx. 29 min)

Visit www.rejseplanen.dk to plan your travel in detail.

Tickets need to be picked up at the registration desk "ECCO Interaction: Hearts and Minds" located in Hall E at Bella Center.

Access to the event is strictly granted with ECCO Interaction tickets only. Please make sure to bring your ticket with you. **No ticket sale onsite at Øksnehallen!**

Y-ECCO Networking Corner

- Unique opportunity to meet key opinion leaders from the Governing Board and Operational Board of ECCO and to network with fellow Y-ECCO Members
- Where/When
 - At the ECCO Interaction: Hearts and Minds 2019
 - Øksnehallen, Halmtoeret 11, 1700 Copenhagen
 - 20:30-21:30
- Welcome drinks and food will be served
- Join the main interaction following this great event
- Make sure you are registered and have your ticket with you!

Corporate sponsors

(as of February 1, 2019)

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:



Industry exhibition

Opening hours


Thursday, March 7, 2019	10:30 – 19:45
Friday, March 8, 2019	07:15 – 19:45
Saturday, March 9, 2019	08:00 – 13:00

List of exhibitors & sponsors

Company	Booth number
AbbVie	8
AbbVie	9
Allergan	36
Amgen	4
Arena Pharmaceuticals	40
Biogen	25
Bühlmann Laboratories	2
Calpro AS	16
Celgene	18
Celltrion	26
Diversigen	28
Dr. Falk Pharma	37
EFCCA	E1
Eli Lilly	24
Eurospital	29
Roche	19
Ferring	6
Fresenius Kabi	38
Gilead	17
Grifols	30
Immundiagnostik	27
Janssen	5
Janssen R&D	7a
Janssen	7b
La Lettre de l'Hépatogastroentérologue (EDIMARK)	E2

Company	Booth number
Mauna Kea Technologies	35
Mendes S.A.	34
MSD	32
Nanjing FMT Medical	44
Nestle Health Science	23
Nikkiso	33
Norgine	43
Pfizer	1
Pfizer	3
Pharmacosmos	42
Pharmanovia	46
Predictimmune	20
R-Biopharm	15
Reprocell Inc.	11
Robarts Clinical Trials	10
Sandoz	31
Shire International	39
Takeda	13
Takeda	14
Tani Medikal	45
Theradiag	21
Thermo Fisher Scientific	12
Tillotts	22
Wisepress	E3

Exhibition plan



Floor plans

Bella Center

Hall A, Ground Floor

- Plenary Hall
- Auditorium 15
 - 3rd School for Clinical Trialists
 - 4th Advanced ECCO: EduCational COurse for Industry
- Office 60-181

Hall B, Ground Floor

- Course Rooms
- Meeting Rooms
- Poster Exhibition and Internet Lounge

Hall C, Ground Floor


- Exhibition Hall
- Members' Lounge
- C1 M0-5

Hall E, Ground Floor

- ECCO Booth
- Registration
- Cloakroom
- Bag distribution
- UR-CARE Training Centre
- Speakers' Centre
- Cash Catering

Level 1


- ECCO Congress Office
- Meeting rooms



Hall B, Bella Center

Hall B


- 1st ECCO-ESGAR Basic Imaging Workshop (B3 M1-2)
- 1st Guideline Methodology and GRADE Workshop (B3 M7-8)
- 4th D-ECCO Workshop (HB4 M1-2)
- 4th H-ECCO IBD Masterclass (B3 M9-10)
- 5th Y-ECCO Basic Science Workshop (B3 M7-8)
- 6th ECCO-ESGAR Ultrasound Workshop – Advanced (B3 M1-2)
- 7th SciCom Workshop (B3 M9-10)
- 10th N-ECCO School (B3 M5-6)
- 11th Y-ECCO Career Workshop (B3 M7-8)
- 17th IBD Intensive Advanced Course (HB4 M1-2)
- Satellite Symposia
- Poster Exhibition and Internet Lounge



Hall C, Bella Center

Hall C

- 4th ECCO-AOCC Forum (C1 M3)
- 6th P-ECCO Educational Course (C1 M0)
- 8th S-ECCO IBD Masterclass (C1 M2)
- 13th N-ECCO Network Meeting (C1 M0)
- Basic Science Session (C1 M4-5)
- Digital Oral Presentations Sessions 1-10 (C1 Rooms)
- Satellite Symposia
- Members' Lounge
- Exhibition Hall
- Cash Catering



Index of speakers and abstract authors

A bdelaal, T.	OP27	Assa, A.	OP05, OP18, DOP31, DOP42, DOP89	Bendele, A.	DOP21
Abhyankar, B.	4 th Advanced ECCO: EduCational COurse for Industry, DOP53	Atia, O.	DOP31	Bender, A.	OP10
Abitbol, V.	DOP74, DOP78	Atreja, A.	OP17	Bendtsen, F.	DOP82
Abramas, L.	OP05, DOP42	Atreya, R.	DOP67	Ben-Shoshan, M.	DOP36
Abreu, M. T.	OP37	Trott, K.	DOP02, DOP14, DOP19	Benítez, J. M.	DOP44
Adams, A.	DOP10	Aylin, P.	DOP61	Berends, S.	DOP56
Adamina, M.	10 th N-ECCO School	Azana, S.	N03	Bergemalm, D.	DOP10
Afhim, S.	DOP30	Azevedo, L.	OP04	Berliba, E.	OP38, DOP46
Afif, W.	DOP75			Bernardo, S.	DOP59
Agrusti, A.	DOP34			Berti, G.	DOP20
Ainsworth, M.	4 th Advanced ECCO: EduCational COurse for Industry	Bae, D.	OP23	Bessissov, T.	DOP75
Ajioka, Y.	DOP69	Bäbler, K.	DOP14, DOP19, DOP24	Bettenworth, D.	5 th Y-ECCO Basic Science Workshop, 10 th N-ECCO School
Akbar, A.	DOP61	Baek, J.-Y.	OP23	Bewick, G.	DOP60
Al Draiweesh, S.	DOP39	Baek, J.	DOP83	Beyer-Berjot, L.	8 th S-ECCO IBD Masterclass
Alberts, E.	DOP06	Baert, F.	1 st ECCO-ESGAR Basic Imaging Workshop,	Beyrend, G.	OP27
Aldelemi, S.	DOP20		17 th IBD Intensive Advanced Course, OP25, OP35, DOP33	Bhagat, S.	OP13
Alexakis, C.	DOP85	Bager, P.	13 th N-ECCO Network Meeting	Bhandari, B.R.	OP38, DOP46
Algaba-Chueca, F.	DOP05	Baines, J. F.	DOP12	Biedermann, L.	OP06
Alkhattabi, M.	DOP39	Baker, T.	DOP47	Biron, C.	DOP74, DOP78
Allez, M.	OP20, DOP74	Baldaiia, C.	DOP59	Bisschops, R.	1 st ECCO-ESGAR Basic Imaging Workshop
Allimant, C.	DOP80	Balicer, R.	DOP89	Bisset, C.	DOP87
Allin, K. H.	DOP88	Ballet, V.	DOP26	Bitton, A.	DOP75
Almoudaris, A.	DOP61	Banerjee, A.	OP08	Blackwell, J.	DOP85
Aloï, M.	DOP34	Banerjee, R.	Scientific Session 5	Bleich, A.	DOP12
Altweeg, R.	OP24	Bar-Gil Shirrit, A.	DOP29, DOP31	Blevi, H.	DOP38
Alves, I.	OP04	Baribaud, F.	OP36	Bliss, C.	DOP49, DOP51
Alvisi, P.	DOP34	Barnhoorn, M.	5 th Y-ECCO Basic Science Workshop, OP22	Blixt, C.	3 rd School for Clinical Trialists
Alzinyati, M.	DOP29	Barrachina, M. D.	OP03	Bloom, S.	OP16
Amil, M.	DOP74	Barreton, G.	DOP12	Boivineau, L.	OP24
Amiot, A.	DOP74	Basic, M.	DOP12	Bommelaer, G.	DOP80
Andersen, V.	OP15	Bassett, P.	DOP61	Bonifacio, C.	1 st ECCO-ESGAR Basic Imaging Workshop
Andoh, A.	4 th ECCO-AOCC Forum	Bassolas-Molina, H.	DOP25	Bonovas, S.	1 st Guideline Methodology and GRADE Workshop
Angin, M.	DOP07	Beaugerie, L.	3 rd School for Clinical Trialists	Behren, A.	DOP17
Anzai, S.	DOP22			Beigel, F.	OP12
Arancibia, C.	OP28, DOP11			Belousova, E.	OP15
Arebi, N.	OP15, DOP29			Bemelman, W.	8 th S-ECCO IBD Masterclass, DOP73
Argmann, C.	OP17			Ben-Horin, S.	17 th IBD Intensive Advanced Course, 4 th Advanced ECCO: EduCational COourse for Industry, 7 th SciCom Workshop, DOP36, DOP62
Armengol-Debeir, L.	DOP74, DOP78			Bottle, A.	DOP85
Armstrong, S.	OP07			Bouguen, G.	OP24, DOP78
Armuzzi, A.	OP29, OP35, DOP20			Bouhnik, Y.	OP25, DOP74, DOP78
Arnauts, K.	OP11			Bourreille, A.	OP21, DOP23
Arora, V.	OP38, DOP46				
Arrigo, S.	DOP34				
Arroyes, M.	DOP25				
Asayag, N.	DOP89				

Boyle, D.	DOP53	Cataldi, F.	4 th Advanced ECCO:	D'Antiga, L.	DOP34
Bozon, A.	OP24		EduCational COurse for	D'Alessio, S.	Scientific Session 9
Böcher, W.	3 rd School for Clinical		Industry, OP08, OP14,	D'Haeus, G.	Scientific Session 1,
	Trialists, 4 th Advanced		DOP49, DOP50, DOP51		OP08, OP25, OP35,
Brahmania, M.	ECCO: EduCational	Cañete, F.	DOP44		DOP48, DOP56, DOP73
Bramuzzo, M.	COurse for Industry	Cecil, E.	DOP85	D'Hoore, A.	8 th S-ECCO IBD
Brandse, J.	DOP39	Ceuppens, J.	DOP26	D'Inca, R.	Masterclass, OP30
Brassard, P.	DOP34	Chalmers, I.	DOP84	Dahlerup, J. F.	OP15
Braun, T.	DOP56	Chan, G.	DOP43	Daly, M.	OP15
Brazier, F.	DOP75	Chande, N.	DOP39	Dan, N.	OP01
Breiteneicher, S.	OP19, DOP36	Chang, D. K.	DOP04	Danese, S.	DOP89
Breynaert, C.	OP24	Chanteloup, E.	DOP74, DOP78		Scientific Session 1,
Brignone, C.	OP12	Chapman, D. S.	DOP41		Scientific Session 12,
Brindle, W.	DOP26, DOP70	Cheifetz, A. S.	DOP45		4 th Advanced ECCO:
Brodmerkel, C.	DOP07	Chen, H.	DOP21		EduCational COurse for
Broide, E.	OP17, OP36	Chen, K.	DOP17		Industry, 4 th ECCO-AOCC
Brokalaki, H.	OP18	Chen, L.	DOP64		Forum, OP26, OP35, OP37,
Brooks, J.	N02	Cheon, J. H.	DOP55		DOP47, DOP48, DOP49,
Brufman, I.	OP10	Chiorean, M.	OP09, DOP41		DOP50, DOP51, DOP54
Buck, J.	DOP89	Choi, K.-W.	DOP55	Dart, R. J.	OP32
Buisson, A.	OP07	Choi, Y. I.	OP23	Davani, N.	OP30
Burgess, C.	OP24, OP25, DOP74,	Choung, R. S.	DOP35	Davidson, K.	13 th N-ECCO
Buskens, C.	DOP78, DOP80	Chuah, C. S.	DOP87		Network Meeting
Burisch, J.	DOP84, DOP87	Clark, M. M.	OP20	Davies, M.	DOP48
	Scientific Session 5,	Cleynen, I.	5 th Y-ECCO Basic	Davis Thomas, S.	OP19
	5 th Y-ECCO Basic		Science Workshop	Dawn, F.	N01
	Science Workshop,	Clos-Parals, A.	DOP44	De Cruz, P. P.	DOP81
	OP15, DOP76, DOP82,	Coban, D.	DOP80	de Groof, E. J.	DOP73
	DOP86, DOP88	Cohen, R. D.	DOP41	De Hertogh, G.	4 th H-ECCO
Busenhart, P.	DOP14	Cohen, S.	OP05, OP18,		IBD Masterclass, DOP71
Byeon, J. S.	DOP65		DOP42, DOP89	de Jong, M.	DOP72
Byron, C.	N01	Collij, V.	OP01	de Ridder, L.	4 th Advanced ECCO:
	Masterclass, DOP73	Collins, M.	OP19		EduCational COurse
		Colombel, J.-F.	Scientific Session 1,		for Industry
			8 th S-ECCO IBD Masterclass,	De Salvo, C.	OP29
			OP17, OP26, OP35, DOP35	De Vallière, C.	DOP24
Cabell, C.	OP09	Colombo, G.	DOP01	De Vos, M.	DOP33
Caesar, J.	OP12	Constable, L.	DOP06	deBruyn, J. C.	DOP58
Cahan, A.	DOP89	Cornillie, F.	4 th Advanced ECCO:	Deceneux, C.	DOP17
Caillo, L.	DOP74		EduCational COurse	Dedman, H.	DOP21
Calafat, M.	DOP44	Corraliza, A. M.	for Industry	Dehairs, J.	DOP38
Calatayud, S.	OP03	Correia, A.	DOP25	Delaney, C.	8 th S-ECCO IBD
Campbell, R.	6 th P-ECCO	Correia, L.	OP04		Masterclass
	Educational Course	Cosin-Roger, J.	DOP59	De Dond, L. A.	OP19
Campmans-Kuijpers, M.	4 th D-ECCO	Coste, J.	OP03	Derikx, L.	DOP72
	Workshop	Coulombe, J.	DOP40	Dewit, S.	DOP29
Canavan, J. B.	OP38, DOP52	Cremer, A.	DOP75	DeWouters, T.	DOP02
Canet, F.	OP03	Cremer, J.	DOP29	Dexheimer, P.	OP19
Carbonnel, F.	DOP40	Creyens, B.	DOP26, DOP70	Di Martino, L.	OP29
Carding, S.	OP07, OP10	Cucchiara, S.	DOP26, DOP70	Di Palma, F.	DOP08
Carroll, M. W.	DOP58	Curran, M.	DOP34	Di Segni, A.	DOP36
Carstensen, M.	DOP76	Cvancarova, M.	OP36	Diab, J.	DOP15
Carvello, M.	8 th S-ECCO IBD		DOP90	DIAMOND2 Study Group	DOP32
	Masterclass			Dias, A.	OP04
Casanova, M. J.	DOP44			Dib, N.	DOP74, DOP78
Castro-Poceiro, J.	DOP44			Diculescu, M.-M.	OP35
				Digby-Bell, J.	DOP06, DOP60
				Dijkgraaf, M.	DOP73
				Dijkstra, G.	OP01, DOP24

Dinarello, C.	Scientific Session 12	Feagan, B. G.	4 th Advanced ECCO: EduCational COurse for Industry, OP26,	Gacesa, R.	OP01
Dinarzo, A.	OP17		OP38, DOP39, DOP46,	García García, M. J.	DOP44
Ding, N. S.	5 th Y-ECCO Basic Science Workshop,		DOP71, DOP79	Gardner, R.	DOP10
	10 th N-ECCO School	Feehans, R.	4 th H-ECCO IBD Masterclass, DOP20	Garrick, V.	6 th P-ECCO Educational Course
Distante, M.	DOP34	Feldman, B.	DOP89	Garrido, A.	DOP25
Divekar, D.	OP07	Felice, C.	DOP20	Gasbarrini, A.	OP29
Dotan, I.	17 th IBD Intensive Advanced Course, DOP31	Feng, D.	DOP79	Gecse, K.	1 st ECCO-ESGAR Basic Imaging Workshop, 3 rd School for Clinical Trialists, DOP73
Douglas, K.	DOP21	Fernandes, D.	DOP10	Geert R. D'Haens, G.	OP38, DOP46
Dreesen, E.	OP25	Fernandes, S. R.	DOP59	Genazzani, A. A.	DOP01
Drenth, J.	DOP72	Fernández-Clotet, A.	DOP25,	Gerasimidis, K.	4 th D-ECCO Workshop, 10 th N-ECCO School
Drohan, C.	1 st Guideline Methodology and GRADE Workshop	Fernández-Veledo, S.	DOP44	Geremia, A.	OP28, DOP11
Drouin, J.	DOP40	Ferrante, M.	DOP05	Giannotta, M.	OP15
Dubinsky, M. C.	OP17, DOP43, DOP50	Scientific Session 4, 17 th IBD Intensive Advanced Course, 3 rd School for Clinical Trialists, 10 th N-ECCO School, DOP11, OP30, OP35,	OP38, DOP26, DOP29, DOP37, DOP38, DOP46, DOP52, DOP70	Giannoulatou, E.	DOP20
Durand, T.	DOP23	Ferreiro-Iglesias, R.	DOP44	Gibson, G.	OP19
Durante, M.	OP38, DOP46, DOP52	Ferslew, B.	DOP53	Gillespie, S.-L.	DOP87
Duricova, D.	OP15	Festen, E.	OP01	Gilletta De Saint-Joseph, C.	DOP29
Durieu, E.	DOP23	Fewings, I.	DOP68	Gilletta, C.	OP24
Durlik, M.	DOP03	Filippi, J.	OP24	Gils, A.	OP25, DOP33
Dutré, J.	DOP33	Fischer, I.	DOP57	Gineste, P.	OP21
Dzyngele, B.	OP16	Fischer, S.	DOP67	Giobbi, C.	DOP34
D'Haens, G.	OP26	Fiorino, G.	1 st Guideline Methodology and GRADE Workshop	Gisbert, J. P.	DOP44
E ast, J.					
Efroni, G.	1 st ECCO-ESGAR Basic Imaging Workshop	Fleshner, P.	8 th S-ECCO IBD Masterclass	Glanville, T.	DOP28
Ehrlich, H.	DOP36	Flint, S.	DOP18	Glauber, R.	DOP13
Eigner, W.	OP21	Florholmen, J.	DOP15	Glerup, H.	Scientific Session 1
Ejarque, M.	DOP86	Flourié, B.	OP24	Gluud, L. L.	DOP88
Elangovan, S.	Scientific Session 7	Focht, G.	DOP31, DOP89	Goetsch, M.	DOP49, DOP51
El-Matary, W.	DOP58	Forry, M.	N01	Godwin, N.	N01
Eliakim, R.	DOP36	Forsdahl, G.	DOP15	Goldis, A.	OP15, OP35
Ellinghaus, D.	DOP55	Foster, K.	DOP18	Goll, R.	DOP15
Ellul, P.	OP15	Fotos, N.	N02	Golovchenko, O.	OP35
Elorza, A.	DOP44	Franchimont, D.	DOP33	Gomollón, F.	Scientific Session 2, 17 th IBD Intensive Advanced Course, OP35
Epi-IBD	OP15	Franke, A.	DOP55	González Lorenzo, M.	1 st Guideline
Eriksson, C.	DOP29	Frey-Wagner, I.	DOP24		Methodology and GRADE Workshop
Esaki, M.	DOP32, DOP69	Friedman, G. S.	DOP41	Gonczi, L.	DOP75
Escher, H.	OP27	Friedman, J. R.	OP13, OP17, OP36, DOP71	Goodman, W.	OP29
Espin, E.	DOP05	Friedrich, S.	OP38, DOP46	Gopalakrishnan, S.	DOP12
Esteller, M.	DOP25	Fu, J.	OP01	Gordillo, J.	DOP44
Esteve, M.	DOP25	Fujii, S.	DOP69	Gorelick, K. J.	OP08, DOP49, DOP51
F acchin, S.					
Fadia, M.	4 th D-ECCO Workshop	Fukata, N.	DOP32	Gotman, N.	OP19
Faiz, O.	DOP68	Fukuchi, T.	DOP69	Gottier, C.	DOP02
Fan, H.	DOP61	Fulforth, J.	DOP87	Goutorbe, F.	DOP80
Farrell, D.	13 th N-ECCO Network Meeting, N01	Fumery, M.	OP15, OP24, OP35, DOP74, DOP78, DOP80	Goutte, M.	DOP80
Fazekas, D.	OP10	Furfaro, F.	1 st ECCO-ESGAR Basic Imaging Workshop	Govek, S.	DOP21
				Graham, R.	DOP53
				Grant, S.	OP05
				Greenaway, B.	DOP11
				Greenbaum, L. E.	OP36
				Gregor, J. C.	DOP39
				Greguš, M.	DOP49, DOP51

Greveson, K.	10 th N-ECCO School, 13 th N-ECCO Network Meeting	Hebutterne, X. Hegazy, A. Hellstern, P. A. Hellström, P. Helwig, U. Henderson, P. Hering, L. Hermangild Kottoor, S. Hernandez, V. Hernandez-Medrano, I.	OP14 Scientific Session 9 DOP49, DOP51 OP35 DOP57 DOP84, DOP87 DOP14, DOP19 DOP06 OP15 Session 11 OP35 OP38, DOP32, DOP46, DOP48	Ilott, N. Imai, Y. Imenez Silva, P. H. Inoue, S. Inoue, T. Inspector, Y. Ipland, N.-P. Iqbal, S. Iqbal, T. Irizar, H. Irving, P. M.	OP28 OP36 DOP24 DOP32 DOP69 Scientific Session 2 DOP76 DOP20 OP16 OP17 17 th IBD Intensive Advanced Course, OP32, DOP06
Griffiths, A. M.	Scientific Session 6, 4 th Advanced ECCO: EduCational COurse for Industry, DOP58			Izaneac, J.	DOP54
Grimaud, J.-C.	OP35				
Gropp, R.	OP12				
Groß, E.	1 st Guideline Methodology and GRADE Workshop				
Gubonina, I.	OP35				
Gul, L.	OP07				
Gupta, A.	1 st ECCO-ESGAR Basic Imaging Workshop	Hibya, S. Higgins, P.	OP31 DOP50	Jäghult, S.	10 th N-ECCO School, 13 th N-ECCO Network Meeting
Gupta, C.	DOP49, DOP51	Higgs, R.	DOP52	Jain, A.	DOP81
Gutierrez, R.	DOP35	Hindryckx, P.	11 th Y-ECCO Career Workshop	Jairath, V.	OP09, DOP39
Guz Mark, A.	OP18	Hiraguri, Y. Hirai, F.	DOP22 DOP32, DOP69	Jang, B. I.	DOP62
Günther, C.	DOP13	Hirschmann, S.	DOP67	Jansen, B.	DOP10
H a, N.					
Haberman, Y.	OP23	Hisamatsu, T.	OP37, DOP32, DOP47	Jansen, J.	DOP56
Haerty, W.	OP19, DOP36	Hoekman, D.	DOP56	Jefferson, M.	OP07
Hahnloser, D.	DOP08	Hoentjen, F.	DOP29, DOP72	Jeffrey, R.	OP20, DOP20
8 th S-ECCO IBD Masterclass					
Hale, M.	DOP81	Hollowbone, S.	DOP30	Jenkinson, P.	DOP87
Halfvarson, J.	Scientific Session 3, 17 th IBD Intensive Advanced Course, OP15, OP35, DOP10	Holmes, E.	5 th Y-ECCO Basic Science Workshop	Jensen, C. B.	DOP88
Hall, J.	OP16	Hong, M. Hong, S. N.	DOP83 DOP04	Jensen, E.	DOP15
Hall, L.	DOP08	Hotopf, M.	DOP85	Jess, T.	DOP88
Halling, C.	DOP76	Hu, A.	DOP66	Jeyarajah, J.	DOP45
Ham, N.	DOP65	Hu, S.	DOP01	Jodeleit, H.	OP12
Hamilton, A. L.	DOP81	Huang, B.	OP14	Johanns, J.	OP37, DOP47, DOP54
Hampe, J.	DOP12	Huang, R.	OP17	John, T.	DOP17
Han, S.	DOP17	Hughes, S.	DOP11	Jones, E.	OP07, DOP08
Hansen, R.	DOP84	Humbel, F.	OP06	Jones, G.-R.	DOP87
Hansen, S.	DOP88	Humblet, E.	DOP29, DOP33	Jorgensen, A.	13 th N-ECCO Network Meeting
Hansen, T.	DOP15	Huttenhower, C.	OP19	Joustra, V.	OP35
Hao, K.	OP17	Huynh, G. H.	DOP58	Judge, C.	N01
Hao, L.-Y.	DOP53	Huynh, H. Q.	DOP58	Juillerat, P.	17 th IBD Intensive Advanced Course, OP06
Harris, R.	DOP84	Hwang, S. W.	DOP65, DOP83	Julsgaard, M.	DOP29
Hart, A.	Scientific Session 10, 6 th P-ECCO Educational Course	Hébuterne, X.	OP08, OP21, OP35, DOP49, DOP51, DOP80	Jun, J. H.	OP23
Hartmann, A.	DOP67	Höllt, T.	OP27	Jung, E. S.	DOP55
Hartmann, P.	13 th N-ECCO Network Meeting	Høivik, M. L.	DOP90	Jung, S.	DOP83
Hartwig, J.	DOP12	Højgaard, B.	DOP76		
Hasnain, S.	DOP09	Hübenthal, M.	DOP55		
Hausmann, M.	DOP24				
Hautefort, I.	OP07, DOP08				
Hawinkels, L.	OP22				
Hawkey, C. J.	OP20				
Hayday, A.	OP32				
Hayden, K.	OP13, OP36				
Hayee, B.	DOP60	Iacucci, M.	Scientific Session 6, 1 st ECCO-ESGAR Basic Imaging Workshop, DOP67	Kagramanova, A.	DOP77
		Ibiza, S.	IBD-BIOM Consortium	Kaimakliotis, I.	OP15
			DOP10	Kakimoto, K.	DOP69
				Kamm, M. A.	DOP81
				Kanal, T.	DOP32
				Kanne, H.	DOP72
				Kanno, T.	DOP53
				Kariv, R.	DOP31
				Karns, R.	OP19
				Kasarakis, A.	OP17

Kaser, A.	Scientific Session 1	Kurilshikov, A.	OP01	Li, J.	DOP17
Kashida, H.	DOP69	Klopocka, M.	OP08, DOP49, DOP51	Li, K.	OP13, OP36, DOP71
Kassam, Z.	DOP06			Li, N.	OP27
Katkeviciute, E.	DOP14, DOP19			Li, X.-J.	DOP35
Kato, S.	DOP32	Lacerda, A. P.	OP14, DOP50	Liefferinckx, C.	DOP33
Katsanos, K. H.	OP15	Laghi, A.	8 th S-ECCO IBD	Lindsay, J. O.	4 th H-ECCO IBD
Katsukura, N.	OP31		Masterclass		Masterclass, 17 th IBD Intensive
Kawai, M.	DOP22	Lago, P.	OP04		Advanced Course,
Kawamoto, A.	DOP22	Laharie, D.	OP24, OP25,		OP14, OP20, DOP20
Kayhan, C.	DOP43		OP35, DOP80	Lirio, R. A.	OP26, DOP79
Keshav, S.	DOP11	Lahat, A.	DOP36, DOP62	Lishchinskaya, A.	DOP77
Khanna, R.	DOP39	Lahiff, C.	DOP11	Lissoos, T.	DOP79
Kievit, H. A. L.	OP15	Laird, R.	DOP35	Liu, X.	DOP21
Kim, B. M.	DOP83	Lakatos, P.	17 th IBD Intensive	Lo, B.	DOP82
Kim, E. R.	DOP04		Advanced Course, DOP75	Lo Re, G.	1 st ECCO-ESGAR Basic
Kim, J.	DOP65	Lakatos, P. L.	OP15		Imaging Workshop
Kim, J. Y.	DOP65	Lambrecht, G.	OP25	Loftus, Jr, E. V.	OP14, OP26
Kim, J. S.	OP23, DOP49, DOP51	Lang, D.	DOP57	Lombardi, G.	DOP60
Kim, K.	DOP83	Lang, S.	DOP02	Lopetuso, L. R.	OP29
Kim, S. W.	DOP55	Langholz, E.	OP15	Losic, B.	OP17
Kim, T. J.	DOP04	Lasch, K.	DOP79	Louis, E.	4 th ECCO-AOCC Forum,
Kim, Y.-H.	DOP04	Lau, S.	DOP64		OP08, OP25, DOP29,
Kiss, G.	OP21	Laukens, D.	7 th SciCom Workshop		DOP33, DOP50
Kiszka-Kanowitz, M.	DOP88	Lavon, E.	DOP31	Lönnfors, S.	1 st Guideline
Klaus, J.	OP08	Lawendy, N.	DOP41, DOP43		Methodology and
Klenske, E.	DOP67	Le Berre, C.	5 th Y-ECCO Basic		GRADE Workshop
Kligys, K.	DOP50		Science Workshop, DOP23	Lu, N.	DOP21
Kluthe, C.	DOP58	Leavens, K.	DOP11	Lukas, M.	DOP43
Knyazev, O.	DOP77	Ledder, O.	OP18, DOP89	Lynch, K.	DOP11
Kobayashi, T.	1 st ECCO-ESGAR Basic	Lederman, N.	DOP89	Lyons, M.	DOP87
Imaging Workshop,				Lytras, T.	1 st Guideline
4 th ECCO-AOCC Forum,	DOP52	Lee, C.	DOP04, DOP04		Methodology and
Kok, K. B.	DOP29	Lee, H.-S.	DOP83		GRADE Workshop
Kolterer, S.	DOP57	Lee, J. H.	DOP62	López-García, A.	DOP44
Koning, F.	OP27	Lee, J. B.	DOP65	López-Sanromán, A.	DOP44
Kooy-Winkelhaar, Y.	OP27	Lee, J. W.	OP23	Löwenberg, M.	DOP56
Kopylov, U.	DOP36	Lee, K.-J.	DOP21		
Korcsmaros, T.	OP07, OP10,	Lee, S. J.	DOP62		
	DOP08, DOP70	Lee, S. D.	OP08, OP14	M	
Kori, M.	OP05, DOP42	Lee, S. G.	DOP62	a, C.	DOP39
Koslowsky, B.	DOP31	Lee, S.-M.	OP23	Maaser, C.	1 st ECCO-ESGAR Basic
Kosoy, R.	OP17	Lee, W.-J.	DOP50		Imaging Workshop,
Kotze, P.	1 st ECCO-ESGAR Basic	Lee, Y. J.	OP23		6 th ECCO-ESGAR Ultrasound
Imaging Workshop,		Lees, C.	Scientific Session 3,		Workshop Advanced, DOP57
8 th S-ECCO IBD Masterclass			11 th Y-ECCO Career	Maccioni, F.	1 st ECCO-ESGAR Basic
Krause, T.	DOP29		Workshop, DOP87		Imaging Workshop
Krueger, K.	DOP46	Lefevre, J.	8 th S-ECCO IBD	Machiels, K.	OP30
Krznaric, Z.	OP15		Masterclass	Macken, E.	DOP29, DOP33
Kucharzik, T.	1 st ECCO-ESGAR Basic	Lelieveldt, B.	OP27	Maconi, G.	1 st ECCO-ESGAR Basic
Imaging Workshop,		Leong, R. W.	DOP47, DOP54		Imaging Workshop,
6 th ECCO-ESGAR Ultrasound		Letizia, M.	DOP13		6 th ECCO-ESGAR Ultrasound
Workshop Advanced, DOP57		Leung, W.-K.	DOP64		Workshop Advanced
Kuemmerle, J.	OP02, DOP16	Leventhal, G.	DOP02	Macpherson, A.	OP06
Kugathasan, S.	OP19	Lever, G.	DOP28	Madgwick, M.	DOP70
Kulakov, D.	DOP77	Levine, A.	Scientific Session 7,	Magro, F.	OP15
Kumagai, T.	OP20		Scientific Session 10,	Mahajan, M.	OP17
Kunisaki, R.	DOP32		OP05, DOP42	Maia, L.	OP04
Kunkel, D.	DOP13	Lewis, A.	OP20, DOP20	Mak, L.-Y.	DOP64
Kupcinskas, L.	OP15	Li, C.	OP02, DOP16	Malavasi, F.	DOP01

Maller, E.	DOP43	Montalban-Arques, A.	5 th Y-ECCO Basic Science Workshop, DOP02	Nielsen, K. R.	OP15
Mansfield, J.	4 th Advanced ECCO: EduCational COurse for Industry	Moon, J. W.	DOP83	Nijhuis, A.	DOP20
Mantzaris, G.	N02	Moritz, T.	DOP15	Nijs, J.	DOP29
Marano, C.	OP13, OP37, DOP47, DOP54, DOP71	Mostovoy, Y.	DOP62	Nishimura, R.	OP31
Marcos-Pinto, R.	OP04	Motoya, S.	OP35, DOP32	Nishishita, M.	DOP69
Marks, D. J. B.	DOP11	Mould, D. R.	DOP56, DOP58	Nissen, L.	DOP72
Marotta, P.	DOP39	Moum, B.	DOP90	Nitcheu, J.	OP21
Marshall, J.	DOP66	Moura Santos, P.	DOP59	Noh, S.	DOP65
Martin, S. W.	OP08	Mucha, S.	DOP55	Nojima, M.	DOP32
Martí, M.	DOP05	Muders, M.	DOP12	Noman, M.	DOP33
Martín Arranz, E.	DOP44	Muller-de Jonge, E.	OP22	Nordholm-Carstensen, A.	DOP76
Martín-Cardona, A.	DOP44	Munk Happel, A.	3 rd School for Clinical Trialists	Norsa, L.	DOP34
Masamunt, M. C.	DOP25	Munkholm, P.	OP15	Novacek, G.	OP35
Matallana Royo, V.	DOP44	Murray, J.	DOP35	Nwokolo, C.	OP16
Matar, M.	OP18	Muñoz Núñez, F.	DOP44		
Mathôt, R.	DOP56	Myrelid, P.	8 th S-ECCO IBD Masterclass	O'Brien, C. D.	OP37, DOP47, DOP54
Matsumoto, T.	DOP32	Myung, S. J.	DOP65	O'Connell, R.	DOP21
Matsuoka, K.	DOP41	Márquez, L.	DOP44	O'Donoghue, D.	OP16
Matsuura, M.	DOP32			Odes, S.	OP15
Matthews, Z.	OP07, DOP08			Odukwе, S.	DOP06
Matz, E.	DOP89			Oh, E. H.	DOP65
Mayer, U.	OP07			Oh, W. Y.	DOP55
Maymó-Masip, E.	DOP05			Ohlsen, C.	DOP21
McDonald, T. T.	DOP18			Ohmiya, N.	DOP69
McGovern, D.	Scientific Session 3, 5 th Y-ECCO Basic Science Workshop			Ohtsuka, K.	DOP22, DOP22
McGuckin, M.	DOP09			Oka, S.	DOP69
Mearin, L.	OP27			Okada, L.	DOP81
Mège, D.	8 th S-ECCO IBD Masterclass			Okamoto, R.	OP31, DOP22
Mehta, S.	DOP20			Oksanen, P.	OP15
Menacho, M.	DOP05			Oldenburg, B.	OP25
Merino, O.	DOP44			Olivares Rivas, I.	DOP02
Mertens, E.	DOP37			Oliver, P.	DOP30
Mesoner, F.	DOP44			On, A.	OP05, DOP42
Meyer, A.	DOP40			Ordás, I.	DOP25
Michelassi, F.	8 th S-ECCO IBD Masterclass			Organe, S.	DOP70
Michetti, P.	17 th IBD Intensive Advanced Course, 8 th S-ECCO IBD Masterclass			Orlando, A.	DOP41
Miele, E.	DOP34			Ortiz, A.	DOP21
Milenkovic, Z.	DOP29			Ortiz-Masia, D.	OP03
Milik, A.	DOP21			Osipenko, M.	DOP62
Millan, M.	DOP05			Ossum, A.	DOP90
Milman, P.	OP05, DOP42			Osterman, M. T.	DOP45
Mimms, L.	DOP81			Ouboter, L.	OP27
Minnis, S.	DOP87			Outtier, A.	DOP37
Miquel-Cusachs, J. O.	DOP44			Oxford IBD Cohort study investigators	OP28
Misselwitz, B.	OP06				
Mo, A.	OP19				
Modos, D.	5 th Y-ECCO Basic Science Workshop, OP10				
Moens, A.	DOP29				
Moniruzzaman, M.	DOP09				
		Ng, S.	Scientific Session 5, 17 th Y-ECCO Career Workshop, 17 th IBD Intensive Advanced Course	Pabojo, J.	DOP23
				Palm, Ø.	DOP90
				Panaccione, R.	OP26, OP35, OP37
				Panceri, R.	DOP34
				Panés, J.	4 th Advanced ECCO: EduCational COurse for Industry, 8 th S-ECCO IBD Masterclass, OP09, DOP25, DOP53

Panis, Y.	Scientific Session 4, 8 th S-ECCO IBD Masterclass	Pouillon, L.	OP24	Roman, C.	DOP34
Paolantonio, P.	1 st ECCO-ESGAR Basic Imaging Workshop	Poullenot, F.	OP24	Rosen, M.	OP19
Papamichael, K.	DOP45	Powell, N.	DOP06, DOP60	Rosini, F.	4 th H-ECCO IBD Masterclass
Parfenov, A.	DOP77	Powell, P.	OP07, DOP08	Rowbotham, D.	DOP47, DOP54
Parfionovas, A.	OP26	Powrie, F.	OP28	Rowse, G.	DOP30
Pariente, B.	OP25, OP35	PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service	DOP35	Rubin, D. T.	OP26, DOP43
Park, D. I.	OP08	Subjects) study group	DOP35	Rudant, J.	DOP40
Park, J. C.	DOP65	Princen, F.	DOP35	Ruiz, P.	DOP24
Park, J.	DOP55	Prosser, C.	DOP58	Russell, R.	DOP84
Park, J.	OP23	PROTECT Study group	OP19	Rutter, M.	1 st ECCO-ESGAR Basic Imaging Workshop
Park, S. H.	DOP65, DOP83	Prymak, O.	OP35	Rydzewska, G.	OP35
Park, S. H.	DOP65	Przemyslaw, Z.	OP21	Ryu, K. H.	OP23
Park, Z.	DOP55	Pukitis, A.	DOP62		
Pavlidis, P.	DOP06, DOP60	Pérez-Galindo, P.	DOP44		
Pedersen, N.	OP15				
Peleg, S.	OP05, DOP42				
Pereira, B.	DOP80				
Pereira, M.	OP04				
Perrigoue, J.	OP17				
Perovic, M.	1 st Guideline Methodology and GRADE Workshop				
Peters, H.	DOP33				
Petersen, F.	DOP57				
Petersen, I.	DOP85				
Petralia, F.	DOP35				
Petrova, A.	DOP58				
Peyrin-Biroulet, L.	17 th IBD Intensive Advanced Course, 3 rd School for Clinical Trialists, 4 th Advanced ECCO: EduCational COurse for Industry, OP09, OP24, OP35, OP37, DOP47, DOP50, DOP71, DOP74, DOP78, DOP80				
Picard, O.	DOP36				
Pierik, M.	10 th N-ECCO School, OP25				
Pineton de Chambrun, G.	DOP74				
Pinho, S.	OP04				
Pinto, V.	OP04				
Pinzani, M.	Scientific Session 1				
Pizarro, T. T.	OP29				
Plastaras, L.	DOP74				
Plevris, N.	DOP87				
Plevy, S.	4 th Advanced ECCO: EduCational COurse for Industry, OP17, OP36, DOP35				
Plug, L.	OP22				
Podevin, J.	DOP23				
Pollok, R.	DOP85				
Pomeranc, A. B.	DOP20				
Ponsioen, C.	DOP56, DOP73				
Porta, C.	DOP01				
Porter, C.	DOP35				
Posen, A.	DOP29				
		Rahier, J.-F.	Scientific Session 5, DOP29, DOP33		
		Rajca, S.	DOP74, DOP78		
		Rangrej, J.	DOP66	Sanderson, J.	DOP06
		Rath, S.	DOP57	Sandhu, A.	DOP39
		Rath, T.	DOP67	Sands, B. E.	OP17, OP26, OP37, DOP47, DOP52, DOP54, DOP79
		Reiding, K.	DOP10	Saruta, M.	DOP69
		Reinglas, J.	DOP75	Sato, T.	OP36, DOP35
		Reinisch, W.	OP08, DOP49, DOP51, DOP62, DOP86	Satsangi, J.	OP20, DOP10
				Savoye, G.	Scientific Session 10
		Reymond, M.	DOP80	Saxena, S.	DOP85
		Ricart, E.	DOP25	Scaldaferri, F.	OP29
		Riddle, M.	DOP35	Schabel, E.	4 th Advanced ECCO: EduCational COurse for Industry
		Rieder, F.	7 th SciCom Workshop, 11 th Y-ECCO Career Workshop,	Schadt, E.	OP17
			17 th IBD Intensive Advanced Course	Scharl, M.	7 th SciCom Workshop, OP06, DOP02, DOP14, DOP19
		Rimola, J.	1 st ECCO-ESGAR Basic Imaging Workshop	Schirmer, M.	OP19
		Rinawi, F.	OP18	Schmidt, F.	DOP13
		Rita Gonçalves, A.	DOP59	Schmitz, J.	DOP52
		Rivera-Nieves, J.	17 th IBD Intensive Advanced Course	Schreiber, S.	Scientific Session 9, OP08, OP14, OP35, DOP55, DOP62
		Roblin, X.	OP24, DOP80	Schreiner, P.	OP06
		Rodriguez Sillke, Y.	DOP13	Schwartz, D.	OP15
		Rodríguez-Lago, I.	DOP44	Schwarzfischer, M.	DOP14, DOP19
		Rogers, J.	OP17	Sebastian, S.	OP15, DOP29
		Rogers, R.	OP26	Segal, J.	DOP61
		Rogler, G.	17 th IBD Intensive Advanced Course,	Seidman, E.	DOP75
			OP06, OP20, OP35,	Seksik, P.	DOP74, DOP78
			DOP14, DOP24	Selinger, C.	DOP28
		Rolli-Derkinderen, M.	DOP23		

Seo, S.-K.	OP23	Suarez-Farinis, M.	OP17	Travis, S.	Scientific Session 4,
Seong, G.	DOP04	Subramaniam, K.	DOP68		OP28, OP35, DOP11
Serena, C.	DOP05	Sudhakar, P.	OP07, OP10, DOP08,	Treem, W.	4 th Advanced ECCO:
Serrero, M.	DOP74, DOP78		DOP38, DOP70		EduCational COurse
Seuwen, K.	DOP24	Sugaya, T.	DOP32		for Industry
Shadbolt, B.	DOP68	Suh, D.-H.	OP23	Tremelling, M.	OP10
Shafran, I.	OP26	Suh, J. H.	DOP62	Trescoli-Garcia, A.	OP03
Shamaly, H.	OP05, DOP42	Surowiecka-Pastewka, A.	DOP03	Treton, X.	OP24
Shamir, R.	OP18	Suzuki, K.	DOP22	Treveil, A.	5 th Y-ECCO Basic Science
Shaoul, R.	OP05, OP18,	Suzuki, Y.	DOP32	Workshop, OP07, DOP08	
	DOP31, DOP42	Svrcek, M.	4 th H-ECCO IBD	Triantafyllia, T.	N02
Sheridan, J.	DOP29		Masterclass	Triebel, F.	DOP07
Shimamoto, F.	DOP69	Szapary, P.	OP37, DOP47, DOP54	Tripathi, M.	4 th H-ECCO IBD
Shimizu, H.	DOP22	Szitanyi, P.	4 th Advanced ECCO:		Masterclass
Shin, J.	OP23		EduCational COurse	Tristán, E.	DOP25
Shirasaki, T.	OP31		for Industry	Tsakmaki, A.	DOP60
Shubhakar, A.	DOP10	Sáinz Arnau, E.	DOP44	Tsavdaroglu, A.	13 th N-ECCO
Siebeck, M.	OP12				Network Meeting, N02
Siegel, R.	DOP52			Tsuchiya, K.	OP31, DOP22
Siegmund, B.	1 st ECCO-ESGAR Basic Imaging Workshop, DOP13			Tulchinsky, H.	8 th S-ECCO
Sigall-Boneh, R.	4 th D-ECCO Workshop, OP05, DOP42				IBD Masterclass
SIGENP IBD Working Group	DOP34	Tanaka, S.	DOP69	Turcan, S.	OP15
Silver, A.	OP20, DOP20	Tannahill, G.	DOP18	Turner, D.	OP18, DOP31, DOP89
Simon, M.	DOP74	Tarabar, D.	OP08, DOP49, DOP51	Tuttle, J.	OP38, DOP46, DOP52
Simões, C.	DOP59	Targan, S. R.	OP37, DOP47, DOP54		
Siproudhis, L.	OP24, DOP74	Tarzi, R.	DOP11		
Slevin, S.	DOP11	Tato Marinho, R.	DOP59		
Sloan, S.	DOP54	Taxonera, C.	DOP44		
Smith, M.	OP16	Telesco, S. E.	OP36, DOP35		
Smith, N.	DOP21	Teriaky, A.	DOP39		
Song, E. M.	DOP65	Terrón-Puig, M.	DOP05		
Song, J. H.	DOP04	The IBSEN study group	DOP90		
Song, K.	DOP21	Theede, K.	DOP88		
Song, K.	DOP83	Thomas, M.	3 rd School for		
Song, W.-M.	OP17		Clinical Trialists		
Sosnovski, K.	DOP36	Thomsen, S. B.	DOP88		
Spalinger, M.	DOP02, DOP14	Thorpe, A. J.	DOP41		
Spalinger, M. R.	DOP19	Tole, S.	4 th Advanced ECCO:		
Sparrow, M.	DOP49, DOP51		EduCational COurse		
Spencer, D.	DOP10		for Industry		
Spinelli, A.	Scientific Session 11, 8 th S-ECCO IBD Masterclass	Tomalty, D.	DOP58		
Srinivasan, N.	DOP11	Tomsho, L.	OP36, DOP53		
Staessen, D.	DOP33	Tong, H.	DOP09		
Stallhofer, J.	OP12	Tong, T.	DOP64		
Stanciu, C.	OP35	Topf Olivestone, C.	OP18		
Steens, J.-M.	OP21	Torkzad, M.	1 st ECCO-ESGAR Basic		
Stellingwerf, M.	DOP73		Imaging Workshop		
Stevens, C.	OP01	Torres, J.	Scientific Session 2,		
Stocco, G.	DOP01		17 th IBD Intensive Advanced		
Stojmirovic, A.	OP17		Course, 1 st Guideline		
Strauss, R.	DOP35		Methodology and GRADE		
Strawn, D.	OP13		Workshop, 4 th D-ECCO		
Strigli, A.	DOP12	Tran Minh, M.-L.	DOP78		
Strik, A.	DOP56	Tozer, P.	8 th S-ECCO IBD Masterclass		
Su, C.	DOP41, DOP43	Travelli, C.	DOP01	Vande Casteele, N.	DOP45
				Vantourout, P.	OP32

Index of authors

Vardi, H.	OP15	Wang, R.	DOP09	Yarur, A.	OP09
Vavricka, S.	Scientific Session 2, 17 th IBD Intensive Advanced Course, 1 st ECCO-ESGAR Basic Imaging Workshop, 6 th ECCO-ESGAR Ultrasound Workshop Advanced	Wang, Y.	DOP24	Ye, B. D.	DOP62, DOP65, DOP83, 4 th ECCO-AOCC Forum
Vazeille, E.	DOP80	Wang, Y.	OP08	Yerushalmi, B.	OP18, DOP31
Váňásek, T.	DOP49, DOP51	Warren, D.	DOP06	Yilmaz, B.	OP06
Vegh, Z.	OP15	Warusavitarne, J.	8 th S-ECCO IBD Masterclass	Youn, G. S.	OP23
Vendrell, J.	DOP05	Wasmann, K.	8 th S-ECCO IBD Masterclass, DOP73	Young IBD Group from GETECCU	DOP44
Ventham, N.	DOP10	Watanabe, K.	DOP32, DOP69	Younge, L.	13 th N-ECCO Network Meeting, N03
Veny, M.	DOP25	Watanabe, M.	7 th SciCom Workshop, OP31	Yui, S.	DOP22
Verdón, C.	DOP75	Watana, S.	DOP22, DOP32, DOP48	Yzet, C.	OP35
Verfaillie, C.	OP11	Watson, A.	OP07, OP10		
Vermeire, S.	OP09, OP10, OP11, OP21, OP25, OP26, OP30, DOP26, DOP29, DOP33, DOP37, DOP38, DOP49, DOP51, DOP70	Wawrzyniak, M.	DOP19	Z agozda, M.	DOP03
Verspaget, H.	OP22	Weder, B.	DOP24	Zakościelna, E.	DOP03
Verstockt, B.	OP10, OP11, DOP26, DOP33, DOP37, DOP38, DOP70	Weersma, R.	OP01	Zallot, C.	DOP78
Verstockt, S.	5 th Y-ECCO Basic Science Workshop, DOP38, DOP70	Weidinger, C.	DOP13	Zand, A.	Scientific Session 7
Vester-Andersen, M. K.	DOP82	Weill, A.	DOP40	Zeissig, S.	7 th SciCom Workshop, DOP12
Veyrand, P.	OP24	Weiss, B.	OP18, DOP36	Zeissig, Y.	DOP12
Vicente, R.	DOP44	Whiteley, L.	N03	Zhang, H.	OP37, DOP47, DOP54, DOP71
Vich Vila, A.	OP01	Wijmenga, C.	OP01	Zhang, J.	OP09
Vicuña, M.	DOP44	Wild, G.	DOP75	Zhang, L.	DOP17
Viennot, S.	OP24, DOP74, DOP78	Wileman, T.	OP07, DOP08	Zhernakova, A.	OP01
Vilanova, M.	OP04	Wilkens, R.	1 st ECCO-ESGAR Basic Imaging Workshop,	Zhou, Q.	DOP50
Villarroel Aguilera, C.	OP12		6 th ECCO-ESGAR Ultrasound Workshop Advanced	Zhou, W.	OP14
Vind, I.	DOP82	Wilson, D.	4 th D-ECCO Workshop, 6 th P-ECCO Educational Course, DOP84, DOP87	Zhu, L.	DOP17
Visschedijk, M.	OP01	Wine, E.	OP05, DOP42, DOP58	Ziv Baran, T.	OP05
von Känel, R.	OP06	Wisniewska-Jarosinska, M.	OP21	Zmora, O.	8 th S-ECCO IBD Masterclass
Vossenkamper, A.	DOP18	Witte, A.	OP27	Zoufir, A.	OP10
Vuitton, L.	DOP74, DOP78	Wollants, W.-J.	DOP70	Zundler, S.	DOP67
Vutcovici, M.	DOP75	Wolthuis, A.	OP30	Zvyaglova, M.	DOP77
W adman, E.					
Wagner, B.	OP13				
Wagner, C.	DOP21				
Waldner, M.	7 th SciCom Workshop	X avier, R. J.	OP01, OP19		
Wall, C.	4 th D-ECCO Workshop, 10 th N-ECCO School	Xie, W.	OP14		
Walsh, S.	4 th H-ECCO IBD Masterclass	Xu, Y.	DOP17		
Walters, T. D.	OP19				
Wang, F.	DOP17	Y ablecovitch, D.	DOP36		
Wang, H.	DOP68	Yanai, H.	17 th IBD Intensive Advanced Course		
Wang, J.	DOP79				
Wang, J.	DOP12	Yang, D. H.	DOP65		
Wang, L. M.	DOP11	Yang, F.	OP13, DOP71		
Wang, M.	DOP17	Yang, S.-K.	DOP65, DOP83		
Wang, P.	DOP35	Yang, Z.	DOP17		

Imprint

Publisher

ECCO – European Crohn's and Colitis Organisation
OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH

Ungargasse 6/13
1030 Vienna, Austria
Phone: +43-(0)1-710 22 42
Fax: +43-(0)1-710 22 42-001
E-Mail: ecco-congress@ecco-ibd.eu
Web: www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation

To visit the ECCO website, please scan this code
or look at www.ecco-ibd.eu



Dieses Produkt entspricht dem Österreichischen Umweltzeichen für schadstoffarme Druckprodukte (UZ24).
This product conforms to the standards of the Austrian Environmental Seal of Approval for environmentally friendly printing products (UZ 24). Grasl Druck & Neue Medien, Bad Vöslau, UW-Nr. 715, www.fairprint.at



INVESTIGATOR OPPORTUNITY



**Learn more about a phase 3 clinical
trial program for an oral,
selective S1P modulator
in inflammatory bowel disease.**

— booth 40 —

Paid advertisement by Arena Pharmaceuticals



Meet the Pfizer Team at booth **3**

Working together to advance science and patient care

